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Uro-neurological disorders are those in which there is a disturbance of bladder function related to a 
neurological cause. However, many patients with a combination of urological and neurological 
symptoms, such as bladder voiding dysfunction and leg weakness or numbness, are not found to 
have explanatory abnormalities despite adequate clinical and radiological investigation, so-called 
‘scan negative’ patients.  In this PhD patients with ‘scan negative’ uro-neurological diagnoses were 
primarily investigated through studies of patients presenting with suspected Cauda Equina 
Syndrome and to a lesser extent Chronic Urinary Retention (including Fowler’s syndrome).  
 
The PhD goal was to deeply phenotype patients with ‘scan negative’ Uro- neurological disorders and 
in so doing, to improve our scientific understanding of these presentations and inform the 
development of clinical trials. 
 
The PhD explores the historical literature linking patients with idiopathic urological dysfunction and 
functional disorders, reviews the incidence, research and definitions of cauda equina syndrome and 
phenotypes patients in a retrospective and prospective manner who present with acute scan 
negative urological dysfunction (‘scan negative’ cauda equina syndrome)  as well as investigates for 
evidence of functional disorders in chronic scan negative urological dysfunction (Fowler’s syndrome) 
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The bladder and brain are in constant communication to ensure that voiding can occur in a safe and 
socially appropriate way.  Many patients with bladder dysfunction and neurological symptoms are not 
found to have any clear cause of their symptoms despite investigation, including brain and spine 
imaging.  My research focused on Cauda Equina Syndrome (CES) which, when due to a structural 
cause, describes damage to the nerves in the lower back which supply bladder, bowels, sexual 
function and the legs usually from slipped discs in the spine.  
 
 CES is as common as multiple sclerosis and is diagnosed using an MRI scan of the spine. However, 
about 50% of people presenting with the symptoms of CES have MRI scans which do not explain their 
symptoms, ‘scan negative’ patients. These patients are typically not given an explanation and are 
baffled by their disabling symptoms.  This PhD includes the first large clinical studies focusing on 
neglected ‘scan negative’ CES patients to investigate why patients have weak legs and bladder 
problems when there is no abnormality on the tests. There is evidence that some patients have a 
functional neurological disorder which currently goes undetected but could be usefully diagnosed and 
treated with treatment like physiotherapy. Functional Neurological Disorder is a common problem in 
neurology where patients develop leg weakness and numbness related to a problem in the function 
rather than structure of the nervous system. Other important factors such as severe back pain, 
medications, panic and underlying bladder dysfunction affect all parts of the bladder brain network 
and we hypothesise ways these could lead to bladder dysfunction.   
 
I also found evidence of an unusually high frequency functional neurological disorder in patients with 
chronic unexplained urinary retention including Fowler’s syndrome where the person is unable to 
urinate and often requires catheters. I also found evidence of milder urological dysfunction in patients 
with functional disorders who attend neurology outpatient clinics.   
 
The goal of these studies was to increase knowledge, awareness and treatment of these patients thus 
improving quality of life.   
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Uro-Neurology is the connection between urological symptoms and the neurological system, 
comprising a complex bladder-brain network involving the brain, spinal cord, sacral nerves and 
peripheral (pelvic) nerves.  Bladder problems such as urinary incontinence or difficulty passing urine 
are very common1,2 and are usually due to pathomechanical outflow dysfunction such as pelvic floor 
weakness or benign prostatic hypertrophy.  Understanding and management of outflow dysfunction 
is undertaken by urologists or gynaecologists, and often results in good outcomes.  Bladder 
problems seen in patients with neurological disease however, are due to coordination dysfunction 
between the brain, spinal cord and the lower urinary tract (bladder, urethra and sphincters) and are 
much less well understood3.   
Functional neurological disorders (FNDs), previously called psychogenic disorders, describe genuine 
neurological symptoms such as limb weakness in patients with a structurally normal nervous system.  
They exist at the interface between neurology and psychiatry and are often triggered by 
physiological events such as pain, panic, syncope or injury. Symptoms are usually driven by abnormal 
functioning due on an involuntary state of abnormal focused attention4,5.  Positive evidence of the 
potential for the nervous system to functional normally (e.g. become briefly strong in Hoover’s sign 
or tremor stopping briefly with the ballistic movements) is now part of the diagnostic criteria6.  
Specific and effective treatment for functional neurological disorders exists but, without this, the 
prognosis is poor7.  FNDs often co-exist with the much more common functional disorders such 
irritable bowel syndrome, non-cardiac chest pain and chronic widespread pain8.  
The last twenty years has seen a resurgence in FND interest and research however, within the 
existing literature, the overlap between FNDs and urological disorders has not as yet been studied.  
In the last ten years there has only been one single centre Uro-Neurology case series of patients with 
functional movement disorder and bladder disorders9 and two articles  in the psychiatric 
literature10,11.   
Urological disorders, particularly urinary retention in women, were previously associated with 
functional disorders and formed part of the DSM III diagnosis for conversion disorder.  Psychogenic 
urinary retention appeared frequently in the literature up until the 1980s when it was discovered 
that some women with chronic idiopathic urinary retention had abnormal urethral EMG 
readings12,13.  These findings, of decelerating bursts and complex repetitive discharges, were felt to 
be in keeping with a channelopathy and the diagnosis of psychogenic urinary retention was  
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thereafter very infrequently made.  Patients were instead diagnosed with dysfunctional voiding, 
Fowler’s syndrome, chronic idiopathic urinary retention14.   
 
My PhD aims to take the first steps of re-investigating the relationship between Uro-Neurological 
disorders and functional neurological disorders.  I chose to focus my main research around a group 
of patients who are often seen with acute onset bladder disorders but have normal or non-
explanatory imaging and investigations.  These patients present with suspected cauda equina 
syndrome.  
Cauda equina syndrome (CES) is a devastating condition caused by compression of the cauda equina 
nerve roots resulting in bowel, bladder and sexual dysfunction and potential lower limb weakness15.   
CES requires urgent surgery and has serious potential morbidity and medico-legal consequences16. 
Suspected acute CES has a minimum incidence of 11 per 100,000 making it twice as common as 
multiple sclerosis. However, at least 43% of patients with clinical CES have normal or negative MRI 
scans,  'scan-negative', and receive no other diagnosis17. These patients have previously been 
acknowledged but never studied in depth to ascertain their phenotype or explore possible 
mechanisms of their bladder, bowel, sexual dysfunction and pain. 
Smaller studies of patients with a form of chronic urinary retention, Fowler’s syndrome, and bladder 
dysfunction in patients with functional disorders attending outpatient neurology were chosen to 
give an overall feel for whether a relationship existed between patients with FND and bladder 
disorders in a chronic context. 
Aims 
The main aims of my PhD were:  
Aim1:  To determine what proportion of patients with ‘scan negative’ CES have a functional disorder 
by clinical consensus 
Aim 2: To describe associated clinical features relevant to diagnosis, mechanism and aetiology in 
patients with Scan negative and scan positive CES 
Aim 3: To determine what proportion of patients with urinary retention from Fowler’s syndrome or 
idiopathic causes (chronic idiopathic urinary retention/dysfunctional voiding/bladder outlet 
obstruction) have comorbid functional neurological disorder. 
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Aim 4: To determine what proportion of patients with functional neurological disorders have lower 
urinary tract dysfunction. 
 
Methods 
My PhD started with exploring the current understanding in literature of the relationship between 
Uro-Neurological disorders and functional neurological disorders.  A systematic review of the 
incidence of cauda equina syndrome followed to investigate incidence as well as problems with 
cauda equina syndrome nomenclature and diagnosis.  A pilot study allowed an examination of 
whether evidence existed for my hypotheses: that at least some of the symptoms in patients with 
CES symptoms but normal or non-explanatory scans, ‘scan negative’ CES, could be due to a 
functional disorder.  The main part of the PhD was two studies of patients with cauda equina 
syndrome; a retrospective and a prospective case: control study of patients with CES and patients 
with ‘scan negative’ CES.  Following these, a review of comorbidity in patients with Fowler’s 
syndrome and a study of urological symptoms and levels of distress caused by lower urinary tract 
dysfunction in patients presenting with functional and pathophysical disorders to outpatient 
neurology clinics was also undertaken to address aim four.  Finally, limitations of study methodology 
were explored, and conclusions drawn.   
 
All major components have been published or submitted for publication. They are bookended by an 
introduction and conclusion which explains the rationale for each article, how the study addressed 
the PhD aims and the conclusions drawn.  This is in keeping with the University of Edinburgh thesis 
guidelines point 1.12 “it is in the interest of candidates to include any relevant published papers in 
their thesis.  When published paper are to be included as a thesis chapter these must include an 
introduction and conclusion and be bound into the thesis at the appropatie point. These should either 
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Paper One:  Hoeritzauer I, Phe V, Panicker JN.  Urological symptoms and functional neurologic 
disorders.  Hand Clin Neurol; 2016; 139:469-481 
 
Introduction:  To explore the current understanding of the relationship between urological 
symptoms and functional disorders, including functional neurological disorders, a review of old and 
new literature was required, summarised in this book chapter.   
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Urologic symptoms and functional neurologic disorders 
I HOERITZAUER,1* VERONIQUE PHÉ,2 AND JALESH N. PANICKER3 
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The term functional urologic disorders covers a wide range of conditions related broadly to altered 
function rather than structure of the lower urinary tract, mainly of impaired urine voiding or storage. 
Confusingly, for a neurologic readership, these disorders of function may often be due to a urologic, 
gynecologic, or neurologic cause. However, there is a subset of functional urologic disorders where 
the cause remains uncertain and, in this chapter, we describe the clinical features of these disorders 
in turn: psychogenic urinary retention; Fowler's syndrome; paruresis (shy-bladder syndrome); 
dysfunctional voiding; idiopathic overactive bladder, and interstitial cystitis/ bladder pain syndrome. 
Some of these overlap in terms of symptoms, but have become historically separated. Psychogenic 
urinary retention in particular has now largely been abandoned as a concept, in part because of the 
finding of specific urethral electromyogram findings in patients with this symptom now described as 
having Fowler's syndrome, and their successful treatment with sacral neurostimulation. 
In this chapter we review the poorly researched interface between these “idiopathic” functional 
urologic disorders and other functional disorders (e.g., irritable-bowel syndrome, fibromyalgia) as 
well as specifically functional neurologic disorders. We conclude that there may be a relationship and 
overlap between them and that this requires further research, especially in those idiopathic 
functional urologic disorders which involve disorders of the urethral sphincter (i.e., voluntary 
muscle). 
Keywords 
lower urinary tract dysfunction, overactive bladder, functional urologic disorders, functional 
neurologic disorders, psychogenic urinary retention, dysfunctional voiding, interstitial 
cystitis/bladder pain syndrome, paruresis, Fowler’s syndrome, opiate 
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Functional neurologic disorders, such as functional tremor or functional limb weakness, are 
diagnosed based on positive signs, such as entrainment of functional tremor or Hoover’s sign of 
functional leg weakness, which demonstrate an underlying intact structure to the nervous system. 
Confusingly, for a neurologic readership, there is much less of a dichotomy in the urologic literature 
between functional and structural disorders. The term functional urologic disorders covers a wide 
range of disorders in which abnormal functioning of the lower urinary tract (LUT) causes urologic 
symptoms. Most functional urologic symptoms have a clear organic pathology (e.g., urologic, 
gynecologic, or neurologic) that is uncovered during clinical assessment or investigation. There are, 
however, some functional urologic disorders where the LUT dysfunction is evident through 
investigations, but the etiology is unclear.  
Functional disorders of the LUT manifest as voiding dysfunction, storage dysfunction, or both. The 
symptoms of storage dysfunction include urinary urgency, daytime frequency, nighttime frequency, 
nocturia, and/or urge urinary incontinence (Abrams et al., 2002; Hayllen et al., 2010). Voiding 
dysfunction manifests with symptoms of urinary hesitancy, intermittent flow and slow stream, 
straining to void, a sensation of incomplete bladder emptying after voiding and double voiding, 
characterized by the need to urinate again soon after voiding (Abrams et al., 2002). In the most 
severe case, patients may even be in urinary retention.  
We start this chapter with a description of LUT function in health and a summary of what is known 
about the brain–bladder axis. We then focus on the following presentations where there is no clear 
cause for dysfunction: psychogenic urinary retention; Fowler's syndrome; paruresis (shy-bladder 
syndrome); dysfunctional voiding; interstitial cystitis/bladder pain syndrome, and overactive bladder 
(OAB). Some of these overlap in terms of symptoms, but have become historically separated.  
We then discuss what evidence there is for an overlap between these disorders and functional 
somatic disorders such as fibromyalgia (FM) and irritable bowel as well as functional neurologic 
disorders such as functional movement disorders or dissociative (nonepileptic) seizures. Functional 
somatic disorders have been recognized in patients with idiopathic functional urologic disorders, and 
LUT dysfunction has also been documented in patients with a range of functional somatic disorders. 
The nature of the association, however, is uncertain and whether these are the manifestations of a 
common underlying abnormal working of the nervous system, or merely represent the coincidental 
existence of two independent processes, is yet to be systematically explored.  
LOWER URINARY TRACT FUNCTIONS IN HEALTH  
In health, the LUT remains in the storage phase, acting as a low-capacity reservoir of urine, 99% of 
the time. Storage is dependent on sympathetic and somatic-mediated contraction of the internal and 
external urethral sphincters, respectively, and sympathetic-mediated inhibition of the detrusor. 
During the storage phase, the pontine micturition center (PMC) is tonically inhibited by activity from 
cortical and subcortical centers, such as the prefrontal cortex, anterior cingulate gyrus, and insula (de 
Groat et al., 2015). Increasingly stronger signals through the sacral afferents during the storage phase 
are primarily responsible for initiating a switch to the voiding phase (Valentino et al., 2011). When 
deemed socially appropriate and safe, tonic inhibition of the PMC from the periaqueductal gray 
(PAG) is released, resulting in relaxation of the urethral sphincters and relaxation of the pelvic floor, 
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and parasympathetic-mediated activation of the detrusor and voiding ensue (Panicker and Fowler, 
2010). 
CURRENT MODELS OF THE BRAIN–BLADDER AXIS 
A more indepth review of the complex higher cortical pathways is useful to gain a better 
understanding of the bladder–brain axis and explore the association between functional disorders 
and LUT symptoms. Current understanding of LUT regulation suggests connection between the LUT 
and higher centers, including emotion, arousal, and motivation. Additionally, three circuits of 
micturition are postulated (Griffiths, 2015). The micturition system works largely unconsciously via 
PAG and parahippocampal regions of the temporal cortex to monitor the slowly filling bladder (Kavia 
et al., 2010; Tadic et al., 2013). Once it is socially appropriate and safe to void, activation of the 
medial prefrontal cortex triggers the PAG to activate the PMC. This circuit is hypothesized to be 
closely linked not only anatomically to the amygdala, but also emotionally linked to the crucial aspect 
of safety required for voiding.  
In patients who experience the threat of involuntary leakage with or without the sense of urgency, 
two other circuits are activated. One involves the insula and prefrontal cortex. The insula is known to 
receive homeostatic information from the whole body, with increasing activation as the bladder 
progressively fills. The prefrontal cortex has connections to the limbic system, associated with 
emotional and social contextualized decision making and involved in working memory. In response to 
the threat of involuntary voiding, the medial prefrontal cortex is inhibited by activity from the insula 
and lateral prefrontal cortex. Reduced medial prefrontal cortex activation inhibits PAG activation and 
raises the threshold micturition level (Tadic et al., 2011).  
The anterior cingulate gyrus is responsible for motivation and adjustments of bodily arousal states in 
response to mental stress. It is coactivated with the supplementary motor area, which controls 
striated muscles such as those in the pelvic floor and external urethral sphincter (Critchley, 2003). In 
response to the threat of involuntary voiding and the sensation of urge, activation of both the 
supplementary motor cortex and the dorsal anterior cingulate gyrus occurs. These two areas are 
thought to be responsible for simultaneous pelvic floor and urethral sphincter contraction and the 
anterior cingulate gyrus is thought to create the motivation to visit a toilet (Schrum et al., 2011). 
The PAG is thought to play a significant role linking between higher centers and the LUT, with 
projections to the thalamus, hypothalamus, and amygdala, while also receiving information from the 
bladder (Griffiths and Fowler, 2013; Griffiths, 2015). The PAG modulates the voiding threshold using 
the information received from the higher centers. If it is unsafe or socially inappropriate to void, the 
micturition threshold will be increased and the need to void reduced until there are higher bladder 
volumes. Brainstem nuclei such as the locus coeruleus modulate behaviors related to LUT function. 
The locus coeruleus system initiates and maintains arousal and facilitates shifts between focused 
attention and scanning attentiveness (Berridge and Waterhouse, 2003). Activation of the PMC and 
hence the locus coeruleus results in a switch from nonvoiding to voiding-related behaviour. 
Experiments in rodent models have shown that the expected pattern of increased activity from the 
locus coeruleus with increasing bladder pressure is lost 2 weeks after partial bladder outlet 
obstruction, even when bladder pressure increased to the micturition threshold (Rickenbacher et al., 
2008). This may be relevant in understanding why some individuals with chronic urinary retention 
may have high volume retention without a sensation of urge or bladder fullness. It also suggests that 
persistent outlet obstruction leads to a loss of central regulation of LUT function.  
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As well as the loss of sensitivity to increases in bladder pressure, the locus coeruleus neurons also 
showed increased basal activity of 40% compared with sham rats (Rickenbacher et al., 2008). This 
elevated basal activity is associated with hyperarousal, difficulty focusing on an ongoing task, and 
neurobehavioral impairments such as anxiety and sleep impairment. Theta oscillations were 
prominent on electroencephalogram, which ties in with loss of ability to differentiate between 
differing bladder pressures. Theta oscillations play a role in sensorimotor integration by coordinating 
activity in various brain regions on the basis of sensory input to update motor plans (Caplan et al., 
2003). The presence of these may also cause difficulty with nonbladder sensorimotor processing.  
ASSESSMENT OF FUNCTIONAL UROLOGIC DISORDERS 
History and examination are essential to consider potential urologic and gynecologic pathologies 
such as prostate enlargement, pelvic organ prolapse, tumors, or neurologic disorders such as 
multiple sclerosis, spinal pathology, or Parkinson’s disease. A bladder diary aids with assessment of 
the functional bladder capacity, urinary frequency, and the number of leakage or urgency episodes. 
Noninvasive investigations such as uroflowmetry and measurement of the postvoid residual by 
ultrasound or in–out catheterization help to uncover voiding dysfunction and incomplete bladder 
emptying. Urodynamics helps to identify the pattern of LUT dysfunction, such as detrusor instability 
or voiding dysfunction, but does not necessarily inform the etiology. Although the majority of 
patients presenting with “functional” problems with their bladder will have a cause identified during 
the course of investigations, many will not, and these are the disorders we consider in this chapter.  
PSYCHOGENIC URINARY RETENTION 
There are numerous causes for urinary retention and most commonly this arises in the setting of 
structural urologic lesions or an established neurologic disorder (Panicker et al., 2010; Smith et al., 
2013). Reports of an association between psychologic factors and urinary retention began to appear 
in the 1800s, under the term “hysterical ischuria” (Charcot, 1877; Dejerine andand Gauckler, 1913). 
We have found reports of 109 patients with a diagnosis of “psychogenic urinary retention,” with the 
majority (n = 84) reported prior to 1985. The diagnosis was made after medical investigations to 
exclude urologic, gynecologic, or neurologic causes (Margolis, 1965; Bridges et al., 1966; Blaivas et 
al., 1977; Barrett, 1978; Korzets et al., 1985; Nicolau et al., and 1991; Bilanakis, 2006). Triggering 
events and secondary gain were then sought and urologists were urged to look for recent life 
stressors and positive psychologic features to make the diagnosis (Wahl and Golden, 1963). 
Psychogenic urinary retention was reported most commonly in young women, with an average age 
of onset of 29 years based on a review of 15 papers. Emotional deprivation during childhood seemed 
to be a predisposing factor (Wahl and Golden, 1963; Montague and Jones, 1979) in many cases, and 
there were several reports of patients having nocturnal enuresis and urinary tract infections (UTIs) 
(Wahl and Golden, 1963; Lamontagne and Marks, 1973; Christmas et al., 1991). 
The literature is replete with predisposing and precipitating factors, including perceived stress, such 
as unhappy marriage or home life (Montague and Jones, 1979; Korzets et al., 1985), feelings of guilt 
or fear of punishment, often for promiscuous sexual activity (Wahl and Golden, 1963; Montague and 
Jones, 1979), and depression and anxiety (Blaivas et al., 1977; Montague and Jones, 1979). Patients’ 
unhelpful thoughts about genitourinary sensations as being “dirty” (Williams and Johnson, 1956) and 
“tense and unassertive” (Lamontagne and Marks, 1973) or “emotionally overcontrolled” (Montague 
and Jones, 1979) personalities were also felt to predispose to abnormal bladder functions. In several 
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patients, urinary retention was precipitated by physical triggers such as UTI, road traffic accident, 
surgery, or childbirth (Cardenas et al., 1986).  
Modeling from parents with genitourinary problems, sudden death of a friend or colleague from 
renal disease, iatrogenesis due to recurrent questions about urinary dysfunction, or minor symptoms 
which escalated with frequent medical reviews were also reported (Norden and Friedman, 1961; 
Wahl and Golden, 1963). Rape (Williams and Johnson, 1956; Montague and Jones, 1979) and 
murderous rage (Williams and Johnson, 1956) were reported in only 2 patients, but are often quoted 
in case series introductions or discussions as potential precipitating factors.  
Many patients reported unexplained sensory symptoms or pain and headaches (Williams and 
Johnson, 1956; Lamontagne and Marks, 1973; Montague and Jones, 1979). These symptoms 
improved with improving urinary symptoms. Psychogenic urinary retention was only associated with 
renal dysfunction in 2 cases (Knox, 1960; Korzets et al., 1985). Perceived benefits included freedom 
from unhappy home or sexual situations, the ability to exert control in situations in which the patient 
was being exploited, and being unburdened from many household duties expected of a woman at 
that time (Wahl and Golden, 1963; Montague and Jones, 1979). 
Treatment outcomes were generally only published in patients who significantly improved. However, 
many patients underwent unnecessary surgery, such as urethral dilatation, urethral elongation, and 
hysterectomy before a diagnosis of psychogenic urinary retention was made and specific treatment 
commenced (Montague and Jones, 1979; Cardenas et al., 1986). It is unclear, however, what 
proportion of patients diagnosed with psychogenic urinary retention were left with a permanent 
indwelling catheter or escalating surgical options for long-term treatment (Blaivas et al., 1977). 
Treatment was initially described with psychoanalysis, but in more recent literature, studies of 
systematic desensitization with relaxation training and biofeedback-monitored relaxation training 
were described ( Lamontagne and Marks, 1973; Montague and Jones, 1979; Nicolau et al., 1991). 
Reviewing the literature, there are also case reports of psychogenic urinary retention, which in 
hindsight clearly had a nonpsychogenic cause. For example, a case was reported in 1891 of a young 
woman developing urinary retention and was attributed to her being frightened by a man with a 
traveling bear. However, there was also mention of abnormal sensations of tight rings around her 
lower thighs, reduced sensation and power in her legs, and bowel disturbance, which gradually 
improved over 6 months (Little, 1891), and it seems possible that this was due to an inflammatory 
conus lesion which would not have been diagnosed with the investigations at the time. The danger of 
making a diagnosis of psychogenic or functional neurologic disorder in the absence of positive signs, 
such as Hoover’s sign of functional weakness, is highlighted by this case and caution should therefore 
be exercised when exploring this area. Although urinary retention was included in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013) as one of 
the symptoms of somatization disorder, there are few studies which refer to this condition in the 
recent literature.  
FOWLER’S SYNDROME 
At a time when several of the cases of unexplained urinary retention were being labeled as 
“psychogenic,” Clare Fowler and colleagues investigated the electromyogram (EMG) activity of the 
striated urethral sphincter and reported abnormal findings in 72% of the 48 women they examined 
(Fowler and Kirby, 1986). The findings they reported were complex repetitive discharges (CRDs) and 
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decelerating bursts (DB), and this abnormal EMG activity suggested a biologic basis for urinary 
retention in young women who hitherto were told they had psychogenic urinary retention. Further 
investigation of this patient subgroup found that they were young women with an average age of 27 
years, who, despite retaining urine, typically more than 1 liter, did not report urgency. They often 
reported an unpleasant sensation of “something gripping” during catheter withdrawal (and 
insertion), which was so severe that 28% of the original cohort received suprapubic catheters (Swinn 
and Fowler, 2001). Two-thirds of patients reported a triggering event at the onset of retention, most 
commonly surgery but also childbirth, UTI, or an acute medical condition. Many women note a long 
history of voiding difficulty prior to their initial episode of urinary retention (Swinn and Fowler, 
2001). Subsequent investigations showed that women with an abnormal EMG often had a high 
urethral pressure profile and sphincter volume (Wiseman et al., 2002). The abnormality is thought to 
be a nonrelaxing striated urethral sphincter, which causes abnormally high urethral pressures and 
impaired voiding. Activation of sphincter afferents is likely to be having a reflex inhibitory effect on 
detrusor afferent and efferent activity, resulting in complete urinary retention and poor sensations of 
bladder fullness (Ramm et al., 2012). Our current understanding of the etiology of Fowler’s syndrome 
is that it likely occurs due to upregulation of spinal enkephalins (Panicker et al., 2012), naturally 
occurring opiates, which reduce bladder sensation and negatively feed back to the sacral nerve roots, 
so that urethral sphincter sympathetic tone remains elevated and the PAG and PMC are not 
activated, even with large-volume bladder filling. The effect of upregulated spinal enkephalins is 
likely to be exacerbated by exogenous opiates.  
The diagnosis is often difficult to establish and women with Fowler’s syndrome see on average three 
consultants before their diagnosis is reached (Kavia et al., 2006). Although the urethral sphincter 
EMG findings are characteristic for this condition, in recent years two papers and two abstracts, one 
of which was a 10-year follow-up of the first, reported that these findings may be seen in the 
external urethral sphincter of apparently healthy women (Kujawa et al., 2001; Ramm et al., 2012; 
Tawadros et al., 2015). The number of participants in these studies were small, but they do raise 
some interesting questions about the specificity of these EMG findings to Fowler’s syndrome, and 
also the effects of the menstrual cycle on EMG changes. The finding of CRDs and DBs in apparently 
asymptomatic young women suggests that only when the inhibitory signal is sufficiently strong will 
urinary retention occur. The EMG changes should therefore be considered with the clinical features 
before making a diagnosis of Fowler’s syndrome. The finding of an elevated urethral pressure profile 
(> 92 – age cm water) or urethral sphincter volume (>1.8 cm3) aids the diagnosis (Wiseman et al., 
2002). The finding of CRDs and DBs, however, remains prognostically useful as patients with these 
changes have improved outcomes following sacral neuromodulation (De Ridder et al., 2007).  
The only currently useful long-term treatment for Fowler’s syndrome is sacral neuromodulation, 
which has successful outcomes, with up to 70% of patients regaining the ability to void normally with 
postvoid residuals of ≤100 mL, with a follow-up of up to 10 years (De Ridder et al., 2007; Elneil, 
2010). Sacral neuromodulation appears to work by overriding the negative feedback from the sacral 
nerves. On imaging studies of 6 women with sacral neuromodulation, the previously reduced activity 
in the PAG and other higher brain centers shows restoration of normal or near normal activity after 
sacral neuromodulation insertion (Kavia et al., 2010). A recent open-label pilot study of 10 women 
demonstrated that urethral sphincter injection of botulinum toxin was associated with improvement 
in their urinary symptoms and objective improvements on urodynamic testing, and this potentially 
represents a less invasive option with few side-effects (Panicker et al., 2016). 
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Somatic comorbidities have been reported in women with Fowler’s syndrome. A retrospective study 
of the hospital records of 62 women with Fowler’s syndrome found that almost a quarter of patients 
(24%) with Fowler’s syndrome had functional neurologic symptoms, including loss of consciousness, 
limb weakness, sensory disturbance, and memory impairment (Hoeritzauer et al., 2015). There are 
no comparison data in patients with other urologic or uro-neurologic disorders; however, based 
upon population prevalence of 2–33 per 100 000 (Reuber, 2008) for dissociative seizure or 1.7% of 
the population for patients with multiple idiopathic symptoms (Engel et al., 2002), this represents a 
high degree of comorbidity burden. Further studies are required to explore the reasons for this, 
whether due to a long diagnostic limbo prior to diagnosis or possibly because patients with Fowler’s 
syndrome are more likely to have functional somatic comorbidities. Patients with Fowler's syndrome 
may be missing a useful opportunity to treat their disorder in the context of other relevant 
comorbidities. In a separate prospective series of 62 patients treated with sacral neuromodulation, 
26.6% of patients with Fowler’s syndrome and 44% of patients with chronic idiopathic urinary 
retention screened with the Patient Health Questionnaire were defined as being at risk for 
somatization based upon their scores (De Ridder et al., 2007). 
Fifty percent of patients with Fowler’s syndrome suffered from unexplained chronic abdominopelvic, 
back, leg, or widespread pain (Hoeritzauer et al., 2015). A recent study of gynecologic pathology in 
patients with Fowler’s syndrome found rates similar to that expected in the general population, so it 
is unlikely that these chronic pain syndromes were caused by an underlying undiagnosed pelvic 
pathology (Karmarkar et al., 2015).  
PARURESIS 
Paruresis, also called “shy” or “bashful” bladder syndrome, is defined by DSM-5 (DSM-5 300.23: 
American Psychiatric Association, 2013) as a social anxiety disorder (social phobia) characterized by 
fear and avoidance of urinating in public toilets when other individuals are present. It is characterized 
by a situation-specific voiding dysfunction which usually occurs in adolescence following an 
unpleasant experience such as being rushed to urinate or being teased or harassed (Hammelstein et 
al., 2005; Soifer et al., 2010). Awareness of others waiting for the toilet often further exacerbates 
symptoms. Paruresis is not associated with the fear of contamination (Vythilingum et al., 2002), and 
20% of patients report no anxiety, but merely the inability to void in public toilets. Despite the 
subgroup with no anxiety, rates of psychologic comorbidity are quite high in the general paruresis 
population. Social anxiety disorders (29%), a major depressive episode (22%), alcohol abuse (14%), 
preparuresis obsessive compulsive disorder or significant problematic embarrassment all occur and 
should be sought (Vythilingum et al., 2002; Kaufman, 2005). 
Paruresis is seldom investigated, and there is poor knowledge about the disorder in medical circles. 
However, it is associated with significant morbidity and patients report high levels of shame, 
limitations to activities such as traveling or dating, and professional work (Vythilingum et al., 2002). 
The prevalence and gender ratios are uncertain; however, men are more likely to seek treatment and 
respond to questionnaires. Prevalence varies depending on how the question is phrased, as many as 
6% of the population are fearful of using a public toilet (Ruscio and Brown, 2008), but situational 
inability to void seems to occur in only about 3% of the population (Hammelstein et al., 2005). 
Perhaps because of its low profile or the embarrassment associated with the condition, only about 
30% of individuals seek treatment. Paruresis is often triggered by the triad of close physical or 
psychologic proximity with the individual, the presence of either familiar persons or the presence of 
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strangers in the toilet, and temporary psychologic states, especially anxiety. Cognitive behavioral 
therapy with graded exposure techniques and biofeedback is the treatment offered for this condition 
(Rogers, 2003; Boschen, 2008; Soifer et al., 2010). 
DYSFUNCTIONAL VOIDING AND HINMAN–ALLEN SYNDROME 
Dysfunctional voiding is characterized by an intermittent or fluctuating urinary flow which occurs due 
to involuntary intermittent contractions of the striated urethral sphincter and/or levator muscles 
during voiding in otherwise neurologically intact individuals (Jeong et al., 2014; King and Goldman, 
2014).  
Despite this being primarily a problem of voiding, individuals with dysfunctional voiding, who are 
most often females, commonly present with symptoms of urgency and frequency. Incomplete 
bladder emptying is common, resulting in recurrent UTIs. Most patients have symptom onset from 
childhood. 
The etiology is unclear; however, it is currently thought that dysfunctional voiding is a learned 
behavior in response to infection, trauma, detrusor overactivity causing stress incontinence, or 
psychologic factors (Karmakar and Sharma, 2014). Rates of depression and anxiety are greater than 
in asymptomatic controls (Fan et al., 2008) and dysfunctional voiding is more common in individuals 
with a history of sexual abuse (Ellsworth et al., 1995; Davila et al., 2003). Dysfunctional voiding is 
found in 2% of adults referred for urodynamic assessment, and the most common finding is a specific 
staccato pattern and dilated proximal urethra seen on voiding cystourethrogram (Glassberg and 
Combs, 2014). Treatment is primarily with biofeedback, which is thought to be successful in 60–90% 
of patients (Chin-Peuckert and Salle, 2001). However, a recent meta-analysis of all randomized 
studies of biofeedback (n = 5) for dysfunctional voiding in children has shown no benefit over 
controls (Fazeli et al., 2015). This may be due to poor trial data and the heterogeneity within the 
dysfunctional voiding group. Biofeedback is thought to be much more successful in patients with 
involuntary intermittent contraction of the levator muscles.  
The more severe form of dysfunctional voiding, known as Hinman–Allen syndrome or nonneurogenic 
neurogenic bladder, is characterized by external urethral sphincter dysfunction, recurrent UTIs, and 
damage to the upper urinary tracts (Phillips and Uehling, 1993; Hinman, 1994). Hinman–Allen 
syndrome has been attributed to primarily psychologic causes since its inception. Children were 
described as having “failed personalities,” and parental divorce and “family disarray” were felt to be 
contributing factors (Hinman and Baumann, 2002). Up to 40% of patients have severe urinary tract 
morbidity, resulting in chronic renal failure (Yang and Mayo, 1997; Silay et al., 2011). The focus on 
psychologic etiology has been questioned with the publication of 9 cases of babies under 30 months 
having features of severe dysfunctional voiding (Jayanthi et al., 1997; Al Mosawi, 2007; 
Chaichanamongkol et al., 2008). There are moves towards allying this condition more closely to 
syndromes of elimination disorders such as urofacial syndrome (Ochoa syndrome or hydronephrosis 
with peculiar facial expression) (Ochoa, 2004; Roberts et al., 2014). Urofacial syndrome is a genetic 
disorder with similar findings on investigation to Hinman–Allen syndrome, but additionally patients 
have a characteristic facies on smiling, akin to crying (Ochoa, 2004; Roberts et al., 2014; Tu et al., 
2014). It occurs due to an abnormality on chromosome 10 in the region of 10q23-q24 which codes 
for the genes HSPE2 or LRIG2 (Ochoa, 2004; Roberts et al., 2014). Only a small genetic study of 22 
patients with Hinman–Allen syndrome has been performed and no abnormalities were detected; 
however, further studies are required (Bulum et al., 2015).  
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OVERACTIVE BLADDER  
OAB is a syndrome defined by the International Continence Society as “urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary incontinence in the 
absence of UTI or other obvious pathology” (Abrams et al., 2002). The diagnosis is made based upon 
the patient’s self-reported symptoms of urinary urgency, frequency, nocturia, and/or urgency urinary 
incontinence. Whilst urgency is difficult to measure clinically, urinary frequency is defined as voiding 
more than eight times per day, nocturia in OAB as passing small amounts of urine several times 
overnight, and urgency urinary incontinence can be recorded using a diary (Gormley et al., 2015). 
There are several conditions that may result in these symptoms; however, in a subset of individuals 
with “idiopathic” OAB, the cause remains obscure despite extensive investigations.  
Patients with OAB report considerable morbidity. They have significantly worse health-related quality 
of life, are less likely than individuals without OAB to be employed, and may report sexual 
dysfunction (Ergenoglu et al., 2013; Tang et al., 2014). Patients with urinary incontinence (wet OAB) 
are more severely affected than those without incontinence (dry OAB). Disease-specific and global 
quality-of-life scores are lower and patients are comparatively less likely to be employed, less 
productive, and have greater health resource allocation (Tang et al., 2014). OAB is a long-term 
problem for the majority of patients and is underreported and undertreated (Getsios et al., 2005; 
Ergenoglu et al., 2013). 
OAB is associated with high levels of anxiety and depression (Matsuzaki et al., 2012; Matsumoto et 
al., 2013; Vrijens et al., 2015). A recent systematic review reported a positive association between 
depression and OAB in 26/35 studies, and between anxiety and OAB in 6/9 studies. There was strong 
evidence of OAB developing in patients who had depression, with an odds ratio 1.15–5.78, although 
it was not possible to assess causality (Vrijens et al., 2015). The occurrence of OAB symptoms is 
associated with worse quality-of-life scores, embarrassment, and social isolation (Wagg et al., 2007; 
Tang et al., 2014).  
Anxiety in healthy individuals can cause increased urinary frequency and urgency. Charcot and 
contemporaries used the term “pollakiuria” to describe “frequent and repeated micturition which 
one experiences under the stress of an emotion” (Dejerine and Gauckler, 1913). Animal studies 
suggested that chronic stress in anxiety-prone animals resulted in bladder hyperalgesia, which may 
contribute to the pathogenesis of LUT symptoms in affective disorders (Lee et al., 2015).  
There is limited literature exploring LUT symptoms in patients with pathologic anxiety disorders. In 
one longitudinal community study, anxiety appeared to have a causative role in the occurrence of 
urge incontinence (Perry et al., 2006). Females aged over 40 years old were asked through a 
community postal survey about anxiety and depression using the Hospital Anxiety and Depression 
scale, and urinary symptoms, and followed up for a year. It was observed that the presence of urge 
incontinence and urinary frequency predicted the development of anxiety and depression. 
Moreover, anxiety predicted urge incontinence, whereas depression did not. In contrast, stress 
incontinence did not predict either anxiety or depression (Perry et al., 2006).  
Four randomized controlled trials demonstrated that successful treatment of OAB resulted in a 
significant improvement in patients’ affective symptoms (Vrijens et al., 2015). The relationship 
between depression, anxiety, and OAB is postulated to be due to altered serotonin and 
norepinephrine levels causing OAB. This is on the basis of animal models demonstrating that 
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serotonin and norepinephrine have a modulatory effect on Onuf’s nucleus, which prevents 
accidental voiding when abdominal pressure increases, that serotonin inhibits the parasympathetic 
voiding activity and stimulates sympathetic activity, and that frequency is reduced after 
administration of selective serotonin reuptake inhibitors (Redaelli et al., 2015). 
An alternative mechanism is through the central effect of increased corticotropin-releasing factor, 
released due to dysregulation of the hypothalamic–pituitary–adrenal axis, causing both bladder and 
mood symptoms, as seen in rodent models (Wood et al., 2013). 
Recently three studies investigated functional somatic syndrome comorbidities in OAB and found 
irritable-bowel syndrome (IBS) occurring in up to one-third of patients with OAB with a background 
population rate of 20% (Matsumoto et al., 2013). Patients with FM were significantly more likely to 
have OAB and more severe OAB symptoms correlated to more severe FM symptoms. There was a 
significant overlap between OAB and functional dyspepsia in population-based studies (Persson et 
al., 2015). A history of sexual abuse was found to be associated with urinary frequency, urgency, and 
nocturia in at least three studies (Davila et al., 2003; Fitzgerald et al., 2007; Link et al., 2007). Among 
these studies, one fulfilled the Bradford Hill criteria for causality (Link et al., 2007).  
INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME AND FUNCTIONAL SOMATIC SYNDROMES 
Interstitial cystitis/bladder pain syndrome (IC/BPS) is defined by the Society for Urodynamics and 
Female Urology as “an unpleasant sensation (pain, pressure, discomfort) perceived to be related to 
the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, 
in the absence of infection or other identifiable cause” (Hanno et al., 2011). Voiding helps to reduce 
pain (Hanno et al., 2011). Patients with IC/BPS have a worse quality of life compared to healthy 
individuals, as well as patients with OAB, due to effects on emotion, social limitations, and personal 
relationships (Kim and Oh, 2010). 
Several studies have shown that patients with IC/BPS report comorbidities with functional somatic 
disorders such as IBS, FM, chronic fatigue syndrome (CFS), and vulvodynia (Aaron and Buchwald, 
2001; Buffington, 2004; Rodríguez et al., 2009). Moreover, patients reporting an increasing number 
of functional somatic syndromes, particularly FM, CFS, and IBS, have a greater risk for IC/BPS (Warren 
et al., 2011). In a systematic review, 16 of 25 publications found overlap between painful urologic 
pelvic pain syndromes and nonurologic syndromes (Rodríguez et al., 2009). Four studies were of 
patients with IC, and these showed higher rates of IBS (22.5% vs. 7% of controls), higher rates of 
backache, dizziness, arthralgia, abdominal cramps, and headache than controls, generalized pain in 
27% vs. 7% of controls, and the women with IC were 11 times more likely to be diagnosed with IBS 
compared with controls. In patients who had FM, 12% of patients met the criteria for IC, and in 
patients with chronic pelvic pain, IBS was found in 22.4% of patients, 40% of whom had IC. Twin 
studies found that twins with fatigue were 2–20 times more likely to have IC than twins without 
fatigue (Rodríguez et al., 2009). Most of the studies exploring the association of LUT symptoms and 
functional somatic syndromes have focused on pain disorders and therefore the association of 
IC/BPS and functional somatic symptoms may be overrepresented in the literature.  
There is also evidence for sexual abuse, high levels of depression, and panic disorder in patients with 
IC/BPS (Peters et al., 2007; Clemens et al., 2008). Several studies have investigated the association 
between abuse and IC/BPS. Physical, mental, or sexual abuse was found in 37% of patients with IC vs. 
24% of symptom-free controls, and sexual abuse occurred in 18 vs. 8% in a population responding to 
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a survey (n = 215 vs. n = 464 symptom-free controls) and 25/76 women (33%) seen in clinic (Peters et 
al., 2007). 
There is no definitive treatment for IC/BPS. Treatment is tailored to the individual patient, with 
holistic multimodal multidisciplinary input to maximize efficacy. First-line treatments include stress 
reduction, patient education, use of nonprescription analgesics, pelvic floor relaxation, and dietary 
manipulation (De Bock et al., 2011).  
Oral medications are generally the first-line treatment therapy, including antiallergics, amitriptyline, 
pentosan polysulfate sodium (Elmiron) and immunosuppressants. The choice of analgesic should be 
made in collaboration with a specialist pain management team. In case of failure of oral therapy, 
intravesical drugs (local anesthetics, hyaluronic acid, heparin) are administered; the intravesical 
route improves drug bioavailability, establishing high drug concentrations at the target, and is 
associated with fewer systemic side-effects. Disadvantages include the need for intermittent 
catheterization, which can be painful in BPS patients, cost, and risk of infection. Although bladder 
hydrodistension is a common treatment for BPS, the scientific justification is scanty. It can be a part 
of the diagnostic evaluation, but has a limited therapeutic role. Botulinum toxin A may have an 
antinociceptive effect through bladder afferent pathways, producing symptomatic and urodynamic 
improvement (Engeler et al., 2015). Sacral neuromodulation is associated with improvements in the 
symptoms of refractory BPS, with good long-term success seen in 72% (Engeler et al., 2015). 
Endourologic destruction of bladder tissue aims to eliminate urothelial lesions, mostly Hunner’s 
ulcers, and can be helpful in the relief of pain and urgency. Ablative organ surgery should be a last 
resort and should be performed only by surgeons knowledgeable about BPS. Unfortunately, no single 
treatment seems to work for patients over a prolonged period of time (Hanno et al., 2011). 
The etiology of IC/BPS is unclear and, whilst many studies have investigated association, causality 
remains elusive. Discussion of etiology involves physiologic and psychologic hypotheses (Aaron and 
Buchwald, 2001; Warren, 2014). The current favored s that central brain processing of pain is 
different in patients with IC than in healthy controls. A recent imaging study using voxel-based 
morphometry of 33 patients with IC and no other comorbidities showed increased gray matter in the 
supplementary motor area, the superior parietal lobule/precuneus bilaterally, and the right primary 
somatosensory cortex. In the right primary somatosensory cortex volume changes also correlated 
with clinical measurement of pain, anxiety, and urologic symptoms (Kairys et al., 2015). It was 
suggested by the authors that increased gray matter in the precuneus might be caused by alterations 
in the higher pain connections in a similar manner to those seen in FM. Alternatively, the increases 
could be due to bottom-up changes to the higher-center connections caused by prolonged severe 
pain. 
FREQUENCY OF UROLOGIC SYMPTOMS IN FUNCTIONAL/PSYCHOGENIC DISORDERS 
Although rarely reported in the literature, LUT symptoms have been observed in patients with 
functional neurologic disorders. The only study of LUT dysfunction in patients with functional 
neurologic disorders is a retrospective review of 150 patients diagnosed with definite or probable 
functional movement disorders between 2006 and 2014 from the National Hospital for Neurology 
and Neurosurgery in London (Batla et al., 2016). Patient notes were screened retrospectively and 
patients with LUT symptoms were administered questionnaires for urinary symptoms and LUT-
related quality of life. Thirty of the 150 patients with functional movement disorders had LUT 
symptoms; 20 of the 49 (41%) patients with fixed dystonia, 8 of the 57 (14%) patients with tremor, 
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and 2 of the 14 (14%) patients with mixed movement disorders. LUT questionnaires were completed 
by 22 of the 30 patients, all of whom were female, the majority of whom had symptoms of OAB 
(n = 14). The remaining patients complained of stress urinary incontinence (n = 5) and low stream 
(n = 3). Opiate use was correlated with low stream (p = 0.02). The 5 most severely affected patients, 
3 of whom had urinary retention and recurrent UTIs, and all of whom were using opiates, underwent 
urodynamic evaluation. No clear pattern of abnormality was evident and no neurologic or urologic 
cause was found. The 3 patients with urinary retention were initially managed with suprapubic 
catheterization and then had successful outcomes with sacral neuromodulation. Patients with fixed 
dystonia had the most severe symptoms, but the quality of life for all patients was negatively 
affected. LUT symptoms in other neurologic disorders are known to negatively affect quality of life; 
further studies in patients with functional neurologic disorders are required (Panicker and Fowler, 
2015). 
OPIATE USE AND LUT DYSFUNCTION 
Pain is a well-known comorbidity in many functional conditions and high rates of prescription opiate 
use have been described (Pearson et al., 2014). The association between opiate use and LUT 
dysfunction is less well known amongst general physicians and patients, and could be contributing to 
LUT dysfunction in patients with neurologic and urologic disorders (Elneil, 2010; Panicker et al., 
2012). In a study of 61 consecutive female patients reviewed at Queen’s Square with unexplained 
urinary retention, 24 patients were taking regular opiates, 3 of whom were taking more than one 
opiate. Five of these patients were diagnosed with Fowler’s syndrome, but 13 of the patients had no 
known cause for their voiding dysfunction. Patients had been prescribed opiates for unexplained 
predominantly abdominopelvic, musculoskeletal, or mechanical pain syndromes(Panicker et al., 
2012). On discontinuing opiates, 2 of the 24 patients reported improvement in LUT symptoms. 
Intravenous (n = 72) (Malinovsky et al., 1998) and intrathecal (n = 45) (Kuipers et al., 2004) opiates 
have been shown to reduce bladder sensation, increase residual volume, and affect the urge to void 
and the ability to micturite in some patients, with dose-dependent effects (Kuipers et al., 2004). 
Opiates are thought to affect the bladder peripherally by increasing parasympathetic tone and 
centrally acting on spinal enkephalins and mu receptors in the PAG (Matsumoto et al., 2004). 
Is there an association between LUT dysfunction and functional disorders?  
The term “functional disorders” encompasses overlapping syndromes including CFS, FM, IBS, 
myofascial pain, and temporomandibular joint disease (Clauw, 2010). The overlap of symptoms is 
well documented (Wessely et al., 1999; Clauw and Crofford, 2003; Wessely and White, 2013). The 
way in which these conditions overlap with functional disorders seen in neurologic practice, such as 
functional movement disorder and dissociative (nonepileptic) attacks, is also now well documented. 
Reflecting on the LUT dysfunction discussed in this chapter and its relationship with functional 
disorders, the initial problem is the dearth of studies that have attempted to specifically answer the 
question as to whether functional urologic disorders could share an etiology with functional 
neurologic and somatic disorders.  
It is known that the LUT is regulated by a complex interconnected network of higher centers involved 
in arousal, focus, understanding of safety and social propriety, emotion and motor activity. This 
system is informed by afferent signals from the LUT via the spinal cord, and the PAG and PMC are 
important brainstem centers involved in the coordination of urethral, pelvic floor, and detrusor 
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contractions. There are many points at which this network can go wrong, yet present with a limited 
repertoire of LUT symptoms. Understanding of the bladder–brain axis is exponentially increasing 
through basic, clinical, and imaging science. Increasing knowledge of neural networks has changed 
the understanding of disease from simply biologic or psychologic processes to an awareness of 
disease as something spanning both, and affected by environment, beliefs, as well as genes, which all 
come together to create the patient’s disease phenotype. In functional neurologic disorders, the field 
is moving away from the dualistic understanding of psychogenic versus organic etiology. This allows a 
functional model to emerge that comfortably incorporates psychologic and physiologic disturbances.  
Considering whether these disorders have features which overlap with functional somatic 
syndromes, such as IBS, FM, or hyperventilation syndrome, the criteria from Wessely et al. (1999) will 
be used. 
Patients with one functional syndrome frequently meet diagnostic criteria for other syndromes 
The prevalence of other functional disorders in patients with OAB, IC,  paruresis, and Fowler’s 
syndrome has been discussed above. 
Sex 
IC, idiopathic OAB syndrome, Fowler’s syndrome, and dysfunctional voiding affect predominantly 
women, whereas paruresis is likely to affect men more often. Some functional neurologic disorders 
such as functional propriospinal myoclonus have a male preponderance (van der Salm et al., 2014). 
Emotional problems 
Depression and anxiety are reported more in patients with idiopathic OAB, IC, paruresis, 
dysfunctional voiding, and Fowler’s syndrome compared to healthy controls. However, the impact of 
a chronic LUT disorder on mood requires further study before attempting to make an association 
between psychologic comorbidities and urologic disorders.  
Physiology 
Much of the current research of IC, idiopathic OAB, and Fowler’s syndrome hypothesizes that there is 
a central mechanism (brain ± spinal cord) causing the disorder rather than an abnormality which is 
solely bladder-based ( Kavia et al., 2010; Tadic et al., 2011; Kairys et al., 2015). Paruresis is treated 
with cognitive-behavioral therapy, recognizing that a central mechanism of inhibition exists that 
must be unlearned.  
History of childhood abuse or neglect 
While this is frequently referenced in older psychogenic urinary retention literature, there are few 
studies which explore this, except in the IC and dysfunctional voiding literature (Ellsworth et al., 
1995; Davila et al., 2003; Mayson and Teichman, 2009). In the Boston Area Community Health study 
(n = 5506), sexual and physical abuse and the prevalence of urinary frequency, urgency, and nocturia 
met the Bradford Hill criteria to suggest causality (Link et al., 2007). Given the frequency of these 
urinary symptoms in the population, background rates of childhood and adult adversity and potential 
pathophysiologic mechanisms should be investigated in a range of neurologic, gynecologic, and 
functional urologic conditions. 
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Many patients with idiopathic functional urologic disorders share similar characteristics with patients 
who have functional somatic disorders. The LUT is unique amongst visceral organs because of the 
highly organized central neural network that regulates its functions and affords higher-level 
voluntary input, and therefore it is likely that there exists an association between LUT dysfunction 
and functional syndromes. Though tests such as urodynamics help to uncover the pathophysiologic 
correlate of LUT symptoms, the test is unable to provide information about the etiology or 
behavioral underpinnings responsible for the LUT dysfunction. Studies are therefore required that 
are designed to specifically evaluate the nature of the association between LUT dysfunction and 
functional syndromes and explore causality. Recognizing the interface between emotion, motivation, 
memory, and LUT functions would allow for a more comprehensive approach to patients presenting 
with functional disorders.  
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Conclusions:  The book chapter developed my knowledge of the literature linking uro-neurological 
and functional disorders and my understanding of urological language.  A major initial difficulty is the 
nomenclature.  Although there are guidelines on what urology terminology should be used18, papers 
intermix different terms which mean the same thing (detrusor overactivity, overactive bladder, 
irritable bladder).  There are also terms which mean a direct correlation is found with a urodynamic 
test (detrusor sphincter dyssynergia) but equally terms which are not tied to a urodynamic diagnosis, 
such as overactive bladder. Overactive bladder can be diagnosed due to detrusor overactivity seen 
on urodynamics but can also be diagnosed when urodynamics do not show any abnormality based 
on symptoms of bladder overactivity.  For the majority of patients diagnosed with conditions which 
may be functional such as overactive bladder syndrome, urodynamics are not undertaken. 
There is additional complexity with nomenclature in relation to functional disorders.  There is a 
category within urology called ‘functional urology’ which describes any disorder not caused by 
structural pathology.  In this functional urology category are things like stress incontinence due to 
dysfunction of the pelvic floor but also unexplained syndromes, like dysfunctional voiding or Fowler’s 
syndrome.  Some ‘functional’ urological disorders such as dysfunctional voiding and Fowler’s 
syndrome seem to have overlap with functional neurological disorders whilst others do not. 
A major component of writing the chapter was understanding the bladder- brain network and how it 
may malfunction either due to bottom up or top down processes leading to a functional bladder 
disorder.  During the writing process I investigated the uncertainty of a urological diagnosis being tied 
to a structural or functional cause. I also investigated ideas about mechanisms and risk factors for the 
urological disorders widely accepted to be functional, such as bladder pain syndrome and 
dysfunctional voiding.  I found the point at which ‘psychogenic’ bladder disorders became seen as 
‘unscientific’ and began to be avoided as a diagnosis.   
Utilising this literature, I was able to start generating ideas about potential clinical features relevant 
to diagnosis, mechanism and aetiology linking uro-neurological and functional disorders. 
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Paper Two:  What is the Incidence of Cauda Equina Syndrome? Hoeritzauer I,2,3 MRCP, Wood 
M1,2, Copley P MRCS 1,2,3, Demetriades AK1,3  FRCSEd and Woodfield J1,2,3 
 
 
Introduction:  Acute onset bladder disorders occurring in patients who presented as though they had 
cauda equina syndrome is the main focus of my PhD study, but I wanted to understand my control 
group with structural causes better.  My Aim 2 was: To describe associated clinical features relevant 
to diagnosis, mechanism and aetiology in patients with Scan negative and scan positive CES.  I did this 
by carrying out a systematic review of the incidence of CES.  Given the importance placed upon CES 
medico-legally and the large financial penalties when the diagnosis is delayed or missed it, I initially 
presumed the condition was well defined, had clear international diagnostic standards and clear 
incidence figures in various populations, such as community incidence and incidence in patients with 
back pain, which would be possible to elicit form the literature.   
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A systematic review of the incidence of cauda equina syndrome (CES).  This research sought to 
establish the populations in which CES presents and whether incidence of CES varies across 
populations.  Accurate incidence of CES could be used to inform investigation and management of 
individual patients as well as healthcare service design and delivery including out of hours imaging 
arrangements.   
 
Methods 
A systematic literature search was undertaken to identify original studies reporting the incidence of 
CES as described in the protocol registered with PROSPERO (CRD42017065865). 
 
Results 
1281 studies were identified and 26 studies were included in the review. The incidence of CES was 
0.3-0.5 per 100,000 per year in two asymptomatic community populations, 0.6 per 100,000 per year 
in an asymptomatic adult population, and 7 per 100,000 per year in an asymptomatic working age 
population. CES occurred in 0.08% of those with lower back pain presenting to primary care in one 
study and a combined estimate of 0.27% was calculated for four studies of those with lower back 
pain presenting to secondary care. In 17 studies of adults with suspected CES, 19% had radiological 
and clinical CES.  
 
Conclusions 
CES occurs infrequently in asymptomatic community populations and in only a small proportion of 
those presenting with symptoms.  
 
Key Words:  Cauda equina Syndrome; Incidence; Systematic Review; Epidemiology; Population 
Introduction 
Cauda equina syndrome (CES) is an emergency with potentially significant consequences including 
bladder, bowel or sexual dysfunction, numbness, weakness, or pain.[1,2] Timely operative intervention 
can prevent symptom progression and potentially reverse existing symptoms.[3-5] Due to the high 
medical, personal, social, and legal costs, prompt investigation with MRI is recommended when CES 
is suspected.[6,7] In the United Kingdom (UK), patients are often transferred for investigation between 
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sites due to a lack of Magnetic Resonance Imaging (MRI) facilities operating outside normal working 
hours in district general hospitals and the potential need for specialist spinal or neurosurgical 
intervention.[8,9] However, many patients who present with clinical symptoms in keeping with CES will 
not have cauda equina compression on MRI[10] which complicates planning service design and 
delivery to encompass the needs of the whole population. Establishing the incidence of CES and 
populations at risk of CES would facilitate planning imaging and operative pathways for patients with 
suspected CES.   
 
This systematic review aims to identify studies reporting the incidence of CES, describe the 
populations in which the incidence of CES has been studied, and any differences in incidence 
between these populations.  
 
Materials and Methods 
A systematic review was undertaken as described in the study protocol ‘Incidence of Cauda Equina 
Syndrome: Systematic Review Protocol’ registered with the International Prospective Register of 
Systematic Reviews (PROSPERO), reference number CRD42017065865, available at: 
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=65865.  
 
Studies were included if they reported original data and assessed human subjects with CES. For 
inclusion, studies had to state the incidence of CES or the proportion of the studied population with 
CES, or provide sufficient figures for this to be calculated. We defined CES as a clinical diagnosis of 
CES with radiological cauda equina compression. Studies including only patients with a clinical CES 
type syndrome without radiological cauda equina compression were excluded. Studies of radiological 
lesions of the cauda equina or cauda equina compression without clinical features of CES were also 
excluded. Reference populations could be either asymptomatic populations or symptomatic 
populations investigated and found not have CES. Case series or studies without a reference 
population where the incidence of CES could not be established were excluded. Case series of 
operated lumbar discs, spinal stenosis, or iatrogenically caused CES were also excluded to ensure all 
included studies were applicable to an initial presentation with suspected CES. There were no 
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restrictions on the language or year of publication, the type, location, or age of the population 
studied, or whether the study was published or unpublished.  
 
The final database search was carried out on the 30th July 2018 in Ovid MEDLINE  Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations, and Daily 1946 to July 27, 2018, Ovid,EMBASE 1980 
to 2018 Week 31 and Scopus.  The MEDLINE search strategy was:  
1. Polyradiculopathy/ 
2. cauda equina.ti,ab. 
3. Cauda Equina/ 
4. 1 OR 2 OR 3 
5. Incidence/ or Prevalence/ 
6. Epidemiology/ 
7. (incidence* or prevalen* or epidemiolog* or frequenc* or rate* or ocurrence*).ti,ab 
8. 5 OR 6 OR 7 
9. 4 AND 8  
No limits were applied. EMBASE and Scopus search strategies are in the supplementary material.  
 
Duplicate studies were eliminated and then all abstracts and titles were screened by two reviewers 
independently (JW, IH, PC, or MW). Where reviewers disagreed, discussion with a third or fourth 
reviewer was undertaken to provide a consensus. The full text of all included abstracts was retrieved 
and independently reviewed by two reviewers (JW, IH, PC, or MW). Any disagreements were 
resolved through discussion with a third or fourth reviewer. The reference lists of all included studies 
were screened independently by two reviewers to identify any additional relevant papers. Studies 
citing the included studies were identified using Scopus and also screened by two reviewers 
independently. Multiple papers or abstracts reporting the same study were treated as a single study.  
 
Data were extracted from each included paper by two reviewers independently and all instances 
where data did not match were checked by a third reviewer (JW, IH, PC, or MW).  The data items 
extracted were: incidence of CES in the population (including confidence intervals and standardised 
estimates where given); number of cases of CES; size of the reference population; description of the 
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population (location, demographics, time period studied, inclusion criteria); and definition of CES 
used in the study including any sub-categorisation.  
 
Study quality and risk of bias was assessed using the following questions adapted from those used in 
prior systematic reviews of incidence of neurological conditions[11,12] based on published quality 
assessment guidelines.[13,14] As there are no validated diagnostic criteria for CES, studies were 
assessed on whether they described the definition of CES used.  
1. Was the target population clearly described? 
2. Were cases ascertained by survey of the entire population or by probability sampling? 
3. Was the sample size >300 subjects? 
4. Was the response rate >70%?  
5. Were non-responders clearly described? 
6. Was the sample representative of the population?  
7. Were data collection methods standardised? 
8. Were the diagnostic criteria used to assess the presence of disease described?  
9. Were estimates of incidence given with confidence intervals? 
10. Were standardised estimates reported?  
 
The incidence of CES was reported per 100,000 population per year in asymptomatic populations. 
The percentage with CES was reported in symptomatic populations. Statistical heterogeneity was 
assessed using the Q statistic and the I2 test.[15] Proportions were combined using the inverse 
variance method and a DerSimonian-Laird estimator for τ2.[16] Confidence intervals for individual 
studies were calculated using Clopper-Pearson confidence intervals.[17] All statistics were calculated 
using the meta package in R version 3.4.0.[18]  
 
Results  
The studies identified and excluded at each stage and reasons for exclusion are shown in the PRISMA 
flow diagram[19] in Figure One. Of the 1281 studies identified after removal of duplicates, 26 were 
included. Four studies reported the incidence of CES occurring in asymptomatic community 
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populations.[20-23] Twenty-three studies investigated the incidence of CES in patients presenting with 




Figure 1. PRISMA Flow Diagram. Studies identified, included, and excluded.  
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Table 1.  
Incidence of Cauda Equina Syndrome (CES) in Asymptomatic Community Populations 
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(ICD: International Classification of Diseases; +: calculated from values given in paper; $: reported as 
total number of people in the population in the total number of years during the study time period) 
 
Population Incidence of CES 
Study details and incidence figures for the four studies reporting the incidence of CES in community 
dwelling asymptomatic populations are shown in Table 1. Hurme et al[20] and Podnar et al[21] 
investigated European community dwelling populations and identified similar incidence figures of 
0.48 and 0.34 cases per 100,000 population per year respectively  despite different methods of case 
ascertainment. Hurme et al[20] identified cases of CES using surgical records, whilst Podnar et al[21] 
used a comprehensive clinical and neurophysiological assessment at a rehabilitation centre. Reito et 
al[22] reported the incidence in an only adult population and found a slightly higher incidence of 0.6 
per 100,000 adult population per year. Schoenfeld et al[23,44] studied an American military personnel 
healthcare database and found a higher incidence of 7 per 100,000 population per year in this 
working age population. Reito et al[22] was the only study to divide CES into sub-categories. Two 
patients had CES with retention and two patients had incomplete CES making the incidence of each 
subtype 0.30 per 100,000 per adult population per year. Both Reito et al[22] and Schoenfeld et al[23] 
used coding to identify cases of CES. Reito et a[22]l also reviewed clinical notes of the identified cases.  
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Meta-analysis of the incidence estimates was not undertaken due to the heterogeneity in the 
reference populations studied and the methods of CES case ascertainment.  
 
Table 2:  
Incidence of Cauda Equina Syndrome (CES) in Patients Presenting with Back Pain 
 





































































(SBNS: Society of British Neurological Surgeons; ED: Emergency Department; ICD: International 
Classification of Diseases; *: not stated in paper) 
 
Incidence of CES in Patients with Back Pain 
Five studies reported the proportion of patients presenting with non-traumatic lower back pain who 
were found to have CES.[22,34,37,39,43] Study findings are shown in Table 2. Henschke et al[34] found 
0.08% of adults presenting to primary care in Australia with lower back pain were diagnosed with CES 
by the study rheumatologist using clinical assessment and investigation. The other four studies 
investigated patients presenting to secondary care and reported proportions between 0.15-
0.54%.[22,37,39,43] The diagnosis of CES was determined by ICD code in two studies,[22,39] the clinician in 
one study.[43] and the method was not reported in one study.[37] Study estimates for the proportion 
with CES in those presenting to secondary care with non traumatic lower back pain were combined 
using a random effects model to give an estimated proportion of 0.27% (95% CI: 0.14-0.54%). Study 
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estimates and confidence intervals are shown in the forest plot in Figure 2. There was a high level of 
statistical heterogeneity with I2=85.2% (95% CI: 63.3%-94.0%) and Q=20.2 (p<0.001).  
The Clinical Features and Prognosis of ‘Scan Negative’ 
Uro-Neurological Disorders: Exploration of the field 
51 
 
Figure 2. Forest plot. Proportion and number (events) of patients with cauda equina syndrome amongst those presenting with non traumatic lower back 
pain to secondary care. Summary proportion calculated using a random effects model 
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Table 3:  
Incidence of Cauda Equina Syndrome (CES) in Patients Presenting with Suspected Cauda Equina Syndrome 
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Time Period 
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(CE: cauda equina; MRI: magnetic resonance imaging; OOH: out of hours; ED: Emergency Department; *: not 




Incidence of Confirmed CES in Patients Suspected of CES  
Eighteen studies reported the proportion of patients presenting with signs and symptoms suspicious 
for CES who had clinical and radiological confirmation of CES. The study details are shown in Table 3. 
Eleven studies included only patients undergoing MRI for suspected CES.[8,24,25,28,30-33,35,38,40,42] The 
other six studies stated they included all patients referred with suspected CES.[9,26,27,29,36,41,45] All 
studies assessed populations referred to either secondary or tertiary care. Banerjee et al[27] studied 
only children. All other studies included adult populations but did not state whether they specifically 
excluded paediatric patients. A diagnosis of CES was established by cauda equina compression on 
MRI or operative intervention for CES. Only two studies described findings on MRI defining a 
diagnosis of CES and this was more than 50% canal compromise in one study[9] and more than 75% in 
another. Three studies stated that cauda equina compression was determined by the reporting 
radiologist but did not state the criteria used.[31,32,38] The cause of cauda equina compression was 
described in six studies. Demetriades et al[30] only included disc prolapses. Five studies included all or 
some of disc prolapses, tumours, trauma, and haematoma.[8,24,29,31,32] One study discussed subtypes 
of CES (with urinary symptoms, or incomplete) but did not report the numbers in each group.[29] 
None of the other studies used subcategories or descriptors. The proportion with confirmed CES in 
those presenting with suspected CES ranged from 0% to 40% in the eighteen studies. We excluded 
the study that included only children,[27] and combined the other estimates using a random effects 
model to give an overall estimate of confirmed CES in 18.9% (95% CI:13.6-25.6%). The forest plot is 
shown in Figure Three. There was a high level of heterogeneity in the study designs and the statistical 
heterogeneity was high with I2 = 91.9% (95% CI 88.6-94.3%) and Q = 197 (p<0.001).  
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Figure Three. Forest plot. Proportion and number (events) of patients with confirmed cauda equina syndrome amongst those referred to secondary 
or tertiary care facilities for assessment for possible cauda equina syndrome. Summary proportion calculated using a random effects model.  
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Hurme 1983 Y Y Y ? N Y Y N N N 
Podnar 2007 Y N Y ? N Y Y Y N N 
Schoenfeld 2012 Y Y Y ? N Y Y Y N N 
Reito 2018 Y Y Y Y Y Y Y Y Y N 
Henschke 2009 Y N Y ? N Y Y Y Y N 
Thiruganasamb-
andamoorthy 2014[1] 
Y Y Y ? N Y Y N N N 
Kiberd 2018 Y Y Y ? N Y ? N N N 
Premkumar 2018 Y N Y ? N Y Y Y N N 
Bell 2007 Y Y N ? N Y Y Y N N 
Crocker 2008 Y Y N ? N Y Y N N N 
Demetriades 2009 Y Y N ? N Y ? Y N N 
Domen 2009 Y Y N ? N Y Y Y N N 
Rooney 2009 Y Y N N N Y Y Y N N 
Balasubramanian 2010 Y Y N ? N Y Y Y N N 
Thangarajah 2011 Y Y N ? N Y N N N N 
Gooding 2013 Y Y N ? N Y ? Y N N 
Haworth 2013 Y Y N ? N Y ? N N N 
Sideris 2014 Y Y Y ? N Y Y N N N 
Ahad 2015 Y Y N ? N Y Y N N N 
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Blades 2015 Y Y Y ? N Y Y N N N 
Hoeritzauer 2015 Y Y N ? N Y Y Y N N 
Hoeritzauer 2017  Y Y N ? N Y Y N N N 
Banerjee 2018a Y Y N ? N Y ? N N N 
Banerjee 2018b Y Y N ? N Y ? N N N 
Hussain 2018 Y Y N ? N Y Y Y N N 
Kostusiak 2018 Y Y Y ? N Y Y N N N 
Studies were assessed against the 11 pre-specified criteria. Y represents “Yes” and N represents “No”. Where no information is given in the study report there is a 
question mark.   
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Study Quality  
Study quality assessment is shown in Table 4. All studies described the population being studied and 
had representative samples. However, only two studies reported excluded patients,[22,40] and only 
one study described the excluded patients.[22] Studies assessing asymptomatic populations were 
larger than those assessing asymptomatic populations. Only three studies assessing those presenting 
with suspected CES included more than 300 participants.[29,38,41] Methods used to ascertain the 
diagnosis of CES varied between studies and many studies did not adequately describe their methods 
in a way that could be easily reproduced. Only two studies calculated confidence intervals for the 
incidence estimates[22,34] and none reported population standardised estimates. Of the 26 studies 
included in this review, nine were published only in abstract form.[26,27,29,30,33,36-38,41]  
 
Discussion 
This systematic review of the incidence of CES identified 26 relevant studies. The incidence of CES 
was 0.34-0.48 per year per 100,000 population in two studies of asymptomatic complete 
populations.[20,21] One study of an adult population reported an incidence of 0.6 per 100,000 per 
year,[22] and one study of an adult working age population reported an incidence of 7 per 100,000 per 
year.[23] In patients with back pain, the proportion diagnosed with CES presenting to primary care was 
0.08% in the single study identified.[34] A combined estimate of 0.27% was calculated from four 
studies of patients presenting to secondary care with back pain. In 17 studies of patients referred to 
secondary or tertiary care with suspected CES the combined estimate with CES was 18.9%.  
 
This is the first systematic review of studies estimating the incidence of CES. One study was carried 
out in Australia,[34] four studies were carried out in North America,[23,37,39,43] and the remainder 
studied European populations. It is not known whether these estimates are relevant outwith the 
populations and healthcare settings studied. Patients with known pathology of the cauda equina 
region such as prolapsed intervertebral discs or tumours were not included, so these estimates 
cannot be applied to patients with known pathology.  
 
This review identified a paucity of literature on the incidence of CES. We included all studies from 
which incidence of CES could be calculated, but few of the studies had a primary aim to calculate 
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incidence. Many did not meet expected epidemiological standards as can be seen from Table 4. 
Sample sizes were small in symptomatic populations and estimates did not have confidence intervals 
and were not standardised for the populations. Few studies described exclusions or missing data. 
Nine studies were only published in abstract form and provided fewer methodological details and 
had not been through the peer review process. All abstracts and full text articles were screened by at 
least two reviewers and we only identified seven further studies[8,24,31,32,35,42,43] through searching 
reference lists and citations. We are confident that these methods should not have missed any 
further important studies on this topic.  
 
The criteria used to establish a diagnosis of CES were described in only 13 of the 26 studies, and only 
two studies subdivided CES into clinical categories.[22] Diagnosis was determined through clinical 
coding, record review, urgent operative intervention, radiology reports, clinical assessment, or any 
combination of these. The variation in definitions and reporting of diagnostic criteria likely reflects 
the lack of agreed definitions and multiple classifications of CES in use clinically and in the 
literatures.[1] The lack of specific clinical phenotyping covered by a broad CES definition hampers 
accurate assessment of incidence and contributes to the statistical heterogeneity as the incidence 
will likely differ depending on the definition and case ascertainment methods used. In addition, 
differing medico-legal concerns or clinical guidelines in different healthcare settings may affect the 
threshold for diagnosing CES, which will ultimately affect estimates of incidence. Adopting agreed 
definitions or defining subtypes such as those listed by Todd and Dickson[46] might enable more 
consistent reporting in future studies and allow more accurate incidence figures to be established.  
 
This systematic review confirms that CES occurs infrequently in the general population, and also that 
the majority of patients presenting with symptoms do not have a clinical and radiological CES. 
Healthcare service planning for the investigation and management of CES needs to balance the needs 
of the majority population with the few CES cases in whom a missed diagnosis or delayed treatment 
could have significant consequences. All but one[31] study reporting the proportion of patients with 
CES from those with suspected CES were carried out in the UK where guidance from the British 
Association of Spine Surgeons recommends an emergency MRI for suspected CES[47] and yet only 14% 
of hospitals in England and Wales surveyed in 2012 reported 24 hour access to MRI.[48]  As clinical 
symptoms and signs in those with radiological cauda equina compression are very difficult to 
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distinguish from those without cauda equina compression,[49] this leads to a situation in which many 
patients are transferred to specialist centres for an MRI and then either transferred back or 
discharged from locations that can be far from home. Although final diagnoses in patients without 
cauda equina compression include demyelination, myelitis, and infection, the majority of patients do 
not have a structural cause found.[10] Either further characterisation of these patients to identify 
potentially distinguishing features such as Hoover’s sign of functional weakness,[10] or an expansion 
of local out of hours MRI facilities could improve care for those investigated for CES with and without 
structural radiological cauda equina compression.  
In conclusion, the incidence of CES is low at fewer than 1 per 100,000 asymptomatic  population per 
year. Only 0.27% of those with lower back pain and only 18.9% of those with signs and symptoms 
consistent with CES will have a final diagnosis of radiological and clinical CES.  
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Conclusions:  The systematic review, particularly the assessment of the quality of literature, was 
useful for highlighting the problems with diagnosis, lack of use of diagnostic categories in clinical 
work and the dearth of good large studies of cauda equina syndrome.   
Although there are clinical and radiological requirements to make a diagnosis of CES, no 
internationally agreed definition of CES either clinically or radiologically exists.   In fact the 
classifications of CES are so manifold that a systematic review solely on the definition of CES exists15.  
The lack of consensus on what CES is creates difficulty in comparing patients diagnosed with CES 
across studies.  Despite the multitude of CES definitions, in the systematic review I found that only 
one of the 18 studies of patients presenting with CES (6%) split patients up based upon the literature 
definitions.  
 
Despite acknowledgement of CES as having major clinical and medicolegal importance most of the 
research is retrospective and based on small numbers19.  58% of all studies contained less than 300 
participants in total and 50% of studies investigating patients who presented with clinical CES were 
only presented as an abstract and never published as a full article.  In all studies of patients 
presenting with clinical CES 0-40% had cauda equina nerve root compression on MRI.   
 
The systematic review was helpful for allowing me to understand the current level of knowledge 
about CES and the lack of agreement of clinical or radiological criteria. This meant I would have to 
decide where patients with ‘impending CES’ fitted into my study, and also helped me appreciate the 
difficulty in finding any current positive predictive factors to diagnose ‘scan positive’ CES or ‘scan 
negative’ CES and the  highly UK-centric CES data. 
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Paper Three:  Hoeritzauer I, CM Doherty, S Thompson, R Kee, A Carson, N Eames, J Stone.  ‘Scan 
Negative’ Cauda Equina Syndrome: evidence of functional disorder from a prospective case series. 
British Journal of Neurosurgery. 2015; 29 (2):178-180.   
 
Introduction:   Before engaging in larger retrospective and prospective studies of CES I carried out a 
pilot study to test my hypothesis that patients with ‘scan negative’ CES were more likely to have 
evidence of a functional neurological disorder.  I wanted to explore some potential mechanisms and 
to investigate whether a clinical sign of functional leg weakness, Hoover’s sign, with good specificity 
and sensitivity in general neurology populations20 would also provide useful information in patients 
with ‘scan negative’ CES. 
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In the first prospective comparison of ‘scan negative’ (n=11) and ‘scan positive’ (n=7) patients with 
Cauda Equina Syndrome (CES) we found that Hoover’s sign of functional leg weakness but not 
routine clinical features differentiated the two groups (p<0.02).  This offers a new direction of study 
in this area although MRI is still required for all patients with possible CES.
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Cauda Equina Syndrome (CES) is a devastating condition which requires urgent surgery and has 
serious potential morbidity and medico-legal consequences(1).  Despite the high profile of CES 
correlation between clinical assessment and MRI findings is often poor, even amongst experienced 
clinicians.  In previous neurosurgical series, nearly 50% of patients presenting with possible CES had 
MRI scans which did not explain their symptoms , so called ‘scan negative’ patients(1),(2).This 
interesting ‘scan negative’ group is not well studied and given their heavy resource utilisation 
certainly warrants scrutiny.  We investigated these patients prospectively for the first time in a pilot 
study and compared them to ‘scan positive’ patients with MRI confirmed CES. 
Methods 
At the Royal Victoria Hospital, Belfast patients with a possible diagnosis of CES are typically admitted 
under the orthopaedic team.  We recruited prospective consecutive cases from weekday 
orthopaedic meetings over a six month period in 2013/4 whose history and examination were 
suggestive enough of CES for the orthopaedic team to request urgent MRI lumbosacral spine 
imaging. We divided them into those with scan positive CES (changes seen on MRI causing CES), scan 
negative CES (normal MRI or changes seen on MRI but not causing CES e.g. L5 nerve root 
entrapment) and ‘other’ (with an alternative explanation for symptoms). We aimed to see all 
patients blind to the diagnosis. 
We collected data on:  Age ;  Sex; Symptoms (back pain, leg weakness and numbness, urinary and 
bladder dysfunction and saddle anaesthesia); Presence of dissociation (using Peritraumatic 
Dissociative Experiences Questionnaire (PDEQ)); whether there were symptomatic criteria for a 
Panic attack (using DSM-IV);  physical examination (tone, power, sensation, reflexes, plantars); a 
specific sign of functional (also called psychogenic/non-organic) limb weakness was performed 
(Hoover’s sign: weakness of hip extension that returns to normal with contralateral hip flexion 
against resistance) (3); residual bladder volume on bladder scan or volume on initial catheterisation 
if recorded; lumbosacral MRI scan reported by a consultant radiologist; length of in-patient stay; 
follow up length and clinical outcome through information on their Electronic Care Record which 
documents all A&E, out-patient  hospital attendances, admissions and mortalities in Northern 
Ireland.  Statistical significance was determined using Fisher’s exact test and unpaired t-test.   
Results 
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Twenty patients were seen as part of the prospective study, of whom 18 were suitable for inclusion.. 
Two patients were excluded as other diagnoses were made to explain the presentation (n=1 thoracic 
malignant lesion, n=1 neurosarcoid). Of the 18 included patients, eleven (61%) were ‘scan negative’ 
(7 females, mean age 38 yrs.) for CES and seven (39%) were ‘scan positive’ for CES (4 females, mean 
age 57yrs). They are described in table 1. 
The most striking differences between the’ scan negative’ and ‘scan positive’ groups  were found in 
the frequency of Hoover’s sign of functional leg weakness (9/10 scan negative and 0/3 scan positive, 
100% seen blind to the diagnosis: no assessment possible in 7 cases (table 1)). There were also 
notable differences in the frequency of symptoms compatible with a panic attack (8/11 scan 
negative (72%) vs 2/7 scan positive (29%), p 0.14) and in Peritraumatic Dissociative Experiences 
scores (5/11 scan negative (45%) >20 PDEQ vs 1/7 scan positive (14%) >20 PDEQ, p 0.32). 
By contrast classical CES symptoms showed poor ability to discriminate between  ‘scan negative’ and 
‘scan positive’ patients: the frequency and nature of leg pain, weakness and numbness, urinary 
retention and/or saddle anaesthesia;  use of opioids (scan negative (63%), scan positive (71%)). 
Only four patients had bladder scans done, of whom three were in the ‘scan negative’ group (600mls 
and 900mls and 1000mls) and one in the scan positive CES group (1200mls).   
Four of the eleven patients in the ‘scan negative’ group had definite nerve root impingement on MRI 
(L4 (n=1), L5 (n=1), S1 (n=2)) but no changes explaining their CES symptoms. In the ‘scan negative’ 
group the average length of inpatient stay was one day with only two patient’s admission lasting 
more than two days.   
Follow up data was available on all patients (‘scan negative’ mean= 5.7 months, ‘scan positive’ 
mean=6.8 months).  None of the eleven’ scan negative’ patients represented with CES. One scan 
negative patient had a discectomy 3 weeks after initial presentation for back pain, urinary 
incontinence and possible S1 root compression on MRI but no CES.  All scan positive patients had 
improvement on follow up. 
Discussion 
Our prospective study demonstrates that a high proportion of patients with CES symptoms are ‘scan 
negative’.  CES represents an important disabling disorder and patients consume significant 
emergency resources. 
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Two previous retrospective studies found 43%(2) and 48%(1) of patients with CES were scan 
negative but were unable to determine any discriminating clinical features to help differentiate them 
from scan positive patients. Likewise in this study our ‘scan negative’ patients had similar CES 
symptoms and progression to the patients with imaging confirmed CES.   
However, on the basis of our clinical experience and the published literature, we propose the 
hypothesis that some of the ‘scan negative’ patients may be experiencing acute functional (non-
organic) weakness, numbness and possibly even urinary retention triggered by acute back pain1. We 
know that functional weakness can present with CES symptoms and that urinary symptoms are often 
present in patients with functional symptoms.  Functional limb weakness is commonly triggered by 
injury or pain and is commonly acute and “stroke like” with symptoms of panic or dissociation like 
these scan negative CES patients3. We were able to test this systematically in our prospective study 
and  found some preliminary evidence to support this hypothesis with the presence of a blinded 
assessment of Hoover’s sign of functional leg weakness (90% vs 0% ) a panic attack (72% vs 29%) 
symptoms of dissociation (45% vs 14%) all performing as possible useful discriminators in the clinical 
assessment of patients with CES symptoms. 
It could be that some of our ‘scan negative’ patients may have had a dynamic problem in the disc, 
with scanning in the supine position not demonstrating disc changes present when standing or 
flexed. Alternatively, other issues such as incomplete radiology or the presence of a non-structural 
causes for CES such as acute inflammatory or infectious lumbosacral polyradiculopathy or vasculitis 
which would not necessarily appear on imaging(1). Our MRI scans were reported by a consultant 
radiologist with an interest in spinal imaging or a consultant neuro-radiologist.  Rapid improvement 
and quick discharge in the majority of ‘scan negative’ patients and lack of any new explanation at 
follow up suggests that a missed structural or other organic cause of CES symptoms is unlikely. 
In some cases there could be acute on chronic sacral nerve degeneration.  This may only be found 
using bulbocavernous reflex or anal sphincter EMG testing which is not commonly performed 
although could be in patients with ongoing sacral nerve symptoms.   
Limitations of this data include: the small sample size and ability to detect differences between 
group; the risk of non-blinding influencing the data; possible missed alternative organic causes of 
CES symptoms in the ‘scan negative’ group; incomplete data in some cases (for example 4 of the 
‘scan positive’ CES patients could not be examined for a Hoover’s sign) and lack of detailed 
systematic follow up. 
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Our preliminary findings were in keeping with two previous studies, showing that ‘scan negative’ 
cauda equina syndrome accounts for up to half of cauda equina emergency admissions and is 
associated with similar disabling symptoms. What our prospective study adds is a new description of   
some positive clinical findings which may differentiate’ scan negative’ and ‘scan positive’ patients. 
MRI will continue to be an essential part of the investigation of all patients with possible CES, 
whether or not they have positive features of a functional disorder. However, if these findings are 
confirmed by larger prospective studies they may significantly alter the subsequent clinical 
management of those CES patients who are ‘scan negative’. Patients with functional limb weakness 
benefit from specific explanation and physiotherapy approach which emphasises the positive nature 
of the diagnosis.(4)  
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Conclusions:  This was the first study investigating whether a difference existed in a positive sign of a 
functional neurological disorder (Hoover’ sign of functional leg weakness) between patients with  
‘scan negative’ and ‘scan positive’ CES.  I found that patients with ‘scan negative’ CES were much 
more likely to have a positive Hoover’s sign (90% vs. 0%), although the numbers in the study were 
small.  I also found that there were some potentially important differences in reports of dissociation 
(45% vs 14%) and panic symptoms (72% vs 29%) between the groups which were not statistically 
significant but did provide further evidence to support a possible hypothesis in how uro-neurological 
and functional conditions overlap.  The study was limited by the small numbers of patients involved 
but provided useful pilot evidence supporting my PhD hypothesis. 
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Paper Four:  Hoeritzauer I, Pronin S, Carson A, Statham P, Demetriades AK, Stone J. The clinical 
features and outcome of scan-negative and scan-positive cases in suspected cauda equina 
syndrome: a retrospective study of 276 patients.  J Neurol. 2018 Dec;265(12):2916-2926. doi: 
10.1007/s00415-018-9078-2   
 
Introduction:   This study was designed to address Aims 1 and 2.  Aim 1: To determine what 
proportion of patients with ‘scan negative’ CES have a functional disorder by clinical consensus and 
Aim 2: To describe associated clinical features relevant to diagnosis, mechanism and aetiology in 
patients with Scan negative and scan positive CES.  I undertook a retrospective notes review of all 
patients who were referred with possible CES to the neurosurgeons between August 2013 and 
November 2014 investigating their clinical features, whether there was evidence of comorbid 
functional or psychiatric disorders and outcomes such as pain, re-presentation rate and long term 
bladder function.   
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Background: The majority of patients presenting with suspected clinical cauda equina syndrome 
(CES) have no identifiable structural cause for their symptoms (‘scan negative’ CES) Understanding 
these patients aids clinical differentiation and management in CES. 
Methods: A retrospective electronic notes review was undertaken of patients presenting with 
suspected CES, defined as ≥1 of acute bladder, bowel, sexual dysfunction or saddle numbness, to a 
regional neurosciences centre.  We investigated radiology, clinical features, psychiatric and 
functional disorder comorbidities and outcome of patients with ‘scan negative’ CES and patients 
with MRI confirmed compression of the cauda equina (‘scan positive’ CES). 
Results: 276 patients were seen over 16 months. There were three main radiologically defined 
patient groups:1. ‘scan positive’ CES(n=78, mean age 48yrs, 56% female), 2.‘scan negative’ CES 
without central canal stenosis but with lumbosacral nerve root compression not explaining the 
clinical presentation(n=87, mean age 43yrs, 68% female) and 3. ‘scan negative’ CES without neural 
compromise(n=104, mean age 42yrs, 70% female). 
In the two ‘scan negative’ groups (no neural compromise and nerve root compression) there were 
higher rates of functional disorders (37% and 29% vs. 9%), functional neurological disorders(12% and 
11% vs 0%) and psychiatric comorbidity(53% and 40% vs 20%). 
On follow up (mean 13-16months) only one of the 191 patients with ‘scan negative’ CES was 
diagnosed with an explanatory neurological disorder (transverse myelitis). 
Conclusions: The data supports a model in which scan negative cauda equina syndrome arises as an 
end pathway of acute pain, sometimes with partly structural findings and vulnerability to functional 
disorders. 
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The majority of patients presenting with clinically suspected cauda equina syndrome will 
have a normal or non-explanatory scan (‘scan negative’ CES). 
Roughly half the patients with ‘scan negative’ CES have some nerve root compression (L3-S2) 
not explaining the clinical presentation. 
Patients with ‘scan negative’ cauda equina syndrome are significantly more likely to have a 
functional disorder or psychiatric comorbidity. 
Patients with ‘scan negative’ cauda equina syndrome are significantly more likely to have 
chronic pain on follow up.  
Patients with ‘scan negative’ cauda equina syndrome are unlikely to have a new diagnosis 
explaining their symptoms on follow up. 
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Cauda equina syndrome (CES) is a devastating medical emergency caused by compression of the 
cauda equina nerve roots which without timely surgery results in bladder, bowel and sexual 
dysfunction with potential lower limb weakness and numbness[1]. Diagnosis is based on the clinical 
picture and MRI findings of cauda equina nerve root compression (‘scan positive’ CES).  However, at 
least half of all patients presenting with the acute clinical CES phenotype (acute bladder, bowel and 
sexual dysfunction, saddle anaesthesia and pain) have no radiological correlate, so called ‘scan 
negative’ CES.  A systematic review of the correlation between history, physical examination and 
MRI scan result found that the mean prevalence of patients having both clinical and radiological 
evidence of CES was 14-48% with no single individual sign or symptom being helpful in diagnosing 
CES[2]; senior neurosurgical trainees asked to predict who would have a positive scan based on 
history and clinical findings had an accuracy of only 56%[3].   
There has been little descriptive study of the ‘scan negative’ CES group but a better understanding of 
their presentation may aid clinical differentiation and management. Based on our clinical experience 
and an initial pilot study of 18 patients from a different centre which demonstrated Hoover’s sign of 
functional leg weakness in 82% of patients with ‘scan negative’ CES and 0% of patients with ‘scan 
positive’ CES, we hypothesised that some patients with ‘scan negative’ CES would have evidence of a 
functional disorder and this may explain at least some of their clinical presentation[4].  By a 
functional disorder we mean a disorder which is genuine but which is due to an abnormality of 
nervous system functioning rather than of structure[5].  Functional neurological disorders describe 
symptoms of abnormal motor and sensory function such as limb weakness or numbness, but does 
not include chronic pain, even when that is unrelated to a structural cause.  Common examples of 
functional disorders are irritable bowel syndrome and functional neurological disorders. We 
investigated the radiological findings, demographics, clinical features, comorbidity and outcomes of 
a retrospective consecutive series of patients referred to a tertiary neurosurgery centre with 
suspected clinical cauda equina syndrome.  Our aims were to better phenotype patients with ‘scan 
negative’ CES, to test our hypothesis that at least some patients had evidence of a functional 
disorder and to generate hypotheses about how functional disorders, medication, pain with or 
without nerve root compression may interact to explain the bladder symptoms that cause patients 
to present actuely with ‘scan negative’ CES. 
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MATERIALS AND METHODS 
Definitions 
Clinical CES was defined using the Fraser et al criteria for CES : one or more of bladder, bowel, sexual 
dysfunction or saddle numbness +/- lower limb neurological deficit[1].   
Radiological cauda equina compression was defined as >75% canal stenosis or lack of CSF around the 
cauda equina nerve roots[5]. ‘Impending’ CES was defined as a) Fraser et al clinical criteria b) an MRI 
scan showing a compressive lesion which was large enough to compress the cauda equina nerve 
roots but which did not meet our radiological criteria and c) the opinion of the consultant 
neurosurgeon that the compressive lesion was causing the clinical symptoms and would progress to 
irreversible CES unless urgently treated.  
Patients were defined as with ‘scan positive’ CES if they had both clinical and radiological evidence 
of CES or ‘impending’ CES based on the definitions above.  Patients were defined as ‘scan negative’ 
CES if they satisfied the Fraser et al criteria, had an urgent MRI scan for possible CES and had no 
evidence of radiological cauda equina compression on their MRI. 
Method 
Recruitment 
In July 2016 we carried out a retrospective electronic record review of consecutive referrals with 
possible cauda equina syndrome to our regional neurosurgery service in Edinburgh between August 
2013-November 2014 with electronic notes follow up until July 2016.  Consecutive neurosurgical 
referrals documented as possible cauda equina syndrome were reviewed manually by two of the 
authors (IH, SP).  Patients were only included in the study if they met clinical criteria for CES. All 
patients with ‘scan positive’ CES were included as they were all assessed in the local health board, 
NHS Lothian, and had clinical symptoms, comorbidities and follow up outpatient appointments 
recorded in NHS Lothian.  Many patients referred to the neurosurgery service were from other NHS 
Scotland regions with a different electronic notes record which it was not possible to access centrally 
and were not seen in NHS Lothian; these patients were not included.  To ensure  that clinical data 
and follow up were as complete as possible, patients with ‘scan negative’ CES were only included if 
referred from an address within the local health board with NHS Lothian documentation of their 
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signs and symptoms or referred via the local health board accident and emergency department. The 
study received local ethical approval from NHS Lothian (Caldiott Guardian ref 1594). 
Measures 
With respect to the initial admission, all patients had urgent MRI lumbosacral scans which included  
the cauda equina down to the S5 foramina of the sacrum.  A local protocol dictates that a T2 sagittal 
of cervical and thoracic spine should be done if the MRI lumbosacral spine is normal.  All scans were 
reported by a consultant neuroradiologist.  
Using a standardised proforma we assessed the radiological features, demographics, clinical 
symptoms and signs, completeness of clinical documentation, timing of operation (urgent: classified 
as during the initial admission; elective: classified as after discharge but scheduled due to symptoms 
and radiology from admission).  
We carried out follow-up using electronic records until July 2016 by interrogating scan requests, 
accident and emergency attendances, all secondary care inpatient and outpatient visits.  Information 
was obtained on:  functional disorder comorbidity (fibromyalgia; irritable bowel syndrome; chronic 
fatigue syndrome; non-cardiac chest pain); functional neurological disorders (as defined in DSM 5 
including functional motor disorders  and non-epileptic seizures); psychiatric comorbidity (such as 
anxiety/depression/Post traumatic stress disorder (PTSD)/personality disorder/ obsessive 
compulsive disorder(OCD)/suicidal ideation or deliberate overdose/ anorexia nervosa); the presence 
of chronic pain documented in letters; urological symptoms; re-presentations with clinically 
suspected CES and new diagnoses which explained suspected CES presentation in patients with ‘scan 
negative’ CES.  When patients had urological symptoms documented during their follow up, 
electronic notes were retrospectively reviewed back to 2009 to accurately document the onset of 
urological symptoms. 
Statistics  
Statistics used were Chi squared or Fisher’s exact two-sided testing for all symptoms, signs, 
comorbidities and outcomes.  ANOVA was used for comparing mean ages.  Statistics were carried 
out using Statsdirect (http://www.statsdirect.com). All p values are comparisons between one of the 
‘scan negative’ groups and the ‘scan positive’ group. 
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276 patients were referred with clinically suspected cauda equina syndrome between August 2013-
November 2014 (Table 1 and Supplementary Figure One). 
Radiological and Demographic findings 
During initial admission seven patients were found to have alternate neurological causes mimicking 
or causing sacral nerve dysfunction: two patients had evidence of demyelination on MRI of their 
thoracic cord and both were subsequently diagnosed with multiple sclerosis; two patients had 
infections causing bladder or sacral symptoms (urinary retention due to urosepsis (n=1) and systemic 
infection with abscess at L2/3 (n=1)); three patients had CES mimics, (thoracic subdural haematoma 
(n=1), L1 lumbar fracture (n=1) and metastatic epidural deposit causing thoracic cord compression 
(n=1)).  We excluded these seven patients from further analysis. 
Patients divided into three main radiological groups:  
- 78 had ‘scan positive’ clinico-radiological CES, including ‘impending’ CES (mean age 48yrs 
(range 21-91), 56% female), 
- 87 had ‘scan negative’ CES but with nerve root compression of at least one nerve root L3-S2 
(mean age 43yrs (range 20-79), 68% female). We separated this group on the grounds that 
some L3-S2 nerve root compression would not have caused sphincter dysfunction but may 
have impacted on bladder function or promoted functional motor/sensory symptoms in the 
legs. 
- 104 had ‘scan negative’ CES without neural compromise (mean age 42yrs (range 16-81), 70% 
female) 
We will continue with these subdivisions: ‘scan positive’ CES, ‘scan negative’ CES with root 
compression and ‘scan negative’ CES without neural compression, throughout the rest of the paper. 
 ‘Scan positive’ diagnoses and surgical timing 
Of the 78 patients with ‘scan positive’ CES, 67 (86%) were caused by disc protrusion, the other 
eleven had various lesions compressing the cauda equina nerve roots: n=4 fractures, n=4 had 
metastatic deposits, n=1 fracture and a metastasis, n=1 a primary tumour and n=1 large cyst.  
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68 patients (87%) with ‘scan positive’ CES had an emergency operation, seven were treated 
conservatively (n=2 too unwell, n=2 symptoms >1 week and resolving, n=2 metastatic deposits, n=1 
vertebral fracture).  In three of these patients sphincter symptoms of CES either turned out to have 
another cause or resolved but the patients were operated on electively anyway for leg pain. 
Sixteen patients with ‘scan negative’ CES had an operation, two urgently, both of whom had nerve 
root compression and severe pain which did not settle after admission, and fourteen electively for 
leg pain. 
Table One: Clinical Features of Scan positive and negative cauda equina syndrome 
 Scan +ve 
(n=78) 
n (%) 
Scan -ve with root 
compression (n=87) 
n (%)                   P value 
Scan -ve no root 
compression (n=104) 
n (%)                      P value 
 Age (mean, SD) 
Gender 













































Reduced awareness 4 (5%) 6 (7%) 3 (3%)  
Hesitancy/difficulty 
passing  
15 (19%) 18 (21%) 11 (11%)  
Mixed problems  0 3 (3%) 11 (11%)  0.01  
Normal 22 (28%) 15 (17%) 9 (9%) 0.0005 









Constipation 11 (14%) 8 (9%) 11 (11%) 
Reduced awareness 1  2 (2%) 2 (2%) 
Normal 27 (35%) 39 (45%) 42 (40%) 
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Bilateral Sciatica 32 (41%) 17 (20%)               <0.001 22 (21%)  0.001 
No 5 (6%) 7 (8%)  12 (11%)  

































18 (23%) 4 (5%)   13 (12%)   
Whole leg 1 (1%) 8 (9%)  9 (9%)   
No numbness 6 (8%) 20 (23%) 0.01 17 (16%)  
Non-dermatomal 
numbness 
2 (2%) 16 (18%) 0.001 16 (15%) 0.004 
Saddle numbness*  
 
50(64%) 47 (54%)  0.04 54 (52%)  0.02 
Normal 18 (23%) 35 (40%)  42 (40%)  
Digital rectal exam* 














1 refused (1%) 





















5   (5%) 
6   (6%) 
81 (78%) 
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P values refer to comparison against scan positive group and are only shown if significant 
SD*=standard deviation 
Saddle numbness*: as assessed by pin prick sensation 
 
Clinical features 
Urinary function (n=263, 98%), lower limb pain (n=250, 93%) saddle sensation (n=247, 92%), lower 
limb power (n=229, 85%) and sensation (n=225, 84%) were often documented.  Bowel function 
(n=177, 66%), anal tone from digital rectal examination (n=151, 56%) and sexual function (n=14, 5%) 
were poorly or very poorly documented. 
Symptoms 
Patients with scan positive CES were more likely to have symptoms of bilateral sciatica and, 
surprisingly, were less likely to have documented bladder dysfunction than patients in either of the 
‘scan negative’ CES groups (see table one).  These are two controversial findings so we reviewed 
them in detail.  Even when both ‘scan negative’ groups were combined bilateral sciatica was still 
significantly more likely in patients with ‘scan positive’ CES’ (38% vs. 20%, n=30/78 vs. n=39/191, 
p=0.002).  The patients with normal bladder function met our criteria as ‘impending’ cauda equina 
syndrome.  These patients all had radiological evidence of cauda equina compression and one or 
more other signs of clinical cauda equina syndrome, most commonly saddle numbness, documented 
in twenty patients or bowel or sexual dysfunction in four patients each. 
Signs 
Patients with ‘scan positive’ CES were more likely to have saddle numbness (64% vs 54% and 52%, 




Comorbidity functional and psychiatric disorders 
Both patient groups with ‘scan negative’ CES were more likely to have a comorbid functional 
disorder, functional neurological disorder and psychiatric diagnoses than patients with ‘scan 
positive’ CES when assessed at follow up in July 2016 (see Table Two).  The specificity of finding a 
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comorbid functional neurological disorder in ‘scan negative’ CES at presentation was 1 (0.95-1) 
although sensitivity was low, 0.09 (6-14). 
Table Two: Functional and Psychiatric Comorbidity in Scan positive and negative cauda equina 
syndrome 
 Scan +ve 
(n=78) 
(n) % 
Scan -ve with root 
compression (n=87) 
n (%)               P value 
Scan -ve no root 
compression (n=104) 
(n) %                    P value 
Functional Disorder 
comorbidity 
7 (9%) 26 (30%)  0.0007 39 (37%)  <0.0001 
Functional Disorders** 
Irritable Bowel Syndrome 
Non-cardiac chest pain 















































8   (10%) 
0 
















Timing of FND in relation 
to CES presentation 
Prior  












FND= Functional Neurological Disorder. OCD= obsessive compulsive disorder.  PTSD= post-
traumatic stress disorder. **Several patients had more than one disorder.   
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Outcomes: Pain, Re-presentation rate, and Bladder function 
There were no significant differences between the three groups in follow up frequency (93% vs. 89% 
and 87%) or mean duration of follow up (average 13 months, 16 months, 16months) (Table Three) 
Only one patient in the scan negative groups presented at follow up with an alternative neurological 
explanation for CES. This patient had transverse myelitis.  They had no comorbid functional 
disorders. 
Four patients with ‘scan positive’ CES (4%) re-presented during the study time with a new episode of 
clinical cauda equina syndrome, two of whom required re-operation.  Representations with possible 
cauda equina syndrome necessitating an urgent scan during follow up occurred in 22 of the 191 
patients (11%) with ‘scan negative’ CES, all of whom continued to have negative scans. Fifteen 
patients re-attended once, five re-attended twice and two patients re-attended three times (see 
breakdown in Table Three). Only five patients (23%) re-presented within one month suggesting their 
recurrent presentations related to one episode of ongoing symptoms, the other seventeen 
presented over a longer period suggesting multiple different episodes of symptom occurrence.  
Patients with ‘scan negative’ CES in both groups were more likely to have chronic pain recorded in 
the electronic patient record on follow up (26% vs 58% and 59%).   
Rates of bladder dysfunction in the electronic patient record were not significantly different in all 
groups.  Pre-existing bladder symptoms were found in two patients with ‘scan positive’ CES, one 
patient within the ‘scan negative’ CES with root compression group and in four patients in the ‘scan 
negative’ without neural compression group.  One patient from each group had prior episodes of 
urinary retention.  After CES presentation, idiopathic urinary retention affected one person in the 
‘scan negative’ with root compression group and three patients without neural compression.  
Table Three: Follow up and Outcomes 
 Scan +ve 
(n=78) 
n (%) 
Scan -ve with root 
compression (n=87) 
n (%)            P value 
Scan -ve no root 
compression (n=104)        
n (%)             P value 
Average follow up/ months 13 16 16 
No Follow up 10 (13%) 6 (7%) 12 (11%) 
Deceased or palliative 4  1 
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Cause of clinical CES found  100% 0 1  (1%) 




















Prior ‘scan positive’ CES 
Prior ‘scan negative’ CES 















































1 bladder outlet 
obstruction 
1 enuresis 
Timing of Urological 
diagnoses 
Before CES presentation 
Stress urinary incontinence 
Urge incontinence 
Idiopathic urinary retention 
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We found that patients with ‘scan positive’ and ‘scan negative’ CES presented with similar core 
symptoms. Saddle anaesthesia and bilateral sciatica with radicular sensory abnormalities were 
common in patients with ‘scan positive’ CES; whilst non-dermatomal sensory loss and mixed urinary 
problems were more commonly seen in patients with ‘scan negative’ CES.  However, as in previous 
studies, no individual clinical symptom or sign could accurately differentiate between scan positive 
and ‘scan negative’ CES[7]. The explanation for scan negative CES does not appear to be latent 
neurological disease, of which there are many causes (Table Four)[8–19], at least in the majority of 
patients, since we only found one patient where this was the case at follow up.  
The neurological differential diagnoses for ‘scan negative’ CES were considered by the authors and 
encompasses inflammatory, infectious, vascular, neoplastic and neurodegenerative disorders (Table 
four).  In some cases, these conditions can be difficult to diagnose and may present initially as 
peripheral disorders but are caused by central mechanisms.  This is particularly the case in patients 
with arteriovenous malformations including dural AV fistula[15]. Patients may present several times 
prior to diagnosis but symptoms are progressive and ultimately upper motor neurone signs appear.  
Transient infectious causes of lumbosacral polyradiculitis, such as Elsberg syndrome, caused by HSV, 
may also be difficult to pick up as lumbar puncture results normalise quickly and can have poor 
positive predictive value[12].  In a recent study at the Mayo clinic five patients over a 16year period 
were felt to have Elsberg sydnrome causing cauda equina radiculitis[12]. Bladder symptoms affect 
approximately 75% of patients with multiple sclerosis and are often cited as one of the most 
unpleasant symptoms by patients[8].  However, it is unusual for patients to present with bladder 
symptoms only and the diagnosis of multiple sclerosis is based upon clinical events and lesions 
separated in time and space. 
In keeping with our hypothesis, patients with ‘scan negative’ CES did have notably more functional 
somatic disorders, psychiatric comorbidity and especially functional neurological disorders than 
patients with scan positive CES who had similar sphincter and leg symptoms. The specificity for 
functional neurological disorders in this scenario for ‘scan negative’ CES was 1 (0.95-1) although 
sensitivity was 0.12 (7-17) with around half of patients developing their functional neurological 
disorders during their ‘scan negative’ CES presentations (Table Two).   
The data supports our earlier pilot study and strongly suggests that at least some patients with ‘scan 
negative’ CES have symptoms due to acute functional limb weakness, numbness and functional, pain 
or medication related urinary symptoms.  Our findings are in keeping with other studies showing 
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functional neurological disorders are commonly triggered by pain. For example a systematic review 
of 869 patients with functional motor and sensory symptoms found that physical injury preceded 
onset in  37% cases[20, 21].  In the last ten years the understanding and awareness of functional 
neurological disorders has increased significantly.  Diagnosis is made on the basis of positive clinical 
signs, such as Hoover’s sign of functional leg weakness – weakness of hip extension which 
normalises with contralateral hip flexion, which have good diagnostic sensitivity and specificity[22].  
A positive diagnosis and tailored physiotherapy seems to be more effective for functional motor 
disorder than standard treatment with 72% of patients improving in a recent randomised trial 
compared to only 18% of the control group[23]. Understanding of the mechanism of functional 
neurological disorders has expanded from Freudian ideas of conversion to Bayesian ideas of ‘top 
down’ expectation and abnormal self-directed attention overriding the normal sensory and motor 
pathways[24, 25]. 
Psychiatric disorders are not uncommon in the population however levels of 40 or 50% are higher 
than would be expected even in patients with chronic neurological disease[26] and in higher than 
psychiatric comorbidity in some studies of patients with chronic back pain[27].  Patients with 
avoidance and panic are more likely to develop chronic pain so knowledge and appropriate 
treatment of these comorbidities are important[28].  Urological symptoms requiring urology input 
were similar in both groups.  This is noteworthy given that urological symptoms are one of the most 
common reasons why patients with ‘scan positive’ CES must be urgently operated on.   High 
numbers of patients in the ‘scan negative’ groups represented with clinical CES requiring an urgent 
scan which was always negative. This suggests that not only are patients having recurrent symptoms 
which correlate with clinical CES, as per the Fraser et al criteria, but that they are high resource users 
and we should make more effort to understand and treat them. 
Hypothetical Mechanisms for ‘scan negative’ CES 
The excess of abnormal bladder symptoms in the patients with ‘scan negative’ CES were of particular 
interest and potentially counter to many clinicians expectations. There are several possible 
hypotheses about the origin of bladder symptoms in patients with ‘scan negative’ CES.  Firstly, pain 
causing sympathetic hyperactivity and increased inhibitory signals via the hypogastric and pelvic 
nerves could be resulting in increased contraction of the internal urethral sphincter and override 
normal voiding parasympathetic processes causing difficulty voiding.  Secondly, pain or panic may 
have exacerbated underlying bladder dysfunction including incontinence which occurs in up to one 
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fifth of middle aged women[29] and is more common in patients with anxiety and depression[30] or 
chronic back pain[31].  Thirdly, analgesic medications have significant effects on the bladder.  
Medications such as pregabalin, gabapentin and benzodiazepines can cause or exacerbate urinary 
incontinence[32, 33].  Opiates are well known to affect the bowels but the effect on the bladder, 
which if severe can lead to chronic urinary retention, is less well recognised[34]. Opiates can also 
cause severe constipation and there is a case report of constipation causing pelvic nerve entrapment 
and mimicking cauda equina syndrome[35].  From the authors experience, it is much more common 
that patients are constipated from medications and this results in more pain and difficulty passing a 
bowel motion. Fourthly, a cause of chronic urinary retention triggered by pain or medications is 
Fowler’s syndrome, which describes primary failure of the external urethral sphincter to relax.  
Patients with Fowler’s syndrome have high rates of chronic pain and functional neurological disorder 
comorbidity[36]. Fowlers syndrome has detectable neurophysiological changes and its aetiology 
remains uncertain but one possibility is that it represents a primary functional disorder of the 
urethral sphincter and a chronic model of the type of retention or voiding dysfunction seen in some 
patients with scan negative cauda equina. Lastly, previous studies of patients presenting for routine 
lumbar decompression found bladder symptoms in 55%[37] and an additional urodynamics study of 
a similar patient group found 26% had urodynamic evidence of detrusor areflexia all of whom 
reported abdominal straining to void[38].  This may be due to downstream effects of compression or 
inflammation from higher nerve roots, however, there was only one patient with idiopathic urinary 
retention in the ‘scan negative’ with root compression group on follow up so this explanation seems 
unlikely to be a major cause of symptoms in the ‘scan negative’ groups.  
Considering these ideas, we propose that at least some patients with scan negative CES patients can 
be best understood to have a functional disorder explaining some, or all, of their presentation.  We 
hypothesise that many patients have a vulnerability either to functional disorder and/or a prior 
underlying bladder dysmotility disorder.  In some cases, patients may respond to severe back muscle 
spasm or pain from disc herniation and nerve root entrapment with panic and dissociation> resulting 
in either inability to contract the pelvic floor causing incontinence or inability to relax the pelvic floor 
and urethral sphincter causing urinary retention.  Acute or long-term analgesia such as opiates may 
cause further retention, or gabapentinoids may cause incontinence, worsening the bladder 
dysfunction.  Patients then present to hospital with clinical CES where they typically receive 
reassurance (although no explanation for why they had sphincter symptoms), pain relief and 
physiotherapy.  However, for the 50% who develop chronic pain and the 11% who have recurrent 
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episodes of suspected CES, fear of movement and an attentional focus of symptoms may lead to 
deconditioning and a centrally generated pain syndrome with consequent inability to return to 
normal activity.  
Limitations 
The retrospective nature of the study and its dependence on electronic notes resulted in missing 
data. The design means that data about clinical features were not collected through routine practice 
and not systematically. This may explain our potentially controversial findings of bilateral sciatica 
being more common in patients with ‘scan positive’ CES, although we think this is unlikely, especially 
given the high rate of symptom documentation (95%).  Patients with ‘scan positive’ CES, including 
those with ‘impending’ CES, were more likely to have normal bladder function than patients with 
‘scan negative’ CES which also was an unexpected finding of our study.  The high frequency of 
missing data about sexual function was surprising and may be important in differentiating ‘scan 
positive’ from ‘scan negative’ CES.  Not all patients with normal radiology saw a neurologist, for 
example if they were discharged quickly. This means that functional comorbidity may have been 
underestimated.  All patients with ‘scan positive’ CES from South East Scotland were included 
whereas only ‘scan negative’ CES patients from a smaller area (NHS Lothian) with complete medical 
records were included so this study cannot be used to estimate CES incidence or compare incidence 
of ‘scan positive’ vs. ‘scan negative’ CES. However, this limitation means that scan negative CES is 
likely to be pileven more common than we have demonstrated in this study. Medication records 
were not accurate enough for inclusion in the study and this is a gap in the data.  Primary care data 
about outcome on follow up was not available and this may lead to an underestimation of urological 
or pain symptoms during follow up in all groups.  Some additional neurological diagnoses may have 
been missed however our departmental policy of a T2 sagittal MRI of the thoracic and cervical spine 
for lumbosacral scan negative CES identified seven patients who immediately obtained a non-CES 
diagnosis.  Only one additional diagnosis was found on follow up at 16 months with 88% follow up.  
and among the 22 patients who re-attended and were investigated again for ‘scan negative’ CES, no 
new diagnoses were made.  This suggests that alternative neurological diagnoses are unlikely to 
explain a high proportion of scan negative CES. We believe immediate investigation and diagnosis is 
one of the reasons there was only one new diagnosis at follow up. 
 
Conclusion 
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We found that of 276 consecutive CES patients 28% (n=78/276) were ‘scan positive’, 69% 
(n=191/276) were ‘scan negative’ and 3% (n=7/276) had an alternative cause mimicking or causing 
sacral nerve dysfunction.  There was no single clinical feature which differentiated between the 
groups. Of the scan negative patients, just under half of patients had a nerve root compression that 
may have contributed but did not explain their clinical presentation.  These patients with ‘scan 
negative’ CES were more likely to have comorbid psychiatric and functional disorders and have 
chronic pain on follow up.  The data support a model in which ‘scan negative’ cauda equina arises as 
an end pathway of acute pain, sometimes with partly structural causes, medication side effects and 
vulnerability to functional disorder.  A prospective study with systematically collected clinical data, 
additional imaging and neurological assessment would reduce these limitations.  
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Table Four: Uro-Neurological Differential Diagnoses of clinical Cauda Equina Syndrome with 
Normal MR Imaging   
 Urinary Retention Urinary Incontinence 






Myelitis especially Neuro Myelitis 














Neoplastic: Neoplastic or radiation induced[18] 
Neurodegenerative:  Multiple System Atrophy[19] Parkinson’s Disease[19] 
Urological Differential Diagnoses 
 Fowler’s Syndrome[10] 
Idiopathic Urinary Retention 
Exacerbation of prior urinary 
incontinence (affects 20% women 
over 40)[29] 
Bladder Pain Syndrome[11] 





NSAIDs (risk increases in 





ACE inhibitors/ Diuretics 
Other Possibilities Pain: radiculopathy is a common comorbidity 
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Supplementary Table One: Total ‘scan positive’ CES group vs. combined ‘Scan negative’ CES 
groups 
 Scan positive CES 
(n=78)
  
Scan negative CES 
(n=191) 
Significance;  
two sided Fisher’s 
exact test 
(p<0.05) 
Weakness  (37/60 recorded) 61% (99/171 recorded) 58% 0.7 
Numbness (49/ 52 recorded) 94% (111/148 recorded) 75% 0.002 
Urinary symptoms (57/74 recorded) 77% (165/189 recorded) 87% 0.05 
Bowel symptoms (25/45 recorded) 77% (51/131) 39% 0.06 
Bilateral sciatica (31/73) 40% (39/190) 20% 0.005 
Saddle numbness (50/66) 76% (102/179) 60% 0.007 
Functional 
comorbidity 
5 (6%)  62 (32%)  0.0001 












(17/78) 22% (88/191) 46% 0.0002 
Outcome: chronic 
pain 
(20/78) 26% (97/191) 51%  0.0001 
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Post void residual    1 
Gynaecology 
Review*  
 1 4 
Urology Review*  1 2  
Trail removal of 
catheter 
1   
Urethrogram 1   
Uroflowmetry 2 2  
Cystoscopy  3 2 
Urodynamics 1  2 
Video-urodynamics 2   
Other 1 no information 
but referred to 
urology 
1 UTI diagnosed by 
neurosurgical team 
 
*= no additional investigations 
 




The Clinical Features and Prognosis of ‘Scan Negative’ 






1.  Fraser S, Roberts L, Murphy E (2009) Cauda equina syndrome: a literature review of its 
definition and clinical presentation. Arch Phys Med Rehabil 90:1964–8 . doi: 
10.1016/j.apmr.2009.03.021 
2.  Fairbank J, Hashimoto R, Dailey A, Patel A a, Dettori JR (2011) Does patient history and 
physical examination predict MRI proven cauda equina syndrome? Evid Based Spine Care J 
2:27–33 . doi: 10.1055/s-0031-1274754 
3.  Bell DA, Collie D, Statham PF (2007) Cauda equina syndrome: what is the correlation between 
clinical assessment and MRI scanning? Br J Neurosurg 21:201–203 . doi: 
10.1080/02688690701317144 
4.  Hoeritzauer I, Doherty C, Thomson S, Kee R, Carson A, Eames N, Stone J (2015) “Scan 
Negative” Cauda Equina Syndrome: evidence of functional disorder from a prospective case 
series. Br J Neurosurg 1–3 
5.  Stone J, Carson A (2015) Functional Neurologic Disorders. Contin (Minneap Minn) 21:818–837 
. doi: 10.1212/01.CON.0000466669.02477.45 
6.  Delamarter RB, Sherman JE, Carr JB (1991) 1991 Volvo Award in experimental studies. Cauda 
equina syndrome: neurologic recovery following immediate, early, or late decompression. 
Spine (Phila. Pa. 1976). 16:1022–1029 
7.  Todd N V. (2018) Quantifying the clinical aspects of the cauda equina syndrome – The Cauda 
Scale (TCS). Br J Neurosurg 32:260–263 . doi: 10.1080/02688697.2018.1441975 
8.  Panicker JN, Fowler CJ (2015) Lower urinary tract dysfunction in patients with multiple 
sclerosis, 1st ed. Elsevier B.V. 
9.  Mutch K, Zhao S, Hamid S, Methley A, Elsone L, Singh G, Young C, Emmanuel A, Panicker J, 
Jacob A (2015) Bladder and bowel dysfunction affect quality of life. A cross sectional study of 
60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. Mult 
Scler Relat Disord 4:614–618 . doi: 10.1016/j.msard.2015.07.015 
10.  Swinn MJ, Fowler CJ (2001) Isolated urinary retention in young women , or Fowler ’ s 
syndrome. Clin Auton Res 11:309–311 
11.  Reynolds WS, Mock S, Zhang X, Kaufman M, Wein A, Bruehl S, Dmochowski R (2017) Somatic 
syndromes and chronic pain in women with overactive bladder. Neurourol Urodyn 36:1113–
1118 . doi: 10.1002/nau.23060 
12.  Savoldi F, Kaufmann TJ, Flanagan EP, Toledano M, Weinshenker BG (2017) Elsberg syndrome. 
Neurol - Neuroimmunol Neuroinflammation 4:e355 . doi: 10.1212/NXI.0000000000000355 
13.  Sakakibara R, Yamanishi T, Uchiyama T, Hattori T (2006) Acute urinary retention due to 
benign inflammatory nervous diseases. Steinkopff-Verlag 
14.  Smith MD, Seth JH, Fowler CJ, Miller RF, Panicker JN (2013) Urinary retention for the 
neurologist. Pract Neurol 13:288–91 . doi: 10.1136/practneurol-2012-000478 
15.  Jellema K, Tijssen CC, van Gijn J (2006) Spinal dural arteriovenous fistulas: a congestive 
myelopathy that initially mimics a peripheral nerve disorder. Brain 129:3150–64 . doi: 
10.1093/brain/awl220 
16.  Jeong SJ, Cho SY, Oh SJ (2010) Spinal cord/brain injury and the neurogenic bladder. Urol Clin 
North Am 37:537–546 . doi: 10.1016/j.ucl.2010.06.005 
17.  Romi F, Naess H (2011) Characteristics of spinal cord stroke in clinical neurology. Eur Neurol 
66:305–9 . doi: 10.1159/000332616 
18.  Liberman D, Mehus B, Elliott SP (2014) Urinary adverse effects of pelvic radiotherapy. Transl 
Androl Urol 3:186–95 . doi: 10.3978/j.issn.2223-4683.2014.04.01 
The Clinical Features and Prognosis of ‘Scan Negative’ 




19.  McDonald C, Winge K, Burn DJ (2017) Lower urinary tract symptoms in Parkinson’s disease: 
Prevalence, aetiology and management. Parkinsonism Relat Disord 35:8–16 . doi: 
10.1016/j.parkreldis.2016.10.024 
20.  Stone J, Carson A, Aditya H, Prescott R, Zaubi M, Warlow C, Sharpe M (2009) The role of 
physical injury in motor and sensory conversion symptoms: a systematic and narrative 
review. JPsychosomRes 66:383–390 
21.  Pareés I, Kojovic M, Pires C, Rubio-Agusti I, Saifee T a., Sadnicka A, Kassavetis P, Macerollo A, 
Bhatia KP, Carson A, Stone J, Edwards MJ (2014) Physical precipitating factors in functional 
movement disorders. J Neurol Sci 338:174–177 . doi: 10.1016/j.jns.2013.12.046 
22.  Daum C, Gheorghita F, Spatola M, Stojanova V, Medlin F, Vingerhoets F, Berney A, Gholam-
Rezaee M, Maccaferri GE, Hubschmid M, Aybek S (2015) Interobserver agreement and 
validity of bedside ‘positive signs’ for functional weakness, sensory and gait disorders in 
conversion disorder: a pilot study. J Neurol Neurosurg Psychiatry 86:425–430 . doi: 
10.1136/jnnp-2013-307381 
23.  Nielsen G, Buszewicz M, Stevenson F, Hunter R, Holt K, Dudziec M, Ricciardi L, Marsden J, 
Joyce E, Edwards M (2016) Randomised feasibility study of physiotherapy for patients with 
functional motor symptoms. J Neurol Neurosurg Psychiatry jnnp-2016-314408 . doi: 
10.1136/jnnp-2016-314408 
24.  Edwards MJ, Adams R a., Brown H, Pareés I, Friston KJ, Parees I, Friston KJ (2012) A Bayesian 
account of “hysteria.” Brain 135:3495–3512 . doi: 10.1093/brain/aws129 
25.  Van den Bergh O, Witthöft M, Petersen S, Brown RJ (2017) Symptoms and the body: Taking 
the inferential leap. Neurosci. Biobehav. Rev. 74:185–203 
26.  Dissanayaka NNW, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, Marsh R, 
Mellick GD (2010) Anxiety disorders in Parkinson’s disease: Prevalence and risk factors. Mov 
Disord 25:838–845 . doi: 10.1002/mds.22833 
27.  Reme SE, Tangen T, Moe T, Eriksen HR (2011) Prevalence of psychiatric disorders in sick listed 
chronic low back pain patients. Eur J Pain 15:1075–1080 . doi: 10.1016/j.ejpain.2011.04.012 
28.  Naylor B, Boag S, Gustin SM (2017) New evidence for a pain personality? A critical review of 
the last 120 years of pain and personality. Scand J Pain 17:58–67 . doi: 
10.1016/J.SJPAIN.2017.07.011 
29.  Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein  a. J (2001) How widespread are 
the symptoms of an overactive bladder and how are they managed? A population-based 
prevalence study. BJU Int 87:760–766 . doi: 10.1046/j.1464-410X.2001.02228.x 
30.  Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C (2015) 
Affective symptoms and the overactive bladder — A systematic review. J Psychosom Res 
78:95–108 . doi: 10.1016/j.jpsychores.2014.11.019 
31.  Bush HM, Pagorek S, Kuperstein J, Guo J, Ballert KN, Crofford LJ (2013) The Association of 
Chronic Back Pain and Stress Urinary Incontinence: A Cross-Sectional Study. J Womens Health 
Phys Therap 37:11–18 . doi: 10.1097/JWH.0b013e31828c1ab3 
32.  Tsakiris P, Oelke M, Michel MC (2008) Drug-induced urinary incontinence. Drugs and Aging 
25:541–549 
33.  Kibar S, Demir S, Sezer N, Köseoğlu BF, Dalyan Aras M, Kesikburun B, sun, Dalyan Aras M, 
Kesikburun B (2015) Gabapentin-Induced Urinary Incontinence: A Rare Side Effect in Patients 
with Neuropathic Pain. Case Rep Neurol Med 2015:1–3 . doi: 10.1155/2015/341573 
34.  Panicker JN, Game X, Khan S, Kessler TM, Gonzales G, Elneil S, Fowler CJ (2012) The possible 
role of opiates in women with chronic urinary retention: observations from a prospective 
clinical study. J Urol 188:480–4 . doi: 10.1016/j.juro.2012.04.011 
35.  Lawrentschuk N, Nguyen H (2005) Cauda equina syndrome secondary to constipation: An 
The Clinical Features and Prognosis of ‘Scan Negative’ 




uncommon occurrence. ANZ J Surg 75:498–500 . doi: 10.1111/j.1445-2197.2005.03404.x 
36.  Hoeritzauer I, Stone J, Fowler C, Elneil-Coker S, Carson A, Panicker J (2016) Fowler’s syndrome 
of urinary retention: A retrospective study of co-morbidity. Neurourol Urodyn 35:601–603 . 
doi: 10.1002/nau.22758 
37.  Perner A, Andersen J, Juhler M (1997) LUTS in lumbar root compression syndromes. Spine 
(Phila Pa 1976) 22:2693–2697 
38.  Bartolin Z, Savic I, Persec Z (2002) Relationship between clinical data and urodynamic findings 




The Clinical Features and Prognosis of ‘Scan Negative’ 




Conclusions:  The data led me to split the patients into three groups, those with purely negative 
scans, patients with some nerve root entrapment and patients with ‘scan positive’ CES to assess for 
step wise progression of functional symptoms and signs. Only one of the 191 patients with ‘scan 
negative’ CES, had a diagnosis which explained their clinical CES presentation despite a notes follow 
up of an average of 15months.   
 
Clinical features which were statistically different between the groups included saddle anaesthesia 
and bilateral sciatica, which were more common in the ‘scan positive’ CES group and non-
dermatomal sensory loss in the ‘scan negative’ CES groups.  Functional somatic disorder, psychiatric 
disorders and functional neurological disorders were more common in patients with ‘scan negative’ 
CES. The study of 276 patients demonstrated that 12% (n=23) of patients with normal or non-
explanatory MRI imaging, ‘scan negative’ CES had evidence of a functional neurological disorder.   
 
 I explored possible mechanisms and aetiology of ‘scan negative’ CES focusing on bladder 
dysfunction.  Mechanisms and aetiology discussed including pain overriding normal bladder 
function, exacerbation of commonly occurring bladder dysfunction by pain, panic or medications, 
functional or idiopathic urological problems such as Fowler’s syndrome.  I also explored evidence of 
downstream urological effects caused by higher nerve root compression, although I felt this was 
more unlikely.  A model of how ‘scan negative’ CES may occur as a functional neurological disorder 
was put forward. 
 
The study was limited by its retrospective nature, by the limitations of a notes review and by the 
definitions of CES.  As a retrospective review it was able to investigate the functional comorbidity 
only in so far as it was recorded, which often depended on the patient being seen by a different 
speciality.  The low numbers seen by neurology may suggest that patients with ‘scan negative’ CES 
have symptoms which spontaneously improve but a prospective study was required to investigate 
this and mechanistic hypotheses further. 
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Paper Five: Ingrid Hoeritzauer1,2, Alan Carson1,2,3, Patrick 
Statham4, Jalesh Panicker5, Voula Granitsiotis6, Maria Eugenicos7, David Summers7, Andreas K. 
Demetriades4, Jon Stone1,2  “Scan Negative” Cauda Equina Syndrome: a prospective case control 
study   
 
Introduction: This study was designed to address Aims 1 and 2, building upon the learning from the 
retrospective study.  Aim 1: To determine what proportion of patients with ‘scan negative’ CES have 
a functional disorder by clinical consensus and Aim 2: To describe associated clinical features 
relevant to diagnosis, mechanism and aetiology in patients with Scan negative and scan positive CES. 
I identified and recruited consecutive patients who presented to Edinburgh neurosurgery with 
clinical CES.    198 patients agreed to take part and undergo a semi-structured interview, 
neurological examination and questionnaires with follow up questionnaires at three months. 
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Cauda equina syndrome (CES) is a surgical emergency with major clinical and medicolegal 
consequences.  Yet, between 60 and 100% of patients presenting with clinical CES have no 
identifiable structural lesion causing their symptoms (‘scan negative’ CES).  We planned the first 
large prospective case-control study phenotyping patients with ‘scan negative’ CES in order to 
improve clinical differentiation and management of CES. We carried out a prospective study of 
consecutive patients presenting with the clinical features of CES to a regional neurosurgery centre 
over 28 months comprising semi-structured interview, examination and questionnaire.  198 patients 
presented consecutively over 28 months.  47 were diagnosed with ‘scan positive’ CES (mean age 
48yrs, 43% female).  76 patients had some evidence of nerve root compression or displacement and 
were placed into a ‘mixed’ category (mean age 46yrs, 71% female) and 61 patients had ‘scan 
negative’ CES (mean age 40yrs, 77% female).  Fourteen patients were given an alternative 
neurological diagnosis explaining their clinical CES symptoms during admission. Patients with ‘scan 
positive’ CES were more likely to have chronic leg pain (20% ‘scan positive’ CES vs. 6% and 2% mixed 
and ‘scan negative’ CES groups, p=0.04, p=0.004) and reduced or lost bilateral ankle jerks (78% vs. 
30% and 12%, p=<0.0001).  Patients with ‘scan negative’ CES had more positive signs of a functional 
neurological disorder on examination (11% v. 34% and 68%, p=<0.0001) despite similar rates prior to 
admission (2% vs. 7% and 16%, p=0.5). They were more likely to have their worst ever back pain 
(41% vs. 46% and 70%, p=0.005) and symptoms of a panic attack (37% vs. 57% and 70%, p=0.001) at 
symptom onset.   
Signs typically used to differentiate between ‘scan positive’ and ‘scan negative’ CES such as reduced 
anal tone, saddle numbness and urinary retention showed no significant differences. 
Four patients out of 151 (4%, mixed group n=3, ‘scan negative’ group n=1) had a neurological 
diagnosis after discharge which potentially explained their clinical CES presentation (CNS 
inflammatory disorders (n=2), sacral chordoma (n=1), cervical epidural haematoma(n=1).  The first 
well phenotyped, prospective study of patients with ‘scan negative’ CES, supports the hypothesis 
that many such presentations arise from acute pain and have features consistent with a functional 
disorders.   
 
The Clinical Features and Prognosis of ‘Scan Negative’ 






Cauda Equina Syndrome is a surgical emergency caused by compression of the cauda equina nerve 
roots. It is suspected when patients present with new back or leg pain accompanied by bladder, 
bowel, sexual dysfunction or saddle numbness.  An MRI scan is required to demonstrate cauda 
equina compression and it is recommended that this occurs within 1-4 hours of presentation to 
hospital, creating significant pressure on emergency care, neurosurgical, orthopaedic and radiology 
staff to provide a responsive 24 hour service (Haworth et al., 2013; Todd and Dickson, 2016).  
However, a mean of 81% of patients referred to neurosurgery with cauda equina syndrome (CES) 
have normal or non-explanatory imaging, ‘scan negative’ CES (Hoeritzauer et al., 2019) despite 
having similar rates of pain, bladder and neurological dysfunction.  These patients have never been 
prospectively studied and the mechanism underpinning symptom presentation in ‘scan negative’ 
CES is unknown.   Two previous studies suggest that at least some of the patients presenting with 
‘scan negative’ CES have symptoms partially or fully explained by functional neurological disorders 
(Hoeritzauer et al., 2015, 2018).  This hypothesis has not been tested in a large prospective study   
We aimed to use a case control design to prospectively phenotype patients with ‘scan negative’ CES, 
comparing their radiological findings, clinical features, level of functional disorders and psychological 
comorbidities, and clinical outcome with patient with ‘scan positive’ CES. 
 
Materials and methods 
 
Definitions and Classification of CES patients in this study 
Clinical CES was determined by the Fraser et al definition of: one or more of acute bladder, bowel, 
sexual dysfunction or saddle numbness +/- leg or back pain(Fraser et al., 2009));  
Radiological findings were divided into: 1) ‘scan positive’ cauda equina syndrome - defined as 
compression of the cauda equina nerve roots with >75% central canal occlusion or no CSF around 
the cauda equina nerve roots on axial view(Delamarter et al., 1991); 2) a ‘mixed’ category not 
meeting radiological criteria for cauda equina compression but with some radiological evidence of 
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nerve root compression or displacement 3) ‘scan negative’ cauda equina syndrome with no nerve 
root compression or other radiological reason for any of their clinical CES symptoms; 4) neurological 
or other diagnoses explaining clinical CES presentation identified during admission. 
 
Setting and Recruitment  
A prospective study of consecutive patients with clinical cauda equina syndrome presenting to a 
secondary care regional neurosurgery centre at the Western General Hospital, Edinburgh serving a 
population of over 1.3 million (Carter et al., 2001).  Patients were included if they had: 1) Clinically 
defined CES presentation 2) the presentation necessitated a scan to exclude ‘scan positive’ cauda 
equina compression.  Recruitment was undertaken between November 2015 and December 2017. 
Patients were identified through the daily neurosurgery handover.  Patients were given an 
information leaflet by a member of their clinical care team in person or by post and if interested in 
the study were consented by one of the authors for interview, examination and questionnaire (IH).  
They were seen either during their inpatient stay, or if they had been discharged quickly, were 
contacted by post and were offered the opportunity to take part in the questionnaire components of 
the study (September 2016 - February 2017).   
 
Neuroimaging and other investigations 
All patients with CES symptoms and a normal lumbosacral MRI scan received a T2 sagittal MRI scan 
of the cervical and thoracic spine as per the local neuroradiology protocol.  MRI brain scan and other 
investigations such as lumbar puncture were carried out at the discretion of the clinical team.  All 
scans were reported by a consultant neuroradiologist. 
 
Structured Interview and Examination 
A semi-structured interview encompassed demographics, work status, clinical symptoms including; 
back pain and leg pain (including assessment of S1 radicular pain: “did your leg pain radiate down 
the back of your leg to your ankle?”), leg numbness and arm weakness. Back and leg pain were rated 
by patients on a four-point Likert scale; ‘worst ever’, ‘severe’, ‘somewhat painful’, ‘not very painful’.  
Additional clinical symptoms enquired about included; panic attack at onset as defined by DSM-5 (≥  
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four specific panic symptoms reaching a peak within 10 minutes) ; dissociative symptoms (“did you 
feel disconnected from part of all of your body or disconnected from your surroundings?”(Stone, 
2006)) and; current and prior bladder symptoms based on definitions from the Urogenital Distress 
Index: urge incontinence, stress incontinence, other incontinence, difficulty voiding(Shumaker et al., 
1994).  Medications patients were taking when admitted were recorded which were likely to be 
associated with bladder dysfunction either retention; opiates (classed as tramadol or stronger), 
benzodiazepines, codeine and tricyclics or incontinence; gabapentinoids, or benzodiazepines 
(Tsakiris et al., 2008; Verhamme et al., 2008; Kibar et al., 2015).  Several of these medications also 
have negative effects on sexual function (opiates, gabapentinoids, codeine, tricyclics). 
The structured interview also included past or current history of functional disorders (functional 
neurological disorder, irritable bowel syndrome, chronic pain, chronic fatigue syndrome, non-cardiac 
chest pain) and the structured clinical interview for DSM-IV for current depression, past depression, 
panic disorder, agoraphobia, health anxiety, generalised anxiety disorder, obsessive compulsive 
disorder and post-traumatic stress disorder. IH was trained and supervised in the structured clinical 
interview for DSM-IV, and all case histories were reviewed blind to the diagnosis for the first twelve 
months and thereafter when the diagnosis was unclear by author AC.   
A full neurological examination was carried out by IH or recorded from the notes if the patient 
declined.  Routine clinical testing for CES including saddle sensation, anal tone and post void bladder 
scanning was done by the neurosurgical registrars or other members of the clinical team and 
recorded from the clinical notes.  Functional neurological disorders were diagnosed according to 
DSM-5 criteria on the basis of positive evidence from the clinical presentation and examination by 
IH(Daum et al., 2015) (Hoover’s sign and thigh abductor sign of functional leg weakness, collapsing 
weakness, whole leg non-dermatomal sensory loss, hemisensory loss, dragging gait with hip 
externally or internally rotated, clinical symptoms of persistent postural perceptual 
dizziness((Popkirov et al., 2018). Features were also sought for other neurological disorders which 
may present as ‘scan negative’ CES, such as inflammatory, infectious, vascular, neurodegenerative 
and neoplastic causes (Hoeritzauer et al., 2018).  Abnormal findings were discussed with one of the 
authors (JS). 
Questionnaires 
We administered patient-reported questionnaires about bladder (Urinary Symptom Profile; 
measuring stress incontinence, overactive bladder symptoms and low stream) (Haab et al., 2008), 
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bowel (Neurogenic Bowel Dysfunction Score(Krogh et al., 2006)),  sexual function (Arizona Sexual 
Experiences Questionnaire (McGahuey et al., 2000)), quality of life (Work and Social Adjustment 
Scale), physical function (SF-12 physical function scale), somatic symptoms (Patient Health 
Questionnaire Somatic Symptom Severity Score PHQ-15), anxiety and depression (Hospital Anxiety 
and Depression Scale), dissociation (Peritraumatic Dissociation Questionnaire) and adverse 
childhood experience (Adverse Childhood Experiences questionnaire (Kandel and Davies, 1982)) . In 
an effort to understand premorbid health status patients were additionally asked to fill out all of the 
scales above, apart from illness perception and adverse childhood experience, based upon the 
month prior to symptom onset.   
 
Follow Up -Clinical Outcome and Diagnosis 
Repeat questionnaires were sent out three months after discharge regarding bladder, bowel, sexual 
function, quality of life, physical function, somatic symptoms, anxiety and depression and outpatient 
follow up appointments.  
Diagnostic follow up was carried out using electronic notes review in the ‘scan negative’ and mixed 
groups in October 2018 to determine whether patients had developed a neurological, urological or 
other condition which, with the benefit of hindsight, explained their initial clinical CES symptoms. 
Statistical Analysis 
Questionnaires were only analysed if fully complete. Data was tested for normality with the Shapiro-
Wilk test.  Chi squared 2xk, Fisher’s exact two-sided testing and Mann Whitney U tests were 
performed with scan positive CES as the control group using Statsdirect 
(http://www.statsdirect.com). 
Data Availability 
The authors confirm that the data supporting the findings of this study are available within the 
article and its supplementary material. 
The study received formal ethical approval by the NHS Grampian Research Ethics Committee (Study 
ID 15/NS/0112 - IRAS Project ID: 192413www.clinicaltrials.gov NCT03325374).   
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Recruitment, Radiology and Demographics 
198 patients were consecutively recruited over 24 months and an additional 28 patients declined to 
participate (mean 48yrs old, 71% female).   177 patients were seen as an inpatient.  Twenty-one 
patients were recruited after discharge for questionnaires only (‘scan positive’ CES (n=6), mixed 
(n=9), ‘scan negative’ CES (n=5), alternative neurological cause of CES (n=1). 
 
47 patients (24%) had ‘scan positive’ CES (43% female, average age 48yrs old). 76 patients (38%) 
were in the mixed category (71% female, average age 46yrs old).  Radiologically the ‘mixed’ group 
comprised cauda equina crowding (n=25), bilateral nerve root compression (n=5), unilateral nerve 
root compression (n=27) and unilateral nerve root displacement (n=19).  62 patients (31%) were in 
the ‘scan negative’ CES group (77% female, average age 40yrs old).  Finally, 13 additional patients 
(7%) were identified as having alternate aetiologies which explained their clinical CES presentation 
during or in the immediate aftermath of the initial inpatient admission (54% female, average age 
48yrs old); inflammatory cord lesions (n=4) and one each of acute inflammatory demyelinating 
polyneuropathy, probable paraneoplastic lumbosacral polyradiculitis, high lumbar fracture, abscess, 
discitis, cervical myelopathy, cord infarct, lumbosacral plexus injury following vaginal delivery and 
extraspinal renal tumour.  Data from these thirteen patients was excluded from further analysis. 
81% of patients with ‘scan positive’ CES returned their questionnaires (n=38), 80% of patients in the 
mixed group (n=61) and 66% of patients with ‘scan negative’ CES (n=41).   
 
Clinical Features  
Symptoms 
Patients with ‘scan positive’ CES were significantly more likely than patients in the mixed or ’scan 
negative’ CES groups to describe saddle numbness (73% v. 52% and 53%, p=<0.003 p=0.04) and have 
had leg pain for >3 months (20% v. 6% and 2%, p=0.04, p=0.004).  (Table One) 
At onset of symptoms patients in both the mixed and ‘scan negative’ CES groups were significantly 
more likely to meet DSM-5 criteria for a panic attack (37% v. 57% and 70% p=0.046 and p=0.001).  
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Patients with ‘scan negative’ CES were significantly more likely to describe having their ‘worst ever’ 
back pain (41% v. 46% and 70%, p=0.005) and report dissociation (32% v. 39% and 65%, p=0.03) at 
onset.  On admission patients with ‘scan negative’ CES described more leg weakness, including 
bilateral leg weakness (17% v. 18% and 39%, p=0.02), leg pain which was not in keeping with an S1 
radiculopathy (5% v. 18% and 33%, p=0.0005) and arm weakness (7% v. 10% and 23% p=0.04).   
At admission, the prevalence of all forms of incontinence urge and stress and voiding difficulties was 
similar between groups in the semi-structed interview.  However, in the month prior to admission 
patients with ‘scan negative’ CES described higher rates of urge, stress and other incontinence 
(Supplementary Table One). 
 
Signs 
Four patients in the ‘scan positive’ group, six patients in the mixed group and four patients in  ‘scan 
negative’ group refused examination.  Routine examination findings were taken from the notes.   
Patients with ‘scan positive’ CES were significantly more likely to have reduced or absent bilateral 
ankle jerks than patients in the mixed or ‘scan negative’ CES groups (78% vs 30% vs 12%) (Table 
One).  Patients with ‘scan positive’ CES were also more likely to have abnormal saddle pinprick 
sensation that patients in the mixed group (75% v. 55%, p=0.04) but not than patients with ‘scan 
negative’ CES (75% vs. 70%, p=0.6).   
Despite patients in both the mixed and ‘scan negative’ CES groups being more likely to complain of 
leg weakness, on examination all three groups had similar proportions of patients with leg weakness 
(46% v. 47% and 49%, p=0.9. p=0.8).    Positive signs of a functional neurological disorder causing 
weakness, sensory or gait disturbance were more common in the mixed and ‘scan negative’ CES 
group; overall positive signs (11% v. 34% and 68%, p=0.009, p=<0.0001), in those with leg weakness 
(16% v. 42% and 71%, p=0.002, p=<0.0001), positive functional sensory signs (3% v. 25% and 49%, 
p=0.002, p=<0.0001).    
Abnormal anal tone on digital rectal examination and post void residual of >200mls or >500mls were 
unhelpful in differentiating between the three groups (Table Two). 
 
Medications on admission 
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When admitted the majority of patients in all three groups were on at least one analgesic associated 
with bladder +/- sexual dysfunction (88% v. 81% and 82%).  Patients with ‘scan negative’ CES were 
more likely to be taking benzodiazepines (12% v. 18% and 32%, p=0.01), opiate use was similar 
across all three groups (32% v. 42% and 45%). See Table Two.   
 
Table One: Symptoms and Signs at Onset and on admission 




P value  ‘Scan negative’ 
CES n=57 
P value 
Mean age 48yrs 46yrs  40yrs  
Female % 43% 71%  77%  
SYMPTOMS – at onset n % n %  n %  
“Worst ever” back pain 17  41% 31 (46%) 0.6 40 (70%) 0.005 
Meet DSM 5 criteria for 
Panic Attack  15 37% 38  57% 0.046 40  70% 
 
0.001 
SYMPTOMS  – on 
admission n % n %  n % 
 
Leg weakness 25  61% 52  78% 0.07 49  86% 0.006 
Both legs weak 7  17% 12  18% 0.9 22  39% 0.02 
Both legs numb 13  32% 14  21% 0.2 20  35% 0.7 
Unilateral sciatica 19  46% 36  54% 0.5 18  19% 0.1 
Bilateral sciatica  15  37% 14  21% 0.08 14  25% 0.2 
Non dermatomal leg pain 2  5% 12  18% 0.051 19  33% 0.0005 
Arm weakness 3  7% 14  22% 0.06 15  27% 0.04 
Neurogenic Claudication  13  27% 15  22% 0.3 11  19% 0.2 
SIGNS 





 ‘Scan negative’ 
CES n=571 
 
n % n % n % 
Bilateral reduced/absent 
ankle jerks 32  78% 20  30% <0.0001 7  12% 
 
<0.0001 
Abnormal saddle pinprick 
30 75% 35 55% 
0.04 
 40 70% 
0.6 
Refused  1   1     
Reduced anal tone on 
digital rectum exam 20 61% 19 33% 0.04 28 51% 
 
0.9 
Refused/not done pre 









Any leg weakness 19  46% 31  47% 0.9 28  49% 0.8 
Positive signs of Functional Neurological Disorder from Examination 
Refused FND testing 4 6  4  
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Total number of patients 
with positive FND signs 4  11% 21 34% 0.009 36 68% 
 
<0.0001 
In patients with weakness 
Hoover’s * 
3 of 19  16% 
13 of 
31  42% 0.06 23 of 28  82% 
<0.0001 
Thigh abductor sign * 
2 of 19  11% 
6 of 
31  19% 0.5 15 of 28  54% 
0.003 
Functional Sensory 
Symptoms 1  3% 15  25% 0.003 27 of 55  49% 
 
<0.0001 
Functional Gait Disorder 0  2  3% 0.1 3  5% 0.1 
Statistically significant findings in bold.  Examination findings for these patients were taken from the 




Bladder, Bowel and Sexual Dysfunction from Questionnaire 
The severity of stress incontinence, overactive bladder and low stream from the Urinary Symptom 
Profile in the month prior to admission was significantly greater in patients with ‘scan negative’ CES 
(all p<0.0001) (see Table Two).  On admission severity of voiding dysfunction was similar in all 
groups.  Stress incontinence on admission was significantly more severe in patients with mixed and 
‘scan negative’ CES and overactive bladder symptoms were more severe in patients with ‘scan 
negative’ CES.   There was no difference in rates of bowel or sexual dysfunction between all three 
groups on admission or in bowel function the month before (see Supplementary Table One). 
 
Additional Investigations in Mixed and Scan Negative Group 
In the mixed group (n=76) fifteen patients had an MRI brain scan, all of which were normal.  In the 
‘scan negative’ CES group (n=62) 31 patients had an MRI brain and one had a CT brain.  MRI brain 
scans were abnormal in three patients in the ‘scan negative’ CES group including an incidental 
enlarged pituitary and an incidental temporal cavernoma.   The final patient had possible 
inflammatory brain white matter changes not meeting McDonald criteria for MS, a normal MRI 
whole spine and no unmatched oligoclonal bands in his CSF. This individual did not attend for follow 
up and had not presented with new neurological symptoms 26 months after initial presentation. 
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Eight lumbar punctures were undertaken, three in the mixed group and five in the group of patients 
with ‘scan negative’ CES.  In the ‘scan negative’ group one individual had unmatched oligoclonal 
bands, considered to be a false positive finding after normal MRI of brain and whole spine and 
specialist clinical review. 
 
Table Two: Bladder Dysfunction and Medications 
Bladder symptoms in the month prior to symptom onset 




‘Scan negative’ CES 
n=41 
Questionnaire Data Mean Score Mean Score P value Mean Score P value 
Stress Incontinence 0.54 1 0.3 3 < 0.0001 
Overactive Bladder 1.83 3.62 0.06 5.7 < 0.0001 
Voiding Dysfunction 0.89 0.91 0.5 1.8 < 0.0001 
Bladder symptoms on admission 




‘Scan negative’ CES 
n=41 
 Mean Score Mean Score P value Mean Score P value 
Stress Incontinence 0.92 3.57 0.02 3.8 0.0009 
Overactive Bladder 4.43 6.43 0.07 7.6 0.04 
Voiding Dysfunction 3.73 3.81 0.8 3.8 0.8 
Bed side Investigations of Bladder Dysfunction 
 N % n %  N %  
Post void residual Total n=28  68% n=58  86%  n=49  86%  
>500mls 10  36% 19  33% 0.8 16  33% 0.8 
>200mls 17  61% 24  50% 0.4 23  47% 0.3 
Medications taken PRIOR to admission which could impair bladder dysfunction 
Total taking ≥ 1 36  88% 54  81% 0.4 47  82% 0.5 
Opiates 13  32% 32  42% 0.1 28  45% 0.09 
Gabapentinoids 12  29% 33  43% 0.04 21  34% 0.4 
Benzodiazepines 5  12% 14  18% 0.3 20  32% 0.01 
Codeine 24  59% 30  45% 0.2 23  37% 0.08 
Tricyclics 8  20% 19  25% 0.3 13  21% 0.7 
NSAID 23  56% 25  33% 0.06 24  42% 0.18 
P values compare patients in the ‘scan positive’ CES group with the mixed and ‘scan negative’ CES 
groups. 
Urinary symptom Profile measuring stress incontinence (0-9), overactive bladder symptoms (0-21) 
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Distress and Disability  
On admission patients in both the mixed and ‘scan negative’ CES groups were significantly more 
likely to have impaired social functioning as measured by the Work and Social Adjustment Scale 
(WSAS score >20, (12% v. 80% and 77%, both p<0.0001).  Using the same scale, patients with ‘scan 
negative’ CES reported higher rates of social functional impairment in the month prior to symptom 
onset (9% vs. 11% and 43%, p=0.0007).  Patients in all three groups had similar levels of physical 
function and emotional distress on admission as measured by SF-12 physical function and HADS 
scores (Table Three).  Patients in both mixed and ‘scan negative’ CES groups had higher numbers of 
symptoms on the PHQ (p=0.001, p<0.0001) and higher mean scores on the peritraumatic 
dissociation questionnaire (p=0.005 and p=0.01). 
 
Table Three: Distress and Disability on admission  
Questionnaire Data ‘Scan positive’ CES Mixed ‘Scan negative’ CES 
Work and Social Adjustment Scale 







Median scores  21  28  0.08 31 0.1 
SF-12 Physical Function 
Mean scores (SD) 5(+-2.46) 4(+-1.65) 0.1 5(+-1.910) 0.5 
HADS 
Mean scores (SD) 14(+-0.62) 19(+-10.10) 0.02 17(+-10.11) 0.1 
PHQ 
Mean scores (SD) 9 (5) 13 (6) 0.001 15 (7) <0.0001 
Peritraumatic Dissociation Questionnaire 
Mean scores (SD) 15 (7) 21 (10) 0.005 22 (13) 0.01 




Predisposing Factors: Functional Disorder, Psychiatric Comorbidity, Adverse Childhood events and 
Employment 
Prior to admission patients in the mixed or ‘scan negative’ CES group were more likely to have a 
functional disorder such as pain, irritable bowel syndrome etc.  Pain was the most common 
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functional disorder subtype particularly chronic widespread or back pain (20% v. 51% and 81%, 
p=0.003, p=<0.0001) (Table Four).  However, this study was specifically investigating prevalence of 
functional neurological disorders in patients with ‘scan negative’ CES and there was no difference in 
rates of pre-admission functional neurological disorders between groups (7% vs. 6% and 12%, p=0.8, 
p=0.5).  
There were relatively high frequencies of psychiatric comorbidity in all groups and significantly 
higher total frequencies of psychiatric comorbidity in patients in the ‘mixed and ‘scan negative’ CES 
groups (lifetime rates 51% vs. 84% and 90%, p= 0004 and p<0.0001; current rates 44% vs. 75% and 
90%, p=0.002 and p=<0.0001)(Table Four).  Patients with ‘scan negative’ CES had higher frequencies 
of all assessed psychiatric disorders particularly post-traumatic stress disorder (PTSD) (10% v. 27% 
and 43%, p=0.0003) and panic disorder (20% v. 56% and 61%, p= 0.00002).  Interestingly, there was 
no difference between means, numbers of patients in all three groups with ≥1 or ≥4 adverse 
childhood events or reporting sexual abuse on the adverse childhood events questionnaire. 
Similar rates of all three patient groups were working or on maternity leave on admission (54% v. 
47% and 48%, p=0.4, p=0,6) and expected to return to work (63% vs. 57% and 55%, both p=0.5).  
Patients with ‘scan positive’ CES were more likely to be retired (22% v. 6% and 2%, p=0.02, p=0.002).  
A higher proportion of patients in the both the mixed and the ‘scan negative’ CES group were off sick 
prior to admission (7% v. 28% and 36%, p=0.02, p=0.001) and patients with ‘scan negative’ CES were 
more likely to be on benefits at the time of admission (7% v. 22% and 27%, p=0.01).   
 
Table Four: Predisposing factors 




‘Scan negative’ CES 
N=61 
Total Functional Disorder 
comorbidity * 
10 (24%) 43 (64%) <0.0001 46 (81%) <0.0001 
Subtypes of functional disorder: 









Irritable Bowel Syndrome 











The Clinical Features and Prognosis of ‘Scan Negative’ 

















Other: 1 (n=1 
memory) 
1 (n=1 memory) 1 (n=1 visual,/movement 
disorder) 
Psychiatric Diagnoses (SCID DSM-5) on admission** 
Lifetime Total  21 (51%) 54 (84%) 0.0004 50 (90%) <0.000
1 
Current Total  18 (44%) 48 (75%) P=0.002 50 (90%) <0.000
1 
Current Depression 4 (10%) 26 (41%) 0.0008 21 (38%) 0.002 
Past Depression 14 (34%) 33 (52%) 0.1 37 (66%) 0.002 
Panic 8 (20%) 34 (56%) 0.003 34 (61%) 0.0000
2 
Agoraphobia 5 (12%) 22 (36%) 0.04 24 (43%) 0.003 
Health Anxiety 1 (2%) 7 (11%) 0.1 9 (16%) 0.03 
Generalised anxiety disorder 9 (22%) 18 (28%) 0.6 24 (43%) 0.03 
Obsessive compulsive disorder 5 (12%) 19 (30%) 0.051 23 (41%) 0.002 
Post-Traumatic Stress Disorder  4 (10%) 17 (27%) 0.92 24 (43%) 0.0003 
Adverse Childhood events Score (ACE) from questionnaires 
 ‘Scan positive’ CES 
n=38 (81% total) 
Mixed 
N=61 (80% total) 
‘Scan negative’ CES 
N=41 (66% total) 
Refused 2 1 1 
Mean (SD) 1.5 (2) 1.7 (2) 0.3 2.2 (3) 0.2 
ACE scores ≥1 17 (45%) 37(62%) 0.1 23 (59%) 0.3 
ACEs core ≥4 6 (16%) 12 (20%) 0.6 12 (31%) 0.1 




22 (54%) 30 (47%) 0.4 27 (48%) 0.6 
Off sick on admission 3 (7%) 18 (28%) 0.009 20 (36%) 
  
0.001 
Receiving state related 
disability benefit 
3 (7%) 14 (22%) 0.06 15 (27%) 0.01 
* some patients had more than one disorder.  **Chronic pain in mixed group: n=2 abdomen, n=2 
shoulder, n=1 hip; chronic pain in ‘scan negative’ group: n=6 widespread, n=3 abdominal, n=1 groin, 
***other in ‘scan negative’ group: n=2 hyperventilation syndrome, n=2 CFS, n=1 globus 
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Outcome at 3 months in Mixed and Scan Negative groups 
New Diagnoses 
During follow up (mean duration 24 months, 92% and 89% follow up) four patients acquired 
neurological diagnoses which fully or partially explained their clinical CES symptoms. Table Five and 
supplementary table two detail the diagnoses found.  
Two patients died during follow up (n=1 unexpected death with no cause found at post-mortem in 
the mixed group, n=1 unrelated cardiac failure in the ‘scan negative’) group. 
Fourteen patients represented urgently with possible CES, but none had radiological evidence of CES 
or other explanations for their symptoms (mixed n=6, ‘scan negative’ group n=8). 
Three patients (4%) in the mixed group and ten patients (16%) in the ‘scan negative’ CES group 
received a new diagnosis of a functional neurological disorder after an outpatient neurology 
appointment(16%) during the follow up period.  The most common symptoms in both groups were 
functional limb weakness (n=2 and n=6), followed by dissociative seizures (n=3) which only occurred 
in the ‘scan negative’ CES group, sensory symptoms (n=1 and n=2) and persistent postural 
perceptual dizziness (n=1 in both).   
Twenty patients(26%) in the mixed group and twelve patients (19%) in the ‘scan negative’ CES group 
had persistent urological symptoms on discharge and were referred to urology or gynaecology 
although 5% of both groups did not attend (see Supplementary Table three). Only one patient was 
diagnosed with neuropathic voiding dysfunction after investigation; the patient with the cervical 
transverse myelitis.  Approximately one third of patients (32%) had symptom resolution, normal 
investigations or they were unable to tolerate investigations, 28% had idiopathic voiding problems 
and 12% had storage symptoms, stress incontinence was only diagnosed in patients with ‘scan 
negative’ CES (n=2).  
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‘Scan negative’ CES 
Notes and GP Review 
n= 62 
Follow up achieved 70 (92%) 55 (89%) 
Average follow up/ 
months 
24 23 
Deceased or palliative 1 no cause found on post-mortem 1 unrelated to CES 
presentation, Left ventricular 
failure 
Cause of clinical CES 
presentation partially or 
fully explained with 
hindsight  
3 
Transverse myelitis (n=1) 
Small cervical epidural haematoma 
(n=1)^ 
Presumed CNS inflammatory 
disorder (n=1)* 
1  
Sacral chordoma (n=1) 
Re-presentation with 
clinical CES without 
explanation 
6 (8%) 8 (13%) 
New diagnosis of 
Functional Neurological 
Disorder 
3 (4%) 10 (16%) 
^cervical epidural haematoma picked up on outpatient MRI of cervical spine, patient had fall from 
horse at symptom onset; *spasticity left leg, normal MRI Brain and spine, OCBs unique to CSF 
 
 
Three Month Follow Up Questionnaires 
66% of patients with ‘scan positive’ CES returned the three months follow up questionnaire (n=31), 
62% (n=47) in the mixed group and 47% (n=29) patients in the ‘scan negative’ CES group 
(Supplementary Table Three).  Patients in all groups who returned their questionnaires had high 
rates of overactive bladder symptoms (74-86%) and similar levels of bowel and sexual dysfunction. 
Patients in the mixed or ‘scan negative’ CES groups had higher distress (HADs average 8.3 v. 16.9 and 
16.2, p=<0.0001, p=0.0005), this appeared to be due to a reduction in HADs score in the patients 
with ‘scan positive’ CES.  Employment outcome was similar amongst the groups with approximately 
half of patients in all groups working at follow up and one fifth on disability related benefits. 
The Clinical Features and Prognosis of ‘Scan Negative’ 





This is the first large prospective study of patients with ‘scan negative’ CES, phenotyping patients at 
presentation through a mixture of semi-structured interview, examination and questionnaire. We 
have also supplemented this ‘real-world’ data with follow up mindful of the possibility of other 
neurological explanations for patient’s clinical CES symptoms.  
 
Symptoms and Signs  
As with other studies there was no one clinical symptom or sign of sufficient discriminatory value to 
render an MRI scan unnecessary.  Some symptoms and signs, in our study chronic leg pain and 
absent ankle jerks, may be helpful in increasing pre-test probability of ‘scan positive’ CES. 
There were also potential positive predictors for patients with ‘scan negative’ CES including “worst 
ever back pain”, symptoms of a panic attack or dissociation at onset, non-dermatomal leg pain and 
more bladder symptoms in the month prior to admission. Most strikingly, inpatient assessment 
patients with ‘scan negative’ CES were much more likely to have positive evidence of a functional 
neurological disorder (FND) on examination despite having similar rates of FND prior to their 
admission. For many of the studied variables there was a dose-response effect with higher values in 
mixed, and higher values again in scan negative patients (Figure 1). 
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Figure One: Dose Response of factors in support of ‘scan negative’ CES often being explained by a 
Functional Neurological Disorder (FND)
 
 
Potential explanations of ‘scan negative’ CES 
Alternative neurological disease explanation 
From this prospective study and from previous retrospective work we carried out in 276 individuals 
from the same centre(Hoeritzauer et al., 2018) it does not appear that alternative neurological 
disease explanations are a major cause of ‘scan negative’ CES. In this prospective study only 4% were 
given a new diagnosis partially or fully explaining their symptoms during follow up of mean 23 
months.  This small number supports retrospective work which found only one similar patient out of 
191 scan-negative CES with a follow up of 15 months(Hoeritzauer et al., 2018).   
The authors considered the differential diagnoses for clinical CES throughout the study (see Table 4 
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HSV, Elsberg syndrome, can be difficult to diagnose due to lack of diagnostic suspicion and be 
associated with clinical investigations and symptoms which may normalise quickly.  Elsberg 
syndrome causing cauda equina radiculitis occurred in 5 of 1,035 patients investigated at the Mayo 
clinic with both myelitis and radiculitis between 2000-2016(Savoldi et al., 2017).  Patients were 
predominantly male (80%) and one fifth had prodromal symptoms such as headache, myalgia, fever 
or sacral or oral herpes infection.  Spinal arteriovenous malformations (AVM) often present initially 
as a peripheral disorder and also more commonly affect men, particularly between 55-60 years old.  
Patients may face a significant delay in diagnosis but progressive symptoms with stepwise 
deterioration, distal to proximal sensory loss and emerging upper motor neurone symptoms lead to 
targeted imaging which is abnormal in 67-100% of patients with spinal AVMs(Jellema et al., 2006).  
Both the mixed and ‘scan negative’ CES groups were predominantly made up of middle-aged 
women. The most common inflammatory disorder affecting women in the UK is multiple sclerosis, 
and bladder symptoms are common, affecting approximately 75% of patients.  However, pain and 
bladder dysfunction are unusual as a first presentation in multiple sclerosis. Similarly, Myelin 
Oligodendrocyte Glycoprotein Autoantibody mediated inflammatory disease is associated with 
conus medullaris inflammation and bladder, bowel and sexual dysfunction.  However, it occurs more 
commonly in men in their mid-twenties with viral like prodrome or vaccination and is associated 
with longitudinally extensive spinal cord lesions, multiple cord lesions and bilateral optic 
neuritis(Narayan et al., 2018; Dubey et al., 2019).  As this was a real-world study not all patients 
received imaging of the whole neuraxis, but nonetheless there was no evidence of further clinical 
presentations suggesting that additional missed cases are likely to have been few. 
Potential mechanisms of bladder dysfunction 
How could it be that such clinically significant bladder dysfunction could arise in the absence of a 
clear pathophysiological cause in scan negative CES? There are several pymotential explanations. 
• Direct neural inhibition related to pain. Pain from nerve root entrapment or muscle spasm, could 
cause sympathetic hyperactivity and increased inhibitory signals via the pelvic and hypogastric 
nerves impeding normal pelvic floor function and parasympathetic urethral sphincter relaxation 
and causing difficulty voiding.  In the mixed group high numbers of patients had severe pain 
caused by nerve root entrapment and in the ‘scan negative’ group 70% of patients described the 
pain at onset as their worst ever back pain.  
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• Effects of medication. Medications such as pregabalin, gabapentin and benzodiazepines can 
cause or exacerbate urinary incontinence and opiates can affect bladder as well as bowel 
function causing voiding dysfunction and severe chronic urinary retention(Panicker et al., 2012). 
Over eighty percent of patients in all groups were on more than one medication which can be 
associated with urinary retention or urinary incontinence. 
• Previous bladder dysfunction. Patients may present with suspected CES due to an exacerbation 
of their underlying bladder dysfunction from pain, panic or medications such as stress 
incontinence, overactive bladder syndrome and voiding dysfunction.  Stress incontinence is 
more common in patients with chronic back pain which affected >50% of patients in the mixed 
and ‘scan negative’ CES groups.  Studies suggest that medically refractory overactive bladder 
syndrome symptoms may be due to an anxiogenic state and hyperawareness of normal bladder 
filling rather than an abnormality of the detrusor muscle (Klausner et al., 2009).  All types of 
bladder dysfunction were more severe in patients with ‘scan negative’ CES in the month before 
admission.  
• Shared mechanism with Fowler’s syndrome and Paruresis? Two urological conditions may cast 
further light on mechanism; Paruresis and Fowler’s syndrome.  Paruresis, also called “shy 
bladder syndrome”, is a condition affecting 3-16% of the population causing intermittent 
inability to initiate or maintain urination due to failure of external urethral sphincter relaxation 
with additional inhibitory top-down brain-bladder signals.  Patients are unable to void when 
aware of others around them.  It is usually triggered in adolescence by an anxiety invoking 
experience in a public toilet, is associated with higher than population rates of psychopathology 
(5-70%) (Kuoch et al., 2017) and responds to graded exposure therapy (Soifer et al., 2009).   
Paruresis is an amplification of the normal inhibitory bladder responses to being in an unsafe 
voiding situation.  The insula, medial and lateral prefrontal cortex and brainstem circuit are key 
components of the brain bladder network as well as the “fear network”(Sobanski and Wagner, 
2017).  In health, these brain areas are key to assessing the safety to void.  However, during 
panic the fear network is engaged and abnormal voiding or lack of voiding can occur.  Fowler’s 
syndrome describes chronic urinary retention due to a primary failure of external urethral 
sphincter relaxation and is triggered by pain or medications.  Patients with Fowler’s syndrome 
have high rates of comorbid functional neurological disorders and pain (Hoeritzauer et al., 2016).  
The aetiology of Fowler’s syndrome is uncertain, but it may be a chronic model of the acute 
process affecting patients with ‘scan negative’ CES.   
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Is “scan-negative” CES largely a consequence of a functional disorder? 
In keeping with our hypothesis, in comparison to ‘scan positive’ CES patients, patients with mixed 
and ‘scan negative’ CES had significantly more evidence of a functional neurological disorder (11% 
vs. 34% and 68%), despite having similar low rates of functional neurological disorders pre-admission 
(7% vs. 6% and 12%, p=0.8, p=0.5). Patients were also more likely to have predisposing factors for 
developing a functional neurological disorder: higher frequencies of functional disorder diagnosis on 
admission (24% vs. 64% and 81%) and more current psychiatric comorbidity (rates 44% vs. 75% and 
90%).  The specificity of symptoms of a functional neurological disorder on admission was 0.89 (0.57-
0.97) sensitivity 0.68 (0.53-0.8) when comparing scan positive and scan negative CES groups. 
The data builds on our pilot and retrospective studies suggesting that at least some patients with 
mixed and ‘scan negative’ CES have symptoms due, in broad terms, to a disorder of nervous system 
functioning, rather than pathophysiological disease, with functional or medication related urinary 
symptoms combining with pain and acute functional limb sensory loss and/or weakness. 
Functional neurological disorders are diagnosed based on positive clinical signs with good diagnostic 
sensitivity and specificity (Daum et al., 2015), such as Hoover’s sign of functional leg weakness, 
weakness of hip extension which normalises with contralateral hip flexion.  The understanding of 
what functional neurological disorders are has changed over the last decade.  Previously thought of 
as primarily result of the physical conversion of traumatic emotional events, more recent work has 
led to a recognition of the disorder as being truly a brain-mind disorder with a Bayesian mechanism 
of ‘top-down’ expectation and abnormal self-directed attention overriding normal motor and 
sensory pathways(Edwards et al., 2012; Van den Bergh et al., 2017). It is an important diagnosis to 
make as without specific treatment, 80% of patients continue to have symptoms on 14 year follow 
up(Gelauff et al., 2019) whereas tailored physiotherapy has the potential to improve 
outcome(Nielsen et al., 2015, 2016)).  Pain, panic and dissociative experiences are often triggers for 
functional neurological disorders. In a systematic review of 869 patients with functional neurological 
symptoms physical injury preceded onset in 37% (Stone et al., 2009) and in another study panic was 
found to precede symptoms in 59% of patients with sudden onset functional neurological 
disorders(Stone et al., 2012).  Our study is the first to test the hypothesis that panic is more likely to 
occur in patients with functional neurological disorders compared with a control group with similar 
presenting symptoms.  57% and 70% of patients in the mixed and ‘scan negative’ groups had 
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symptoms of a panic attack at the onset of their symptoms compared with 37% of patients with 
‘scan positive’ CES.  Additionally, 70% of patients in the ‘scan negative’ group had their worst ever 
back pain. 
A proposal for understanding the mechanism of mixed and ‘scan negative’ CES 
We propose that some patients who have a vulnerability to functional disorders (including FND) with 
or without some underlying bladder problems who develop severe back/leg pain from nerve root 
entrapment or simply muscle spasm react with panic and dissociation(Perez et al., 2018) There is 
abnormal bladder function due to inability to contract the pelvic floor (urinary incontinence) or relax 
the pelvic floor (urinary retention) and functional neurological symptoms such as leg weakness and 
numbness. Analgesics taken acutely or long term, particularly opiates, which >40% of patients were 
taking, could compound voiding dysfunction and medications such as gabapentinoids, which more 
than one third of patient were taking, could compound urinary incontinence.  For a significant 
proportion pain may become chronic and when flare-ups of pain occur bladder and neurological 
symptoms reappear, and patients re-present with suspected.  These patients may become trapped 
in a cycle of kinesiophobia, deconditioning, abnormal self-directed attention leading often to chronic 
pain from central sensitisation and functional neurological symptoms (Figure 2). 
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This was a real-world study which had limitations including case definition, blinding, potential bias in 
control and cases selection, questionnaire return rate, measures used and extent of investigations.   
It was not possible to assess the majority of patients blind to the scan results due to the nature of 
patient recruitment and the urgent nature of the operation if a patient was diagnosed with ‘scan 
positive’ CES.  The non-blinding of the examiner may have influenced the frequency of psychiatric 
diagnosis although all structured interviews were discussed with a blinded supervisor for the first 
twelve months.  In Edinburgh there may be a higher frequency of patients admitted to the 
neurosurgery ward with ‘scan negative’ CES compared to other neurosurgical centres due to the 
reduced availability of out of hours MRI in the Edinburgh locality. However, literature suggests ‘scan 
negative’ CES occurs in the majority of patients scanned for suspected CES in UK centres(Hoeritzauer 
et al., 2019).   
 
Conclusion 
We present the first well phenotyped, prospective information about patients with ‘scan negative’ 
CES, a common clinical neuroscience presentation which accounts for at least half of all patients 
presenting with suspected CES.  We have provided evidence for understanding the nature of ‘scan 
negative’ CES based on a hierarchical model which takes in to account a range of probable 
physiological, psychological and “functional disorder” causative factors.   
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Conclusion:  Patients were again divided into three groups; ‘scan positive’ CES, a mixed group 
comprising nerve root entrapment or compression or ‘impending’ CES and patients with normal 
scans ‘scan negative’ CES.  The prospective nature of the study allowed us to investigate our 
hypotheses by asking specifically about pain and panic at onset, examining for positive evidence of 
functional neurological disorders and asking about psychiatric symptoms, medication use and prior 
bladder dysfunction. 
This study provided further evidence of the link between functional neurological disorders and 
patients with ‘scan negative’ CES.  Patients with ‘scan negative’ CES were more likely to have 
evidence of a functional neurological disorder when examined during their admission.  Their 
symptoms also provided support for a mechanistic hypothesis that pain and panic negatively 
affected the normal bladder-brain axis from both top down and bottom up ways.  Pain and panic are 
also known triggers for functional neurological disorders.  There was a stepwise progression of 
functional symptoms between groups, patients with ‘scan positive’ CES had the lowest and patients 
with ‘scan negative’ CES had the highest.  
Predisposing factors such as higher levels of social functional impairment (Work and Social 
Adjustment Score), being off sick, pre-existing stress incontinence and high levels of pain 
medications which could affect bladder function were seen in patients with ‘scan negative’ CES.  
Precipitating factors such as a patients’ ‘worst ever’ back pain and associated panic attack were 
more common in patients with ‘scan negative’ CES.  Follow up investigation after 24 months for new 
diagnoses explaining clinical CES found only 4 patients who had partially or fully explanatory 
diagnoses.  Therefore, the majority of patients do not have an underlying neurological disorder 
causing their symptoms.   
There was only one structurally related urological disorder diagnosed on follow up.  This was in the 
patient with a cervical inflammatory lesion.  Other patients had urological diagnoses which would 
fall under category of functional urological diagnoses.  As discussed earlier, the nomenclature 
around urology is different. However, the disorders diagnosed related most commonly to voiding 
dysfunction which is commonly associated with higher rates of psychological and psychiatric 
comorbidity21.  The aetiology of these disorders is controversial and they are thought to reflect 
abnormalities of brain-bladder axis function not structure21.  
This study was the first deeply phenotyped study of patients with ‘scan negative’ CES.  We were able 
to determine what proportion of patients with ‘scan negative’ CES had evidence of a functional 
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neurological disorder and were able to identify predisposing, precipitating and perpetuating factors 
relevant to the diagnosis and mechanism of ‘scan negative’ CES.  We also found support for our 
hypothesis that at least some patients are best understood to have a functional disorder causing 
most or at least some of their symptoms.  These findings, whilst still preliminary, allow the creation 
of a clinically useful narrative for patients who have thus far been a medical mystery which aims to 
help explain their symptoms and allow targeted physical, psychological and medical therapy (see 
patient information leaflet in appendix). 
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Paper Five:  Hoeritzauer I, Jon Stone, Clare Fowler, Suzy Elneil, Alan Carson, Jalesh Panicker.  Fowler’s 
syndrome of Urinary Retention: a Retrospective Study of Comorbidity. Neurourology and Urodynamics. 
2016; 35(5): 601-603.   
Introduction:  To achieve Aim 3: To determine what proportion of patients with urinary retention from 
Fowler’s syndrome or idiopathic causes (chronic idiopathic urinary retention/dysfunctional 
voiding/bladder outlet obstruction) have comorbid functional neurological disorder I carried out a 
retrospective study of comorbidity in 62 patients who were diagnosed with Fowler’s syndrome between 
2009-2013.  There had been a suggestion clinically and from previous studies of vulnerability to 
psychological and functional comorbidity in patients with Fowler’s syndrome, but this had not been 
directly investigated. 
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Fowler’s syndrome of Urinary Retention: a Retrospective 
Study of Co-morbidity 




To study the frequency of pain, psychological or functional disorders in patients with Fowler’s syndrome. 
Methods 
We carried out a retrospective chart review of patients with a diagnosis of Fowler's syndrome attending 
the Uro-Neurology centre at the National Hospital for Neurology and Neurosurgery between 2009-2013 
looking at triggering events, physical and psychological comorbidities.  
Results 
Of 62 patients with clinical and electromyographic diagnosis of Fowler’s syndrome, 31 (50%) had 
unexplained chronic pain syndromes, 12 (19%) of these were taking opiates. 15 (24%) had "functional" 
neurological symptoms. Abdominopelvic surgery with general anaesthesia was the leading trigger (n=21, 
35%).  
Conclusions 
We found high levels of co-morbidity with patients having some form of pain (50%), a probable functional 
disorder (24%) or psychological symptoms (31%).  There are several potential explanations for this 
association including the effect of developing an apparently unexplained distressing condition, 
confounding effect of opiate use or referral bias. The findings suggest a need for prospective systematic 
study of comorbidity for this disabling condition.     
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Urinary retention in young women is a disabling problem that often occurs in the absence of urological or 
clear cut neurological disease. In 1988, Fowler and colleagues(1) described in a group of young women in 
urinary retention, abnormal findings on urethral sphincter EMG, of complex repetitive discharges and 
decelerating bursts, suggesting a primary  disorder of urethral sphincter relaxation; these findings were 
later shown to be associated with high urethral pressure profiles(2).   Typically such women retained 
volumes of urine over a litre, but had impaired sensation of bladder fullness. Often, they described 
difficulties during intermittent catheterisation, particularly when attempting to remove the urinary 
catheter.  This syndrome has become known as Fowler's syndrome (FS), and sacral neuromodulation has 
been found to be an effective treatment option(3),(4).   Recent work has identified opiates as potentially 
exacerbating underlying physiological abnormalities leading to urinary retention both in patients with 
Fowler’s syndrome and patients with unexplained urinary retention (without characteristic urethral EMG 
findings)(5).  
The  peak age of onset of Fowler's syndrome, in the second and third decades post menarche (6), and the 
observation that urinary retention may be triggered after surgery, childbirth and minor medical 
procedures(6) remain unexplained. Recent studies have suggested a vulnerability to physical and 
psychological comorbidities but these have not been clearly reported(7).  We therefore undertook a 
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Materials and Methods 
A retrospective chart review of women referred to the tertiary referral Uro-Neurology centre at the 
National Hospital for Neurology and Neurosurgery between January 2009 to December 2013 for voiding 
difficulties or urinary retention and undergoing urethral sphincter EMG was carried out. Patients had been 
referred when local urological and local neurological investigations had been unable to find a cause for 
urinary voiding dysfunction. 
Urethral pressure profile (UPP) was measured using the perfusion catheter technique, with a normal 
control range calculated as 92-patient age (years) in cm water, as established in a previous study(8).  
Concentric needle EMG of the striated urethral sphincter using a technique previously described (1)was 
performed in all patients (JP or CJF) using an EMG machine (Keypoint®.NET, Alpine Biomed, Denmark).  
Patients with the characteristic abnormal EMG findings described above were diagnosed as having FS (1).  
From the charts, information about pain and non-urological symptoms such as psychological or psychiatric 
symptoms or diagnoses, functional or "unexplained" physical symptoms were noted.  
 
Results 
In total, 62 women were diagnosed as having Fowler’s Syndrome.  Mean age was 32 years (range 17-64); 
average duration of symptoms was 53 months (range 1-336). 
All patients had complex repetitive discharges and decelerating bursts on urethral sphincter EMG. The 
UPP was elevated in 49 patients out of 52 in whom it could be measured (94%).  Fifty patients (81%) were 
in retention at the time of assessment, 28 of whom spontaneously reported an uncomfortable gripping 
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sensation on withdrawing the catheter used for intermittent self-catheterisation.  Thirty six patients (58%) 
had recurrent urinary tract infections.   
Evaluating factors that triggered urinary retention    
Twenty-one patients (35%) developed symptoms following anaesthesia all of whom had abdominal or 
pelvic procedures: laparoscopy/laparotomy (n=12), caesarean-section (n=2), hysterectomy (n=2) and 
post-partum (n=2), other procedures (n= 3) (colonoscopy, Mirena coil insertion under GA, colposcopy).    
Seven patients (11%) described the onset after experiencing acute pain or some other physical trigger 
(associated with unexplained abdominal, loin or perineal pain and numbness (n=2), fall against door 
frame, fall from horse, lifting heavy object, menstruation (each n=1), and pain and rash (n=1)). Six patients 
(9%) developed symptoms after a urinary tract infection of whom two volunteered a long prior history of 
poor voiding.    Twenty-seven (44%) patients had no clear trigger for their symptoms of whom 14 
volunteered a long history of voiding difficulties. No information on onset was available on one patient.  
Physical and Psychological comorbidity 
Eight patients (13%) had documented pelvic pathology, endometriosis (n=4), ovarian cysts (n=3) pelvic 
inflammatory disease (n=1). 
Thirty one patients (50%) had unexplained chronic pain syndromes (abdominopelvic pain (n=22), back or 
leg pain (n=5), widespread or unspecified (n=4).  Fourteen patients (23%), (6/31 with chronic pain 
syndromes), were taking opiates at onset of retention and 17 (27%), (12/31 with chronic pain syndromes), 
during follow up.    
Fifteen patients (24%) had functional neurological symptoms with overlap of symptoms (loss of 
consciousness (n=7), limb weakness (n=6), sensory disturbance (n=6), memory impairment (n=3)). 
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Nineteen patients (30%) reported symptoms of anxiety/depression (n=18) or obsessive compulsive 
symptoms (n=3).  In total only 19 (30%) patients had no pain symptoms or psychological co-morbidities.  
 
Discussion 
In this retrospective case note review, we found high levels of co-morbidity in patient with Fowler’s 
disease.  The most common comorbidities were pain (50%), functional neurological symptoms (24%) or 
psychological symptoms (30%) though a formal diagnosis was often lacking. It seems likely that these 
figures are an underestimate given the retrospective methodology of the study and the clinical focus of 
the uro-neurology service. Given the relative youth of the subjects, the presence of such high levels of co-
morbidity is thought-provoking.   
Several studies have hinted at high levels of comorbidity amongst women in urinary retention  
(7),(9),(10),(11) although these have used symptom scales and psychological assessments rather than 
describing comorbid diagnoses based on the patient’s medical history.  Fifty per cent of patients (n=31) in 
our review had unexplained pain syndromes, largely abdominopelvic but also back or leg pain, of which 
12 (38%) had been started on tramadol or some similar oral opiates.   
Patients presenting with the phenotype of Fowler's syndrome were previously often labelled as 
psychogenic or hysteric(12,13). The common psychoanalytic view that the symptom arose from sexual 
conflict or infantile guilt was understandably rejected by many clinicians (14). An equally unpalatable 
neurological view of psychogenic symptoms has been that they were feigned or 'not real'(15). Some older 
literature on 'psychogenic retention' made clinical connections between urinary symptoms and other 
physical and psychological comorbid symptoms(16) (12),(17)  
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From this chart review it appears that some women with Fowler’s syndrome also have functional 
neurological symptoms such as non-epileptic attacks or leg weakness.  Functional neurological symptoms 
are genuine disorders which can be understood as an interaction between physiological and psychological 
variable and are not just ‘all in the mind’(18).  A figure of 24% is higher than might be expected as a generic 
stress response, and warrants further investigation.  Although common in neurology, functional 
neurological symptoms, e.g. seizures and leg weakness, are much less common in the general population. 
For example, dissociative attacks have a prevalence of 2 to 33 per 100, 000 (ie 0.002-0.03%). The 
prevalence of functional leg weakness is unknown but based on incidence of 3/100,000(16) and prognosis 
studies(19) is of a similar magnitude. However, the presence of a neurological disease is a risk factor for 
developing superimposed functional neurological symptoms, often typically related to the symptoms of 
that disease. For example in one study, 7% of patients with Parkinson’s disease also had a somatoform 
disorder(20). Systematic reviews of comorbidity in irritable bowel syndrome and fibromyalgia have not 
reported on the frequency of functional symptoms such as seizures and leg weakness, even though they 
recorded numerous other functional symptoms such as fatigue and pain at high frequency giving further 
credence to the hypothesis that our figure of 24% is unusual(21)(22).  Looking at things in reverse, bladder 
symptoms are common in patients with functional limb weakness (28%) (16) and anecdotally voiding 
dysfunction is over-represented in patients with functional neurological symptoms in general, although 
studies are lacking.  
The study was limited by the retrospective methodology, history, examination and investigations were 
available only from letters sent by or received by the clinical team.   Moreover, the clinical focus of the 
Uro-neurology service was on the management of voiding dysfunction, not the systematic collection of 
co-morbidities.  Therefore, it is not possible to determine the true prevalence of co-morbidities in this 
population based upon the results of this study, or to draw causal inferences.   
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Nevertheless, the high levels of comorbidity in women with Fowler's syndrome is intriguing and several 
hypotheses can be considered.  Firstly, it could be that the comorbidity that has been recorded is simply 
a result of the inevitable effect of a distressing medical condition in a population of young women. An 
earlier survey showed that on average these young women had been seen by three hospital consultants 
before a diagnosis was made (23)and levels of psychological morbidity were not that different to other 
neurological disorders in a tertiary setting. The resolution of some of these symptoms in patients who are 
treated with sacral neuromodulation would be in keeping with this.  Secondly, it could be that Fowler’s 
syndrome is triggered in some patients by the use of opiate based medication which exacerbates detrusor 
underactivity and reduced urge(5),(24). The association with functional neurological symptoms could 
simply be a confound related to opiates which are prescribed to patients who have a vulnerability to both 
chronic pain and functional disorders. Thirdly, it may be that patients with unusual or complex 
comorbidity are more likely to find their way to a tertiary Uro-neurology service whereas those that don’t 
are more successfully managed in their local hospital.  In favour of these hypotheses are the relatively 
specific neurophysiological findings which are not found in voluntary striated muscle under normal 
conditions, the raised urethral pressure profiles which are outwith the range for normal volunteers, and 
the presence of patients without comorbidity.  
Knowledge of urethral sphincter EMG findings in women without urinary symptoms is limited but it 
seems likely that complex repetitive discharges and decelerating bursts are a not uncommon type of 
activity to occur in this muscle since two abstracts have reported its presence in healthy volunteers (25–
27).  The striated muscle of the female urethral sphincter has unusual properties: it has been 
demonstrated to be hormonally sensitive, undergoing atrophy with the menopause, and is almost 
continuously electrically active. The actual cause of CDRs and DBs is not known but this type of activity 
appears to be unique to the muscle. The “amount” of the activity in any one individual is difficult to 
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quantify, especially using the sampling technique of needle EMG which examines only a small volume of 
muscle, but it alone may not be the determinant of whether or not a women develops urinary retention. 
Based on the hypothesis that detrusor inhibition is the result of urethral afferent activation, some 
means of measuring that activity in women with the EMG activity, with and with bladder symptoms is 
needed before its significance to the cause of retention can be dismissed. 
It is essential to formally evaluate functional neurological disorders and chronic pain in this population, 
exploring the behavioural underpinnings contributing to these, and the complex interplay, if any, that may 
exist between these and the underlying primary disorder of urethral sphincter relaxation.   
If there is an association between functional neurological disorders and Fowler’s syndrome, this could 
ultimately be of benefit to understanding both disorders and to patients with multiple comorbidities. 
Our findings signal the need for prospective systematic study of comorbidity for this disabling problem.  
A detailed study of comorbidity which involves longitudinal understanding of the sequence of 
symptoms, interaction with medication, and response of those symptoms to successful treatment is 
required to test the hypotheses described above. The inclusion of a control group, for example patients 
in Uro-Neurology clinics without Fowler’s syndrome or patients with defined disease causes for their 
symptoms would be particularly valuable in assessing the specificity of any associations. 
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Conclusion:  This was the first study demonstrating a higher proportion of chronic pain, functional 
disorders and psychological symptoms.  Although retrospective, the study found evidence of a link 
between functional disorders and Fowler’s syndrome.  Almost one quarter (24%) of patients had 
evidence of a functional neurological disorder.  We considered several hypotheses as to why this 
relationship occurred including the effect of opiates, which had previously been found to have a direct 
link in patients with idiopathic chronic urinary retention, the effect of bias from who is referred to 
quaternary referral centres with symptoms and the possibility that Fowler’s syndrome or chronic 
idiopathic urinary retention may be due to a fixed, functional, external urethral sphincter dystonia.  
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Paper Seven: Lower Urinary Tract Dysfunction in patients with Functional Disorders attending neurology 
outpatient clinics.  I Hoeritzauer1, O Shipman-Sharma1, J Stone1,2, A Carson1,2,3   
 
Introduction: This study was done to address Aim 4 of the the PhD; Aim 4: To determine what 
proportion of patients with functional neurological disorders have lower urinary tract dysfunction.  A 
prospective study of patients presenting to general outpatient neurology clinics over a one month 
period in the Western General Hospital in Edinburgh based on the Scottish Neurological Symptom Study 
was performed.  The study asked patients about their bladder symptoms using the Urinary Symptom 
Profile questionnaire to gain information about the type of bladder dysfunction (stress incontinence, 
overactive bladder symptoms or low stream) and the short form-qualiveen to investigate effect on 
quality of life from any bladder dysfunction present.  Patients were then rated by consultant 
neurologists along a four point Likert scale as having their neurological symptoms ‘completely’, ‘largely’, 
‘somewhat’ or ‘not at all’ due to a functional disorder. 
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Ethics approval:  
South East Scotland Research Ethics Committee (Ref 16/SS/0107) 
Abstract 
Aims: To study the prevalence of urological symptoms in patients with functional disorders attending 
neurology outpatient clinics. 
Methods: All patients attending general outpatient neurology clinics over one month were asked to fill 
in a questionnaire about urological symptoms (the Urinary Symptom Profile: subdivided into stress 
incontinence, overactive bladder and low stream scores) and distress caused by these (SF-Qualiveen).  A 
consultant neurologist recorded how likely their neurological symptoms were to be due to a functional 
disorder; ‘not at all’, ‘somewhat’, ‘largely’ or ‘completely’.   
Results: 132 patients were included in the study (mean age 44yrs, 60% female), 33% of whom had 
symptoms judged as ‘largely’/’completely’ due to a functional disorder (n=44). Low stream symptom 
scores were higher in females with symptoms ‘largely’/’completely’ due to a functional disorder (0.3 vs. 
0.85 p=0.005).  Male and female patients with symptoms ‘largely’/’completely’ due to a functional 
disorder were more likely to report at least one significantly affected domain in SF-Qualiveen (66% vs 
45%, p=0.03).  However, symptom scores were low, and quality of life was only mildly affected. 
Conclusions: 
Females with functional disorders attending neurology outpatients have more low stream symptoms 
and are more distressed than patients with pathophysical diseases attending neurology.  
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Lower urinary tract dysfunction (LUT) occurs frequently in patients with a wide range of neurological 
diseases.  Despite the significant impact on quality of life, until recently it has received little attention in 
general neurology literature or practice.  Increasing understanding of the complex brain-bladder axis 
and the anatomical networks linking emotion, attention and the bladder has led to greater interest in 
LUT dysfunction in neurological and psychiatric disease1.  Patients with functional disorders, also called 
somatoform or psychogenic disorders, have also benefited from enhanced interest and understanding 
of brain-body networks, particularly the role that expectation plays in the interpretation and experience 
of bodily sensation2.   
In the Scottish Neurological Symptoms study, a large multi-centre study involving 3781 neurology 
outpatients, functional disorders accounted for the second most common reason why a patient was 
seen in neurology clinic (16% of all referrals).  A smaller number (5.6%) had functional neurological 
disorders/conversion disorder3. Functional disorders refer to the whole range of functional disorders 
seen in neurological practice such as fibromyalgia, hyperventilation and chronic dizziness. The term 
functional neurological disorder is reserved for a subgroup of patients who have positive evidence of a 
functional neurological disorder causing motor, sensory or seizure symptoms as defined in DSM-5; for 
example, leg weakness with positive Hoover’s sign. 
In the Scottish Neurological Symptoms study the prevalence of the 13 most common physical symptoms 
which patients present to GPs with, such as back pain, headaches or fainting spells, were investigated 
using the PHQ-15.  Patients in the functional group were found to have high rates of these comorbid 
physical symptoms. This proved useful in understanding the extent of the overlap between patients with 
multiple physical symptoms who also had functional disorders and in creating hypotheses about 
overlapping mechanisms of action4,2,5.   
However, although this study explored many physical symptoms it did not estimate the prevalence of 
LUT symptoms in patients with functional and pathophysiological disorders attending neurology.  No 
other studies have investigated this question.  LUT symptoms have long been hypothesised to be a 
common comorbidity of patients with functional disorders and neurological symptoms.   ‘Hysterical 
ischuria’ (retention) was mentioned as far back as YEAR by Charcot and in the earlier 20th century there 
have been many case series and reports of ‘psychogenic urinary retention’ usually affecting females.  In 
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the 1980s the criteria for DSM-IV somatisation disorder7 included urinary retention and several studies 
have found some overlap between patients who have functional disorders such as irritable bowel 
syndrome and LUT storage symptoms6.  Therefore, we hypothesised that the prevalence of LUT 
symptoms in patients with functional disorders attending neurology would be high and is likely to be 
distressing.  We further hypothesised that females with a functional disorder would have more low 
stream symptoms. 
Given the success of the Scottish Neurological Symptoms study in recruiting patients, the accuracy of 
diagnoses (only 4 out of 1144 patients’ functional diagnoses changed over an 18 months follow up7) and 
the importance of a neurological control group to compare LUT symptoms with, our study utilized the 
same methods in a single centre to investigate prevalence of LUT symptoms in patients with functional 
and pathophysical neurological disease and levels of associated distress.   
Our study aimed to assess a) type of LUT dysfunction based on our hypothesis that female patients 
would be more likely to have low stream symptoms and b) any associated distress, in patients attending 
general outpatient neurology clinics with functional and pathophysiological diagnoses. 
 
 Materials and Methods 
A single centre study of consecutive patients attending general neurology outpatient appointments over 
a one month period was carried out at the Western General Hospital, Edinburgh.    The study design was 
based on the Scottish Neurological Symptoms Study and used similar classifications to ensure diagnostic 
validity.  Ethics approval was gained from South East Scotland Research Ethics Committee (Ref 
16/SS/0107).  All patients over 18yrs of age, attending a general neurology outpatient clinic during the 
study time, with capacity to consent and who could read the questionnaires in English were eligible for 
the study.  Patients were informed of the study by information leaflet sent with their neurology 
outpatient appointment and then choose whether to take part on the day.  If they expressed an interest, 
patients were consented by an author (OSS) and received questionnaires prior to their appointment.   
Demographics and Urinary Symptom and Quality of Life Measures 
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Demographic data (age and sex) and was obtained from the questionnaire, opiate use from 
neurologist’s clinic letter review.  Bladder symptoms were assessed using the Urinary Symptom Profile 
which provides separate scoring for stress incontinence (Range 0-9), overactive bladder (Range 0-21) 
and low stream (Range 0-9).  The Urinary Symptom Profile is best seen as a descriptive measure, 
demonstrating the three different types of urinary symptoms present with good clinical correlation 
compared with bladder diary and ICIQ-UI SF8, but there are no cut-offs for scores denoting mild, 
moderate or severe urinary symptoms. Distress regarding urinary symptoms was measured using the 
Short Form Qualiveen (SF-Qualiveen). SF-Qualiveen is an eight item questionnaire used to assess the 
extent to which urinary symptoms impact on a patient’s life in four domains: ‘bother from limitations’; 
‘fears’; ‘feelings’ and ‘frequency of limitations’.  Minimally significant scores for each domain were 
defined as 0.82, 0.46, 0.51 and 0.42 respectively and for total scores was 0.939. 
Neurological Diagnosis 
When the patient attended their neurology appointment the consultant neurologist was asked to rate 
how likely the patient’s neurological symptoms were due to a functional disorder with four options; not 
at all, somewhat, largely or completely.  The definition included the same definition of functional 
disorders used in the Scottish Neurological Symptoms Study which has proven diagnostic accuracy7; 
‘tension headache, symptom syndromes (e.g. fibromyalgia, irritable bowel syndrome); physiologically 
explained processes which are thought to be linked to emotional symptoms (e.g. hyperventilation); 
chronic pain or dizziness which is unexplained by a clear structural cause’ and also functional 
neurological disorders diagnosed according to DSM-5 criteria (functional neurological symptom 
disorder/conversion disorder). The DSM-5 criteria is a clinical diagnosis requiring positive evidence of a 
functional neurological disorder, such as the tremor entrainment test of functional tremor.   As in the 
Scottish Neurological Symptoms Study for analysis, patients were grouped into two groups; ‘not at 
all/somewhat’ and ‘largely/completely’ due to a functional disorder.  Neurologists also recorded their 
overall diagnosis of the patient’s neurological problem. 
Analysis 
Comparisons of SF-Qualiveen and Urinary Symptom Profile scores between groups ‘not at all/somewhat’ 
and ‘largely/completely’ due to a functional disorder were conducted non-parametrically using a 
Kruskal-Wallis (multi-group) or Mann Whitney U test (two groups).  Contingency tables for inter-group 
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prevalence of symptoms were analysed using a Chi-Square Test. Urinary Symptom Profile and SF-
Qualiveen scores were analysed in two groups; ‘not at all/somewhat’ and ‘largely/completely’ due to a 
functional disorder and by gender within these groups.  The role of opiates on bladder symptoms was 
explored by assessing urinary symptom scores with and without patients using opiates in both groups. 
Significance level was p=0.05 and adjusted for multiple comparisons, were appropriate, using Tukey’s 
honest difference method.  All analysis was undertaken in Statsdirect (www.statsdirect) or MATLAB 
2015b using custom written scripts. 
 
Results 
(See Figure One). 230 patients attended neurology outpatient clinics over the month-long study 
duration.  165 patients were consented for the study of whom 132 correctly filled out the 
questionnaires.  88 (67%) of patients were classed as having symptoms ‘not at all/somewhat’ due to a 
functional disorder and 44 (33%) ‘largely/completely’ due to a functional disorder.  There was a 
significant difference between genders across the four groups (p=0.01) with the highest proportion of 
females to males in the group with symptoms ‘largely’ due to a functional disorder (6.67:1). 
Neurological Diagnoses  
In keeping with the spectrum of functional disorders seen in the Scottish Neurological Symptom study a 
quarter of with symptoms ‘largely/completely’ due to a functional disorder were diagnosed with 
headache disorders (n=11; migraine n=7 and chronic daily headache n=4).  Half of all patients with 
symptoms ‘largely/completely’ due to a functional disorder were given a diagnosis of a functional 
neurological disorder (FND) (n=22; general FND n=8, dissociative seizure n=7, functional sensory 
symptoms n=2, functional weakness, memory impairment, persistent postural-perceptual dizziness, 
functional gait disorder and dystonia, all n=1).  The remaining quarter of patients were diagnosed with 
anxiety (n=4), chronic pain (n=3) and tic disorder, Insomnia, Chronic fatigue syndrome, Orthostatic 
hypotension (all n=1). 
Only one patient had overlapping structural and functional disease diagnoses, this patient had an MRI 
scan suggestive of white matter inflammation but did not meet McDonald criteria for a diagnosis of 
multiple sclerosis.  Her presenting symptoms at outpatient clinic were felt to be largely or completely 
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due to a functional neurological disorder and she was coded for this study as having a functional 
neurological disorder. 
In patients with symptoms ‘not at all/somewhat’ related to a functional disorder the most common 
diagnostic criteria were headache disorder (n=26, 30% primary headache disorders) and seizure disorder 
(n=25, 29%).  13% of patients had neuropathy (n=11), 5% had demyelinating disease (n=4) and three 
patients (3%) each had Parkinson’s disease, transient loss of consciousness or other neurological 
symptoms (atypical facial pain, facial twitching, tinnitus all n= 1).  Other infrequent diagnoses were 
peripherally induced vertigo, degenerative disc disease, vasculitic disease or anxiety related (health 
anxiety or anxiety about family history) all 2% (n=2).  One patient had each of: stroke, obstructive sleep 
apnoea, REM behaviour disorder, trigeminal neuralgia and motor neurone disease. 
Figure One: Flow Chart of Patient Recruitment 
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There is only one question in SF-Qualiveen which is negatively phrased, Q8 “Can you go out without 
planning anything in advance?”  During preliminary analysis we noted that this one question showed 
large inter-domain variance and a Cronbach’s Alpha=0.29 and was answered by 17/132 (13%) of 
patients with “never” (the maximum score) despite them scoring 0 on all other SF-Qualiveen questions.  
We interpreted this as a problem with the questionnaire rather than a true effect.  In the 16 patients 
(largely/completely n=3 (7%), not at all/somewhat explained n=13 (15%)) who scored 0 in all other SF-
Qualiveen questions adjusting “never” to its corresponding score 0 score “always” increased the inter-
domain agreement and Cronbach’s alpha increased to 0.65.  This may be a problem with the 
questionnaire, and we highlight it as a potential source of bias to other researchers.  We removed these 
16 patients’ answers from our analysis.  Bother with limitations and overall score was calculated on 
other 116 patients.  
Urinary Symptoms and Distress due to Urinary Symptoms 
See Tables One and Two Aside from gender there was no difference in measures between patients’ in 
the largely/completely and not at all/somewhat groups.  Over 80% of patients in both groups scored at 
least one point on the OAB section of the Urinary Symptom Profile (n=73, 83% and n=28,86%). When 
divided by gender women with symptoms largely/completely due to a functional disorder had 
significantly different low stream symptoms (0.3 vs. 0.85, p=0.0005) and were more bothered by 
limitations and fear (p=0.008 and p=0.03) and had higher opiate use (21% vs. 4%, p=0.03).  When 
divided by gender over 80% of females in both groups scored at least one point on the OAB section of 
the Urinary Symptom Profile (n=38,83% and n=28,85%) but a higher proportion of patients in the 
largely/completely group scored more than one point in the low stream score (n=7,15% vs. n=15, 45%).  
However, when we excluded the seven patients taking opiates (widespread pain n=5, chronic back pain 
n=2) then there was no significant different between low stream rates (0.3 vs. 0.4, p=0.1) and the 
number of patients with low stream symptoms fell to nine (33%).   
Distress 
Patient with symptoms ‘largely/completely’ due to a functional disorder were significantly more likely to 
report at least one significantly affected domain in SF-Qualiveen (66% vs 45%, p=0.03).  However, 
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despite more patients being distressed, levels were still 1 to 1.1 suggesting only slight reduction in 
quality of life. 
Table One. Urinary Symptoms and SF-Qualiveen dichotomized 
 Extent to which neurological symptoms explained by Functional Disorder 
 Not at all/Somewhat  Largely/Completely P 
value 
N 88 (67%) 44 (33%)  
Age 45 42 0.4 
Sex F:M = 1.91:1 F:M = 3:1 0.01 
Urinary Symptom Profile (n(%) or mean +-SD 
 Mean Scores all patients 
n=88 




Incontinence 0.72+-1.52 1.27+-2.29 0.3 
Overactive 
Bladder 3.95+-3.57 5.55+-4.65 0.2 
Low Stream 0.75+-1.42 0.95+-1.22 0.1 
SF-Qualiveen  
 Not at all/Somewhat  Largely/Completely P 
value 













0.47+-0.78 17 (39%) 0.76+-0.97 0.06 
Fear 42 (48%) 0.53+-0.78 27 (61%) 1.08+-1.21 0.1 
Feelings 22 (25%) 0.49+-0.88 18 (41%) 0.93+-1.21 0.06 
Frequency 
limitations** 
41 (55%) 0.86+-0.96 
26 (63%) 1.22+-1.22 0.2 
Overall  0.59  1  
P value compares the mean scores of patients in USP and % with distress in SF-Qualiveen 
*SF-Qualiveen scores above cut off ** 16 patients were excluded (see text) 
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Table Two. Urinary Symptoms and SF-Qualiveen dichotomized, Females only. 
 Extent to which neurological symptoms explained by Functional Disorder  
 Not at all/Somewhat  Largely/Completely P 
value 
N 46 (53%) 33 (75%)  
Age 40 42  
Urinary Symptom Profile (mean, SD) 























SF-Qualiveen (mean, SD) 




n (% ) with 
distress* 








Fear 22 (48%) 0.58+-0.83 21 (64%) 1.21+-1.29 0.03 








Overall  0.53  1.1  
Opiate Use 
 Not at all/Somewhat  Largely/Completely P 
value 










Low Stream Questions 
How would you describe your usual urination over these past 4 weeks? P value 
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Need to push with abdominal 
(stomach) muscles or learn 
forward (or require change of 
position) to urinate 
4 (9%) 6 (18%) 0.2 
Very slow from start to finish 0 1 (3%) 0.4 
In general how would you describe your urine flow? 
Difficult to start then normal or 
easy at first but slow to finish 
6 (13%) 12 (36%) 0.02 
Very slow from start to finish 1 (2%) 2 (6%) 0.4 
P value compares the mean scores of patients with USP and % with distress in SF-Qualiveen 
^ Any symptoms= any USP scores >0 
*SF-Qualiveen scores above cut off 
 
Lower Urinary Tract Dysfunction in patients with a functional neurological disorder 
A small number of patients had a functional neurological disorder (n=22) and only preliminary 
observations can be deduced due to the sample size.  Patients with a functional neurological disorder 
were 77% female and had significantly more bother with limitations and overall distress.  Of the 16 
female patients with a functional neurological disorder 50% (n=8) scored one or more on the Urinary 
Symptom Profile and two patients were taking opiates. 
 
Table Three: Lower Urinary Tract symptoms in patients diagnosed with a functional neurological 
disorder 
 Extent to which neurological symptoms explained by Functional Disorder 
 Diagnosis of FND  Not at all/Somewhat  
N 22  88 
Age 42.5 +-15.68 44.9+-18.08 0.5 
Sex F:M= 2.67:1 F:M = 1.91:1 0.09 
Urinary Symptom Profile (n(%) or mean (SD)) 
 All patients All patients P value 
Stress Urinary 
Incontinence 
0.86 +- 1.91 
0.72+-1.52 0.9 
Overactive Bladder 5.63+- 4.86 3.95+-3.57 0.2 
Low Stream 0.91+-1.06 0.75+-1.42 0.2 
SF-Qualiveen (mean, SD)* 
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n (% ) over 
threshold 
All Patients  
Bother with limitations 
11 (50%) 0.98 +- 1.13 20 (23%) 
 
0.47+-0.78 0.02 
Fear 13 (59%) 1.25 +- 1.34 42 (48%) 0.53+-0.78 0.35 
Feelings 9 (41%) 1 +- 1.29 22 (25%) 0.49+-0.88 0.2 
Frequency limitations 14(64%) 1.36+-1.3 41 (55%) 0.86+-0.96 0.2 
Overall  1.14  0.59 0.005 





One third of patients presenting to neurology outpatients had symptoms largely or completely due a 
functional disorder and half of these (n=22, 16%) had a diagnosis of a functional neurological disorder.  
Overall, patients with symptoms ‘largely/completely’ due to a functional disorder scored had similar 
severity of symptoms and were similarly distressed.  However, female patients with functional disorders 
reported more low stream symptoms and detriment to quality of life with respect to their urinary 
symptoms.  Difference in low stream symptoms became insignificant when patients taking opiates were 
excluded. 
Little is known about the severity of lower urinary tract symptoms in a typical range of patients with 
functional disorders and neurological symptoms who attend outpatients.  There has been some 
exploration of lower urinary tract symptoms in functional disorders, including irritable bowel syndrome 
and fibromyalgia with patients commonly having storage symptoms10.  Historically patients with 
functional neurological disorders, including those described previously as having “hysteria”11 and DSM-
IV somatisation disorder12, were associated with the symptom of urinary retention. There have only 
been four studies systematically investigating urinary dysfunction, three in patients with functional 
neurological disorders and one on ‘psychogenic’ urinary dysfunction. One study of lower urinary tract 
symptoms in patients with functional movement disorders found that 20% of patients self-reported 
lower urinary tract symptoms.  The majority of patients described overactive bladder symptoms (63.6%).  
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Patients with fixed dystonia had the most severe bladder symptoms and were more likely to be on 
opiates and have low stream symptoms13.   The other two studies investigated the relationship between 
functional disorders and lower urinary tract symptoms indirectly.  The first study of 107 patients with 
functional leg weakness asked patients if they suffered bladder symptoms at interview, these were 
found in 28% of patients 14.  Unfortunately, no other details about type or severity are available. In the 
other study, 62 patients with Fowler’s syndrome 24% were found to have evidence of a functional 
disorder and half had some form of pain15.  In the only recent study of psychogenic urinary dysfunction 
Sakakibara et al16 defined it as exclusion of any urological, gynaecological and neurological causes in 
patients who had accompanying more obvious psychiatric/psychological features.  The overall 
prevalence of psychogenic urinary dysfunction was 0.7% (n=16) in their specialist Uro-Neurological 
population.  Sakakibara et al found that most patients with psychogenic urinary dysfunction had both 
difficulty urinating and overactive bladder symptoms.  Most urodynamics were normal, although some 
patients demonstrated underactive/acontractile detrusor or had increased bladder sensation.    In 
keeping with this our patients with functional disorders had high overactive bladder symptom scores 
and female patients with functional disorders had more low stream symptoms compared with other 
general neurology patients.   
However, mean scores for all patients were not particularly high and were lower than had been found 
previously in patients with functional movement disorders, particularly if the means of the 
‘largely/completely’ groups were compared.  This may be because patients were only invited to take 
part in the study of functional movement disorders and LUT symptoms if they described LUT symptoms 
to their neurologist.  Furthermore, although more patients in the functional disorders category met the 
criteria for distress caused by urinary symptoms their scores were also not high, with overall average in 
the group around 1.  This may suggest a statistical but not clinically significant difference between the 
two groups as patients had varying levels of slight distress.  Our study demonstrates that although LUT 
symptoms are often recorded by patients with functional disorders and functional neurological 
disorders, they may not be clinically of great importance to patients.  The two specific features found to 
be positive, bother with limitations and bother with feelings, may be important as they enquire about 
distress caused by time spent passing urine or catheterizing and a feeling of bladder problems 
complicating their lives and feeling embarrassed and worried about bladder symptoms.  These may be 
important questions to explore further with patients with functional disorders. 
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There are numerous reasons for low stream symptoms of which medications such as opiates and 
dysfunctional voiding are only two. Whilst there was a higher proportion of women taking opiates in the 
‘largely/completely’ due to a functional disorder group, this still only amounted to less than one quarter 
of the group total.  However, when these patients were excluded the symptom score was similar 
between groups.  This highlights the importance of taking into account medications and other biological 
mechanisms which may impact on patients’ symptoms and be readily treatable.  Resolution of chronic 
idiopathic urinary retention has been reported with stopping opaties17.  Alternative explanations include 
other medications, functional or structural bladder problems including dysfunctional voiding and 
undiagnosed Fowler’s syndrome, which was found to have significant comorbid functional neurological 
disorders in a retrospective study15,18. These were beyond the scope of this small self-report study.   
Limitations 
This study was of self-reported lower urinary tract symptoms and did not explore the dysfunction 
through urodynamics. Assessing patients with urodynamics and post void residual using a bladder 
scanner or in-out catheterization in future studies would provide understanding of the mechanism of 
bladder dysfunction in patients with bladder symptoms, including the prevalence of dysfunctional 
voiding and urinary retention. Our study is limited by the small number of patients with a functional 
neurological disorder (n=22) and the lack of follow up to ensure diagnostic accuracy, although diagnoses 
made in this way have previously been found to be accurate on 18 month follow up.  Additionally, age is 
likely to significantly affect the type and prevalence of lower urinary tract symptoms such as stress 
incontinence, that we did not find any correlation may be due to the small range of ages involved.  The 
Urinary Symptom Profile, although a good tool for self-report of lower urinary tract dysfunction, is very 
sensitive19 and does not have cut offs for symptoms which are mild, moderate or severe.  Therefore, all 
we can say is that patients have certain symptoms, their severity is less easy to interpret.  We collected 
information about opiate use but other medications are associated with urinary retention and urinary 
incontinence but this link was not testable in our study20,21.  We do not feel our findings can be entirely 
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This study is the first to investigate bladder symptoms in a wide range of patients with functional 
disorders attending outpatient neurology clinics.  It also compares these patients to a variety of patients 
attending general neurology outpatients. Despite the importance of symptoms and distress caused by 
them to patients affected by both pathophysical and functional neurological disorders, there have only 
been three other studies investigating lower urinary tract symptoms in patients with functional 
disorders in the last ten years.  We conclude that bladder dysfunction in patients with functional 
neurological disorders is an unexplored, yet clinically significant problem. 
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Conclusion:  The study discovered that patients with functional disorders have similar levels of 
urological symptoms as patients with other neurological disorders but were more distressed by 
them.  Females with functional disorders had more severe low stream symptoms (0.85 vs. 0.3). I 
discussed the small number of studies which address urological dysfunction in functional 
neurological disorders and current thinking about mechanisms causing voiding dysfunction which 
may be associated with medication, pain, trauma and higher psychological comorbidity than control 
urological populations.  Opiates appeared to be a major factor in low stream symptoms in patients 
with functional disorders.  When patients who were taking opiates were excluded, the symptom 
scores between groups was no longer significantly different.  Similar findings in a cohort of patients 
with idiopathic urinary retention resulted in symptom resolution on stopping opiates and highlighted 
the need to investigate all biological factors which may be influencing urological function. 
This study was limited by the questionnaire and by the lack of a simple question ‘do you have any 
bladder problems?’.  The lack of this step made the study less useful as the questionnaire does not 
have a cut-off point for normal/no symptoms.  It was also limited by self-report methodology and 
lack of urological investigation but serves as a first step towards dedicated study of the relationship 
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In this study there are a wide range of limitations and potential biases due to; the populations 
studied, recruitment mechanisms, blinding, the assessments used and the follow up rates achieved. 
The chapter is a reflection of my learning about research methodology.  It will focus on the 
prospective study although the methodological limitations apply to other parts of the study.   
 
Case Definition and Sampling Bias 
Scan positive CES 
There were significant difficulties with defining both controls and cases.  I will start with the 
definition of controls, patients with clinical and radiological evidence of cauda equina syndrome 
(CES).  Cases were based on the definition of controls. 
Difficulties with the definition of ‘scan positive’ CES 
Despite patients with ‘scan positive’ CES being a seemingly well-defined control group there were 
major problems when it came to utilising a simple definition.  First was the lack of any national or 
international consensus on what exactly CES is, either radiologically or clinically.  There are at least 
17 different clinical definitions of clinical CES and even after a systematic review of CES definitions15, 
at least two more different definitions have been suggested with multiple sub classifications19,22.   
Debate rages over whether certain CES phenotypes require surgery urgently or whether surgery 
within 24 or 48 hours of symptom onset corresponds to long term outcome.  Radiologically there is 
little guidance on what constitutes enough cauda equina nerve root compression to have symptoms.  
A famous animal study required >75% canal stenosis or lack of CSF around the CE nerve roots so we 
opted to use this definition with an awareness that it remains open for criticism. 
Difficulties with the definition of the mixed group 
The most scientifically controversial CES definition is ‘suspected’ (usually called impending in clinical 
settings) CES23, which is described as “those with bilateral radiculopathy and/or subjective 
sphincteric problems with no objective evidence of CES, such as objective alteration of perineal 
sensation” 23.  There is no radiological definition of ‘suspected’ CES however, in clinical practice 
radiologically there is a large disc protrusion but no cauda equina nerve root compression seen.  The 
clinical aspects of CES and concern about medicolegal consequences of missing an early CES 
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presentation mean that many patients with impending CES are treated as urgently as patients with 
‘scan positive’ CES.  It is often not possible to tell if patients with impending CES are included in ‘scan 
positive’ CES populations described in literature as definitions of CES even in large studies are usually 
“clinically determined”24,25.  Whether this group of patients with impending CES is included within 
the ‘scan positive’ CES group is important in light of literature which shows that patient factors such 
as female gender, high somatic symptom score and treatment expectations influence how likely a 
patient is to be offered spinal surgery26.  Given our hypothesis that some patients without ‘scan 
positive’ CES have a functional neurological disorder explaining some or all of their symptoms, and 
that patients with many types of functional disorder are more likely to be female and have high 
numbers of somatic symptoms27, it was important to remove them from the ‘scan positive’ CES 
group in order to be able to study as pure a sample as possible.   
What is ‘scan negative’ CES? 
To create as pure a sample as possible, patients with clinical CES but normal scans or scans without 
any nerve root entrapment were placed into a ‘scan negative’ CES group.  We hypothesised that 
these patients would be most likely to have predisposing, precipitating and perpetuating factors for 
FND and have evidence of functional disorders and FND. 
Final Definitions 
All patients had clinical features of CES as per the Fraser et al systematic review criteria; ≥1 of 
bladder, bowel, sexual dysfunction or saddle numbness +/- lower limb neurological dysfunction and 
were divided into three categories based on their radiology: 1) ‘scan positive’ cauda equina 
syndrome - defined as compression of the cauda equina nerve roots with >75% canal filling and/or 
no CSF around the cauda equina nerve roots on axial view28; 2) a ‘mixed’ category in which, patients 
who did not meet radiological criteria for cauda equina compression but did meet the clinical and 
radiological criteria for suspected/impending CES and had either a large disc with <75% canal 
narrowing or cauda equina “crowding” (reduced but not absent CSF volume around the cauda 
equina nerve roots on axial imaging and <75% canal narrowing), bilateral or unilateral nerve root 
entrapment which may have explained some of their symptoms and 3) ‘scan negative’ cauda equina 
syndrome with no nerve root compression or other radiological reason for their clinical CES 
symptoms.   
This stratification was designed by my supervisors and I with input from the neurosurgeons and is 
open to the criticism that it has not been validated in prior studies.   
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Who makes it to neurosurgical wards with ‘scan negative’ CES  
The diagnosis of ‘scan negative’ CES can only be made once MRI imaging has occurred and other 
conditions have been excluded.  This necessitates studying patients in secondary care.  Population 
studies are the best way to examine aetiological associations for a condition.  Patients recruited 
from hospital settings may have features in common, such as depression or anxiety or geographical 
or socioeconomic factors that relate to referral rather than the underlying symptoms or may 
represent more “difficult” patients.  Studying these patients may tell us more about the ability to get 
referred to secondary care than about patients with uro-neurological disorders and negative 
imaging.  There may be many patients who have bladder symptoms and require urgent MRI imaging, 
however, only a small amount of patients will make it to the neurosurgical unit.  This may be 
because patients who are admitted to neurosurgery present via their GP and get direct neurosurgery 
admission, present with more symptoms or are more likely to present overnight out of hours when 
MRI imaging is not available.   These patients may be much more likely to have functional symptoms, 
panic and dissociation.  
 
How have I dealt with this in my study? 
This study aims to be representative of the patients who present as ‘scan negative’ CES, not the 
population of patients with uro-neurological disorders and negative imaging.   It would be almost 
impossible to obtain a population-based sample of patients with ‘scan negative’ CES as patients 
would need to be investigated with examination, bloods and imaging, to ensure that they did not 
have another condition, particularly ‘scan positive’ CES.   
The retrospective study showed that there were a large number of patients presenting with clinical 
CES to a regional neurosurgery unit.  In order to be able to carry out a semi structured interview and 
examination the best way to access patients was via the inpatient neurosurgical ward.  These 
patients may have had more symptoms than others but are representative of many patients, 
represent an unmet need in diagnosis and treatment and could be accessed and recruited in a 
standardised, consecutive way which allowed for additional information to be gathered about 
patients in the acute setting. Patients admitted to other wards in the Western general Hospital after 
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discussion with neurosurgery, and usually a normal scan, were also seen during their inpatient stay 
but it was more difficult to review and examine them and impossible to get the team responsible to 
do the additional MRI brain and lumbar puncture testing which lead to lower quality information 
about these patients. 
 
Diagnostic suspicion bias 
The problem 
How do doctors choose which patients with back pain have possible CES?  How much do they over 
diagnose it in patients with severe pain or prior bladder dysfunction or underdiagnose it when 
patients have bowel or sexual dysfunction or saddle anaesthesia but normal bladder function?  How 
many patients are not asked about sexual dysfunction and are therefore not eligible for scanning?  
Do doctors over-investigate in patients with prior lumbar surgery?  In how many cases are patients’ 
pain or a functional disorder causing the majority of their symptoms, but they get an emergency 
operation anyway due to the distress they present with? 
I have no doubt that there are considerable differences in the thresholds which A&E, GP and even 
differing consultant neurosurgeons involved in the study used to investigate or operate on patients 
with back pain and uro-neurological symptoms.  Some GP and A&E staff will readily investigate for 
possible CES in anyone with back pain and any kind of bladder dysfunction, others require an 
abnormal saddle sensation or post void residual of >200mls. Some neurosurgeons will operate 
during the acute admission on anyone with a disc herniation and any bladder symptoms or if a 
patient is in severe pain whereas others will operate only if patients have both a convincing history 
in keeping with CES and no CSF around the cauda equina nerve roots on imaging.  These more 
conservative surgeons will often watch and wait in patients with suspected CES and even in the 
presence of radiological but not clinical CES.  The difficulty of diagnosing ‘impending CES’ has been 
previously highlighted.  Impending CES symptoms may be caused by the pain, panic, medication or 
functional neurological disorders rather than due to cauda equina nerve root compression. 
 
How have I dealt with this in my study? 
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These patients, and their care, represent the normal clinical course of patients presenting with 
suspected CES and whilst heterogenous, highlight the difficulties faced in observational clinical 
studies.   
 
Diagnostic accuracy bias 
The problem 
How accurate is the diagnosis of ‘scan negative’ CES?  What if many of these patients turn out to 
have a disease that explains their condition such as an inflammatory, infectious, vascular or 
neurodegenerative problem?  Shouldn’t all patients have an MRI brain and a lumbar puncture to 
ensure they don’t have a disease? 
How have I dealt with this in this study? 
Both of my own retrospective and prospective studies have, for the first time, demonstrated a low 
misdiagnosis rate in patients with ‘scan negative’ CES of 1-4% on follow up on an average of 15 and 
24months.  This is in keeping with other studies of misdiagnosis in functional neurological disorders 
and is broadly comparable with all neurological diseases29. 
There are several reasons why I did not include neuroimaging as a prerequisite for entry into the 
study: 
The study was aiming to be an observational case: control study so that results were generalisable to 
neurology services elsewhere.  Compulsory neuroimaging would have interfered with this process 
and may have made neurosurgeons less likely to agree for me to see their patients. 
A normal MRI brain fails to guarantee the absence of a wide range of neurological disorders such as 
neurodegenerative disorder (such as multisystem atrophy or progressive supranuclear palsy), some 
vascular malformations (especially spinal ones) or infectious lumbosacral polyradiculitis.  When 
misdiagnosis did occur an MRI brain would not have changed initial diagnosis (sacral chordoma, 
cervical spine transverse myelitis, spastic leg with normal imaging and cervical spinal haematoma).  
Lumbar punctures in all patients would have strengthened our argument about lack of new 
neurological diagnosis, particularly of newer diagnoses such as anti-MOG antibody but we were 
concerned about iatrogenic implications for patients.  Additionally, most patients were discharged 
before a lumbar puncture could be performed and neurosurgical teams were not keen for patients 
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to have them as they delayed discharge.  Outpatient lumbar punctures could have been performed 
after discharge but infectious polyradiculitis such as Elsberg syndrome would no longer be 
detectable as CSF normalises within the first 48-72hours.  There are also cost and resource 
implications for both MRI brain imaging and lumbar punctures and the resultant delay in discharge 
or use of outpatients.   
In conclusion, on the basis of previous studies, as well as the retrospective and prospective study, I 
expect misdiagnosis to have occurred at a rate of 5-10% in the ‘scan negative’ CES group and 5-10% 
of patients in the mixed group who had radiologically unimportant MRI scan findings.  I do not think 
neuroimaging or lumbar puncture would have significantly altered this rate.  A re-analysis after 
10years would clarify whether this conclusion is correct. 
 
Control Definition and Sampling Bias 
The incorrect control group can be the primary flaw in a case control study.   
How have I dealt with this in the study? 
The controls were selected to answer the questions I felt were most important in phenotyping and 
understanding mechanism in patients with ‘scan negative’ CES: 
To what extent do the factors associated with ‘scan negative’ CES simply reflect a mixture of: 
1. The impact of pain and medications on bladder dysfunction? 
2. The complex process that leads some patients with back pain and bladder symptoms to 
being seen in A&E or by the neurosurgical team while others are not? 
As the study was primarily aiming to phenotype patients with ‘scan negative’ CES, and a 
representative sample was required so that information could be generalisable to other 
neurosurgery centres, patients with complete cauda equina nerve root compression (‘scan positive’ 
CES) which would be expected to completely explain their pain, bladder, bowel and sexual 
dysfunction and lower limb symptoms and patients with nerve root compression which could explain 
some of their symptoms were the best control group possible.  A control group of patients with ‘scan 
negative’ CES who had not been referred to hospital would be the ideal control group.  As already 
discussed, this would have been an impossible group to identify and treat. 
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Confounding in the control groups  
The problem 
What if the factors being examined in this study were particularly prevalent for some reason in the 
neurosurgical controls compared to patients generally with CES symptoms?  Did it matter that most 
patients with ‘scan positive’ CES had discogenic cauda equina compression? How does that affect 
the data? 
How have I dealt with this in this study? 
The criteria for the control groups were designed to be clinically useful.  Patients in the ‘scan 
positive’ CES group were more likely to be males but this is useful information.  Patients in the mixed 
group were similar in age, symptoms and sex to patients with ‘scan negative’ CES and were 
important in assessing whether stepwise functional predisposing, precipitating and perpetuating 
factors existed. 
 
Selection bias of patients with functional weakness by referring neurologist 
The problem 
The biggest criticism that can be made of the recruitment methods of patients with ‘scan negative’ 
CES in this study is that they are not reliability consecutive since they depended on neurosurgeons 
telling patients about the study and patients choosing to take part. 
There may be several additional reasons why recruitment may not have occurred. 
• The neurosurgeon may have forgotten to mention it to the patient 
• The neurosurgeon may not have wanted to involve the patient in case it created more work 
and ordering more scans, or been worried carrying out lumbar punctures may have 
prolonged inpatient stay 
• The patient may not have been sent to the neurosurgery ward and may have been 
discharged directly from A&E or sent to a medical ward if the scan was done early 
• There may have been too many patients to recruit all of them 
How have I dealt with this in this study? 
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There were ethical and pragmatic reasons for choosing this method of recruitment.  Ethically, 
patients had to be approached by a member of their clinical care team to ensure their willingness to 
take part in the study.  Secondly, I wanted to see patients in the inpatient setting to phenotype the 
acute symptoms of patients with ‘scan negative’ to ‘scan positive’ CES and to interview and examine 
them looking for positive evidence of a functional neurological disorder. 
Nevertheless, patients with ‘scan negative’ CES were admitted and not recruited to the study which 
could have biased the study in several ways. 
 
Non-recruitment of cases of ‘scan negative’ CES from other specialists. 
The problem 
The majority of patients I recruited were from the neurosurgery ward and were seen as inpatients.  
There are patients who present to A&E with back pain and bladder dysfunction, or who develop 
these symptoms during their inpatient stays and are never discussed with neurosurgery.  These 
patients may differ significantly from patients admitted to the neurosurgery ward. Patients who 
develop their symptoms in a less acute way may present to neurology or urology but never be 
referred to neurosurgery as their imaging will be normal. 
How have I dealt with this in this study? 
I am aware that the patients with ‘scan negative’ CES I have seen in the study represent an unknown 
proportion of the overall number presenting to general practitioners, A&E departments, in pain 
clinics, attending urology, orthopaedics etc.  Since so many patients had resolution of symptoms, 
especially symptoms of a functional neurological disorder, on follow up, it follows that there must be 
patients who are never referred to neurosurgery.  During my PhD I was asked to see several patients 
who were referred only to outpatient neurology as they had either never presented to A&E, had 
been discharged directly after MRI scanning or did not have severe enough symptoms to warrant 
MRI scanning in A&E.  This is perhaps not a problem with this study given that the aim was to 
phenotype patients with ‘scan negative’ CES.  It is, however, important to remember that the 
patients with ‘scan negative’ CES seen in this study are likely to be only a proportion of the incident 
cases in South East Scotland and may represent the most severe end of the symptom spectrum. 
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Selection bias in recruitment of controls 
The problem 
Controls were recruited from the same neuroscience centre.  Patient factors could have influenced 
who was referred to neurosurgery with possible CES for an urgent MRI scan. 
How have I dealt with this in this study? 
This study reflects usual clinical practice.  We are aware of patient factors which may influence 
which patient with nerve root compression are referred for an urgent scan and tried to assess these 
for differences in our study including assessing pain, panic, dissociation, somatic symptoms, quality 
of life, illness and treatment beliefs. 
 
The overlap with pain and medications 
The problem 
The majority of patients with ‘scan negative’ CES had severe pain and were on medications which 
could impact on bladder function.  Whilst Hoover’s sign and thigh abductor have good sensitivity and 
specificity in other groups, including patients with stroke30, it is unclear what effect pain will have on 
the reliability of the test.  Many patients were on mediations which may have impacted on their 
ability to answer questions accurately by causing drowsiness or confusion.  There was no way to 
control for strong medication use although all patients’ medications were written down.   
How have I dealt with this in this study? 
I had planned on asking a blinded neurological consultant (JS) to check Hoover’s sign and thigh 
abductor and also planned to use weighing scales to detect the difference in weight put through the 
leg on direct versus automatic hip extension.  Unfortunately, I did not achieve either of these.  
Future studies will be designed to create a more streamlined way to get blinded assessment.  
Teaching the neurosurgeons how to do Hoover’s sign would also be a way to have an additional 
assessor.  Although they would be non-blinded to the history, they usually see patients before they 
have an MRI scan. 
Medications which could affect bladder, bowel or sexual dysfunction were documented in all groups.  
Surprisingly, there was no significant differences between overall pain medications in type or 
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number between groups.  On looking at medications individually patients in the mixed group were 
more likely to be taking gabapentinoids and patients in the ‘scan negative’ group were more likely to 
be taking benzodiazepines.  This may have led to bias in the study results but reflect clinical reality. 
 
Heterogeneity   
The problem 
Is it valid to study patients with urinary retention versus urinary incontinence or bladder, bowel and 
sexual dysfunction?  Are the populations of scan negative CES too far removed from patients with 
mixed CES to be studied together?  Are patients with functional symptoms brought on by severe 
pain and a panic attack similar to patients with life-long somatisation?  Are transient signs of a 
functional neurological disorders the same as symptoms severe enough to warrant the diagnosis of a 
functional neurological disorder in outpatient clinic? 
How have I dealt with this in the study? 
The main aim of the study is to phenotype patients who present with ‘scan negative’ CES.  
Generalisability could only be persevered by a consecutive case control study of patients presenting 
with suspected CES.  Rather than eliminate heterogenicity using a poorly tested construct, such as 
patients with only complete urinary retention, the study aimed to encourage it but remain aware of 
the problems, which include: 
• Mixing patients with severe and mild bladder, bowel and sexual dysfunction and 
neurological deficit 
• Mixing patients with transient (days/weeks) and enduring (years) symptoms e.g. 
o Acute Symptoms after bilateral S1 nerve root compression vs. acute worsening of 
chronic pain, functional weakness and bladder symptoms 
 
Refusal rates (non-response bias) 
The problem 
Refusal rates introduces bias because patients who refused could have changed the results.  In 
addition, patients who did not complete all the assessments, or only partially completed 
questionnaires introduce potential bias.   
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How I dealt with this in this study 
Refusal to take part in the study total n=28 (12% total patients) 
1. Patients with ‘scan negative’ and mixed CES – response rate 84%; questionnaire response rate 
66% 
This study was done on patients who were admitted acutely to the neurosurgery ward having 
been brought into hospital in severe pain and who underwent scanning after being warned that 
they could lose bladder, bowel, sexual function and lower limb function.  It was challenging to 
recruit patients particularly as I was allowed to approach them only after a member of their 
clinical team had discussed the study with them.  The neurosurgeons were busy and would 
forget the study unless specifically reminded before the ward round.  Even then some patients 
would have to be approached later by one of the nurses.  All assessments including structured 
clinical interviews for DSM-IV psychiatric disorders had to be done by the bedside where there 
was very little privacy.  However, few patients stopped the interview at that point.  The 
questionnaire was returned in <70% of patients with ‘scan negative’ CES.  Feedback I received 
was that it was too long and too psychological.  I learned from this and only gave the 
questionnaire after we had completed the interview.  The introductory leaflet was non-
psychological. 
It remains possible that the patients who did not take part had particularly low rates of emotional 
disorder or high rates of adverse childhood experiences.  Their demographics are representative of 
the mixed and ‘scan negative’ CES groups.  Their absence remains a source of potential bias.  
Possible directions of bias include: 
• Patients with more emotional disorder may welcome the chance to talk about the way they 
have been feeling and agree to take part in the study more readily 
• ‘co-operative’ or contented patients were more likely to be approached  
• Or conversely patients who were upset by the lack of diagnosis were more likely to be 
offered information about the study 
• Patients with emotional disorders are more likely to be approached because the doctor 
subconsciously thinks they would enjoy or benefit from the assessment 
2. Controls with ‘scan positive’ CES  
As described above, patients presented in pain and were often waiting for an emergency operation.  
I found that if patients were waiting for the operation then waiting until after the operation resulted 
in higher study response rate.  
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It remains possible that patients who did not take part in the study had different symptoms, 
evidence of functional neurological disorders or high levels of emotional disorder.  This is a source of 
potential bias.  Other sources of potential bias as the same as those for patients with ‘scan negative’ 
CES. 
Refusal to complete all questionnaires 
It was disappointing that despite many efforts, I was unable to get all the questionnaires completed.  
The non-completion rate was 0% to 28% for the various measures.  The illness perception 
questionnaires and a question about whether sexual function had changed were particularly poorly 
answered (11% to 28% non-completion rate).  There may have been systematic differences between 
those who did and those who did not complete the questionnaires- for example did the patients 
with ‘scan negative’ CES who did not complete the follow up questionnaires do so because they 
were much better or much worse?  This is a potential source of bias. 
How I dealt with this in this study 
There were significant differences in the numbers of patients returning the questionnaire.  It was 
unclear whether this was due to length, complexity or the particular components of the 
questionnaire.  Because age of school leaving was not enquired about this could not be factored in.  
Some patients circled words they did not understand, such as defecate, and in feedback said they 
did not understand all the wording.  There were also particular problems with some patients feeling 
the questionnaire was too psychological and therefore that I was insinuating it was “all in their 
head”.  Additionally, some components of the questionnaire such as the life events measurement 
questionnaire were so complex and so poorly performed as to be impossible to interpret.  I shorted 
the follow up questionnaire and sent out only the key parts.  This improved the response rate by 
18% (n=20, total n=112) but the number from patients with scan -ve CES remained low (n=28,46%). 
Little can be derived from the ‘scan negative’ follow up data so a notes review looking at new 
diagnoses, urological investigations and diagnoses and functional disorder diagnoses was carried 
out.  This fulfilled the purpose of ensuring any new diagnoses were picked up and a more accurate 
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Non-blinding of the interviewer 
The problem 
As the interviewer I attempted to keep myself blinded to the diagnosis when patients were admitted 
the same day.  However, often patients with ‘scan positive’ CES prior to surgery did not wish to take 
part in the study so information had to be gathered the subsequent day and the diagnosis was then 
known.  This may have skewed the recording of information in the semi-structured interview, the 
examination and the psychiatric interview.   
How I dealt with this in this study 
Having considered this problem prior to starting the study there was no way to avoid this unblinding 
of the interviewer.  I provided anonymised psychiatry data to Prof Carson when assessing DSM-IV 
diagnoses via the structured clinical interview. It is not clear whether the data indicates the presence 
of interview bias in the study of emotional disorder.   
 
Psychiatry Diagnoses: 
I interviewed all patients and provided the psychiatric details to AC in an anonymised way.  
However, the levels of psychiatric diagnoses are higher than would be expected from the 
retrospective study or from literature about patients with chronic pain.  This may be due to 
overdiagnosis or overinterpretation during the semi-structured interview.   
How I dealt with this in this study 
Psychiatric diagnoses were made after the history was taken and the knowledge of whether patients 
were ‘scan negative’ or ‘scan positive’ may have impacted on the psychiatric diagnosis.  However, 
there is a structured way to conduct the interview and all questions were asked to all patients.  
Measurement Bias 
Validity and reliability of the individual measurements  
The problem 
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Urinary Symptom Profile:  I used this questionnaire primarily because it was recommended to me.  
Learning more about the questionnaire and its lack of clinical correlation after I had incorporated it 
into my study was a somewhat painful experience, especially when I realised that the questionnaire 
was so sensitive that it may have over-represented the bladder symptoms of patients.  Additionally, 
it was not possible to say whether patients were symptomatic or not using this questionnaire as it is 
not validated for this interpretation of the results.  Colleagues have published reports counting how 
many patients had a score of zero but this may lead to overinterpretation of the results31. 
 
Timing: Questionnaires were included which are validated to ask about symptoms in a non-acute 
fashion; the Urinary symptom profile is designed to be used based on urological symptoms in the 
last month, the somatic symptom count asks about symptoms over the past month and the life 
events questionnaire asked about life events occurring in last year.  
How have I dealt with this in this study? 
I have recognised that this a potential source of bias.  This was a learning experience and I will 
ensure that I research all questionnaires thoroughly before using them to ensure they are properly 
validated for the specific questions my research is asking. 
 
The difference between categorical and dimensional measures of emotional disorders 
The problem 
There are both categorical and dimensional methods of assessing emotional disorder and it is not 
clear which is most valid. 
How have I dealt with this in this study? 
In this study I used a categorical measure (SCID) and dimensional measure HADS. 
 
Anti-psychological response bias 
The problem 
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Patients with physical symptoms often tend to be ‘offended’ if it is suggested that they are due to a 
psychological problem.  They may therefore not take part in the study, answer interview questions 
or fill out questionnaires truthfully.  This could have affected data on emotional disorder (SCID and 
HADS), distress (SF-36 physical function), dissociation, adverse childhood events, or thoughts about 
what is causing their symptoms. 
How have I dealt with this in this study? 
By assessing illness beliefs at the same time as emotional disorder it was possible to assess if this is 
still the case.  Fewer patients completed the illness beliefs questionnaires (72% scan positive CES vs. 
74% mixed and 67% scan negative CES) than the HADs (100% vs. 98% and 100%.  Patients with ‘scan 
negative’ CES were surprisingly likely to agree that some symptoms may be due to stress (7% scan 
positive CES vs. 18% mixed and 44% ‘scan negative’ CES) and this question was answered by 85% of 
patients with ‘scan negative’ CES.  The discrepancy in both cases and controls between dimensional 
(subjective HADS) and categorical (more objective SCID) measures supports the idea of ‘anti-
psychological bias’.  It may therefore be operating regardless of the diagnosis, or alternatively the 
explanation for these differences is interview bias.   
The difference between self-rated and actual disability 
The problem 
Patients with ‘scan negative’ CES may be over-or under-reporting their disability compared to 
controls with neurological weakness. 
How have I dealt with this in this study? 
Measuring objective disability, for example with activity monitors, was beyond the scope of this 
study and due to the short admission time would likely not have added much information as it would 
only have recorded atypical activity in the acute setting.  I therefore only measured disability 
subjectively by asking about what a normal day at home is like and with SF-12 physical function 
score and the work and social adjustment questionnaire.  A more prominent source of potential bias 
is the poor return rates of questionnaires which is discussed above. 
 
Limitations of the Analysis 
Inadequate correction for multiple comparisons 
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I have carried out multiple comparisons between cases and the two control groups.  Therefore, 
some of the apparently significant results may have occurred by chance.   
How have I dealt with this in this study? 
Although I have attempted to separate out primary data (number of patients with abnormal post 
void residual bladder scanning, abnormal bowel and sexual function as per validated questionnaire 
cut-offs) from exploratory data (signs of functional neurological disorders, panic at symptoms onset) 
the study is still affected by multiple comparisons.  Rather than attempt a complex Bonferroni 
correction I think it more appropriate to highlight this potential limitation and also state that an P 
value of less significance than P<0.01 should be treated with caution.   
 
Low Sample Size 
In any case control study, the sample sizes should be adequately powered to detect a difference.  
This presented a challenge as in the pilot study 90% of cases vs. 0% of controls had Hoover’s sign of 
functional leg weakness.  If this data was used to calculate sample size, then the required size was 
very small.  However, we were unsure of the veracity of out pilot data given the small numbers 
involved (11 and 7).  In order to get the most representative sample we divided patients into three 
discrete categories.  This resulted in a lower than ideal sample size for the two gold standard 
categories (‘scan negative’ and ‘scan positive’ CES).  Despite the low sample size estimated from the 
pilot work I hoped to obtain 100 patients in the ‘scan negative’ category (clinical significance set at 
p<0.05 with 80% power) using the example of detective a difference between 40% and 60%.  I did 
not achieve this.  Sixty-two patients were recruited from the ‘scan negative’ group, 76 from the 
mixed group and 47 patients from the ‘scan positive’ CES group.  
How have I dealt with this in this study? 
Allowing the categories to occur from consecutive patients hopefully demonstrates a representative 
breakdown of patients presenting with clinical CES and makes the data more clinically useful.   
However, the low sample size is a potential for bias and the low sample sizes tends to reduce the 
ability of the study design to detect a difference between groups. 
Confounding 
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In any study of multiple variables, confounding may be an important source of bias.  Confounding 
occurs when two variables A and B are not only related to the development of disease C but are also 
related to each other.  For example, in this study, both DSM-IV disorders and prior functional 
disorders, particularly chronic pain, are associated with ‘scan negative’ CES.  However, chronic pain 
occurs more frequently in patients with DSM-IV disorders.  Therefore, the apparent association 
between ‘scan negative’ CES and chronic pain may be a spurious one which is confounded by 
psychiatric diagnoses. 
How have I dealt with this in this study? 
This was not a matched case control study, where common confounders such as age, sex, duration 
of symptoms can be controlled.  The ‘scan negative’ and mixed groups were similar in these 
variables and the ‘scan negative’ and ‘scan positive’ groups were similar in symptom duration.  
These variables could be important confounders.  However, the study was primarily to phenotype 
patients presenting with ‘scan negative’ CES. 
 
Conclusions 
There were many limitations to this study.  Some of these reflect the nature of observational studies 
and many reflect the learning obtained in research methodology during my PhD.  The acute, painful 
and distressing nature of the clinical symptoms affecting all patients and the new areas of 
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Conclusions and Route Forward 
This PhD has been the exploration of whether a relationship exists between bladder disorders and 
functional disorders more generally.  I have identified academic work pre 1980 which demonstrates 
that this relationship was an uncontroversial one until relatively recently32.  Numerous accounts of 
hysterical ischuria are recorded dating back to the time of Charcot and psychogenic urinary 
retention was one of the criteria for conversion in DSM III33.  Functional neurological disorders have 
not been judged kindly by history and as the pathology of other disorders became clear, the lack of 
pathological findings on dissection or imaging became confused with a lack of ‘realness’ of the 
diagnosis.  Moves in the 1980s by Claire Fowler and colleagues to reclaim patients diagnosed as 
psychogenic urinary retention were clearly, in part, done with the intention of validating patient’s 
experience.   The movement to define patients with idiopathic urinary retention according to 
replicable seemingly scientific data, the urethral sphincter EMG findings, meant patients were 
studied and new treatments sought.  Recent studies, however, have shown that the urethral 
sphincter EMG findings occur in women without urological dysfunction.  These women do not 
develop urology symptoms even on ten year follow up34.  Treatment with sacroneuromodulation has 
been successful in many patients but the focus on a potential channelopathy or other pathophysical 
cause of urinary retention lead to a devaluing of the functional and psychological comorbidities in 
this patient group, which have gone undiagnosed and untreated.   
 
The last decade has brought with it a renewed interest and appetite for scientific and clinical 
information on functional neurological disorders.  Led by clear, open communication with patients, 
positive diagnoses and good clinical assessment the field has reopened to both academics and, for 
the first time, patients.  This has been underpinned by imaging techniques such as fMRI and 
neurophysiological investigations which demonstrate mechanistically important differences when 
comparing patients with functional weakness or movement disorders and with feigning3536–38.  In this 
context a re-exploration of bladder symptoms that may be related to a functional neurological 
disorder, particularly those associated with pain, is a logical and clinically useful next step.  
 
This PhD has set out to explore past and current literature, devise a hypothesis about how functional 
bladder disorders may occur from retrospective case note reviews and test that hypothesis in a 
prospective study by addressing four aims: 
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• Aim1:  To determine what proportion of patients with ‘scan negative’ CES have a functional 
disorder by clinical consensus 
 
• Aim 2: To describe associated clinical features relevant to diagnosis, mechanism and aetiology 
in patients with Scan negative and scan positive CES 
 
• Aim 3: To determine what proportion of patients with urinary retention from Fowler’s 
syndrome or idiopathic causes (chronic idiopathic urinary retention/dysfunctional 
voiding/bladder outlet obstruction) have comorbid functional neurological disorder. 
 
• Aim 4: To determine what proportion of patients with functional neurological disorders have 
lower urinary tract dysfunction. 
 
The literature review improved my understanding of the historical link between urological and 
functional disorders as well as demystifying the complex brain-bladder network in health and in 
disease.   
 
The bulk of my research has involved patients with cauda equina syndrome.  A clinical and 
radiological syndrome which I initially thought was a clear pathophysiological control group soon 
became a poorly studied, slippery collection of symptoms, with no accepted definition or incidence, 
almost no prospective research, and most importantly the same symptoms and radiology eliciting 
differing responses from differing neurosurgeons about the importance and urgency of operation.  
As my understanding of the condition grew from the ongoing prospective work and the 
retrospective notes review it became clear that I would have to divide patients in a way which had 
not previously been done in the literature.  I found the hardest part was deciding where patients 
with ‘impending’ CES should go.  Neurosurgically they are treated exactly the same as patients with 
radiologically confirmed CES and my instinct was to put them into the ‘scan positive’ group.  But the 
definition of who has ‘impending’ CES is broad and is almost completely operator dependent.  
Watching senior neurosurgeons make different decisions than junior ones, I could not honestly say 
they presented a replicable category of patients.  I wondered to what extent factors other than the 
scan findings such as medication, pain catastrophisation, panic and psychopathology were playing a 
role in who had an operation.  These patients were important in my learning because they represent 
the difficulties we face when patients have pathophysiological disease which requires treatment and 
produces symptoms, but we need to consider functional comorbidity, panic, dissociation and 
psychopathology and use this knowledge to create the optimum care for the patient.   
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The retrospective review was strongest in showing that patients with ‘scan negative’ CES or mixed 
CES do not go on to develop pathophysiological neurological conditions.  We provided evidence that 
these patients do not simply have Multiple Sclerosis or other neurological disease which is 
presenting in an unusual way.  The retrospective study also found a stepwise progression of 
functional, psychological and functional neurological disorders from the ‘scan positive’ to the mixed 
to the ‘scan negative’ groups.  It was also important to find that patients had a similar level of 
unpleasant symptoms at onset, especially given the lengths the health service has gone to in order 
to provide a rapid neurosurgical response to alleviate the symptoms of patient with ‘scan positive’ 
CES.  Half of patients with ‘scan negative’ CES developed chronic pain on follow up. 
 
Building on knowledge of the brain-bladder network this study allowed the exploration of a 
hypothesis about how patients could develop ‘scan negative’ CES.  This was a hypothesis which 
attempted to identify the important predisposing, precipitating and perpetuating factors which 
ranged from medication to psychiatric disorders. 
 
Further evidence of a link between functional neurological disorders and urological dysfunction was 
found in the prospective study.  The data showed a ‘dose-response’ increase in pain, back pain, 
psychiatric disorders and positive signs of a functional neurological disorder in the mixed and ‘scan 
negative’ CES groups.  The hypothesis of multiple factors affecting brain and bladder simultaneously, 
leading to functional neurological symptoms and bladder dysfunction had corroboration from the 
prospective study findings. 
 
This information creates a new narrative for patients presenting with clinical CES who have normal 
or non-explanatory imaging.  Following phenotyping there are interesting questions to 
be answered and research on treatment strategies is required.   
 
Future Questions 
A PhD is just a steppingstone of knowledge.  Whilst phenotyping patients who present with 
suspected CES but have normal or non-explanatory imaging is a useful and worthwhile task, further 
questions abound. These can be roughly broken down into three main questions; Is it possible to 
create a sensitive and specific scoring system to predict who will have normal or non-explanatory 
imaging pre scanning?; What is the long term outcome for patients with ‘scan negative’ CES and; Are 
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there key advantages from being admitted to a neurosurgical unit which could be harnessed for 
treatment trials? 
 
Regarding a scoring system, due to the devastating nature of ‘scan positive’ CES, clinically and 
medicolegally, and the large overlap of symptoms, there are unlikely to be symptoms or signs which 
are sensitive and specific enough to exclude ‘scan positive’ CES.  It is therefore likely that patients 
will always require an MRI scan to exclude CES compression.  There are, however, important 
questions which may be useful to answer to allow patients to gain appropriate treatment quickly.  
These include whether patients’ symptoms gradually progress as they attend the GP and then A&E in 
keeping with increased abnormal self-directed attention4,5, or whether they have fully occurred by 
the time the patient attends A&E.  More important than this theoretically interesting question is 
whether A&E and neurosurgical staff can accurately and consistently test for positive evidence of a 
functional neurological disorder.  This, along with other risk factors for poor outcome such as a 
history of chronic pain, kinesiophobia, normal MRI scan and significant current psychopathology 
such as obsessive-compulsive disorder, agoraphobia or post-traumatic stress disorder could be used 
to triage patients to those who need specialist early treatment.  This type of post-imaging scoring 
system to assist the patients who are likely to have poor outcome may be a useful next research 
step. 
 
It is unclear what the five to ten-year outcome for patients with ‘scan negative’ is.  From our 
retrospective and prospective studies, we know that 11-13% have recurrent episodes of CES, 
sometimes repeatedly and 50% have chronic pain.  We also know only a maximum of 4% go on to 
develop a neurological disorder which potentially explains their clinical symptoms.  However, 
physical function, quality of life and social outcomes are unclear.  A larger cohort with these 
endpoints would be helpful for predicting good and poor outcomes and targeting treatment early to 
patients with the poorest likely outcome. 
 
From clinical experience, patients who were admitted to wards other than neurosurgery took longer 
to recover and had fewer positive outcomes.  Patients on other wards were not as positively 
encouraged to move and normalisation of function; walking, as well as bowel and bladder, and early 
discharge was not expected.  The way pain was managed was also very different on the 
neurosurgery ward.  Patients were treated with quickly escalating doses of medications to a level 
where they no longer had pain.   Pain was a major issue highlighted by this PhD.  As well as patients 
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presenting with ‘scan negative’ CES who had their worst ever acute back pain in 70% and chronic 
back pain in 51%, patients with Fowler’s syndrome had high levels of pain, both acute and chronic, 
which must be acknowledged as part of the context of their bladder disorders.  The clinical 
experience of better outcomes after neurosurgery ward admission could be tested against patients 
admitted to other wards with a focus on which factors (if any) improved outcome. 
 
Future Treatment Studies 
Ideally these questions would lead to a multi-centre two step randomised-control study assessing 
whether patients can be accurately diagnosed with ‘scan negative’ CES and whether specialist 
treatment could improve outcomes.  For any treatment trials a focus on early explanation, 
movement, pain relief and encouraging normal bladder and bowel function with early removal of 
catheters seems key.  Particularly in this patient cohort, with over 80% having one psychological 
comorbidity and a high proportion having a panic attack at pain onset, a multi-disciplinary approach 
with physical and psychiatric/psychological input will likely be required.  Whilst improving outcome 
with education, pain management and reducing unhelpful medications and function with 
physiotherapy we also need to consider creating an acute treatment plan for when back pain recurs, 
as it will in the majority of patients.  Pain management often encompasses a biopsychosocial view of 
pain and is based on best current evidence39  being likely to involve advice and education about 
staying active and fist line non-pharmacological therapy and avoidance of opiates and further 
imaging. However, it would be useful to compare patient diagnostic certainty and understanding 
with outcomes.  Pilot treatment studies for motor functional neurological symptoms demonstrate 
that both understanding the diagnosis and having the correct type of physiotherapy is key in gaining 
the best outcomes7.  This allows patients to engage in fear-exposure therapy they would otherwise 
avoid as they understand the diagnosis and know even if pain occurs that no further damage is 
ongoing.  This also seems to be the case in small studies of patients with complex regional pain 
syndrome40 but is often forgotten in clinical practice. 
 
Conclusion 
This PhD has been the exploration of the clinical features and outcomes of patients with uro-
neurological conditions who have normal or non-explanatory imaging.  I have demonstrated a link 
between patients with uro-neurological symptoms and functional neurological disorders in the acute 
and chronic context.  I have laid out a mechanistic hypothesis as to how patients develop urological 
symptoms, combing endogenous and exogenous risk factors to create a model of predisposing 
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factors in addition to pain, panic and dissociation to trigger functional symptoms.  Deep phenotyping 
has led to a better understanding of this vulnerable, large and untreated group of patients who until 
now have been ignored.   
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Understanding Cauda Equina Syndrome: protocol for a United Kingdom multi-centre prospective 
observational cohort study  
ABSTRACT 
Introduction 
Cauda equina syndrome (CES) is a potentially devastating condition caused by compression of the 
cauda equina nerve roots. This can result in bowel, bladder and sexual dysfunction plus lower limb 
weakness, numbness, and pain. CES occurs infrequently but has serious potential morbidity and 
medico-legal consequences. This study aims to identify and describe the presentation and 
management of patients with CES in the United Kingdom (UK).  
Methods and Analysis 
Understanding Cauda Equina Syndrome (UCES) is a prospective, collaborative, multicentre cohort 
study of adult patients with confirmed CES managed at specialist spinal centres in the UK. Participants 
will be identified using neurosurgical and orthopaedic trainee networks to screen referrals to spinal 
centres. Details of presentation, investigations, management and service usage will be recorded. Both 
patient and clinician reported outcome measures will be assessed for one year after surgery. This will 
establish the incidence of CES, current investigation and management practices, and adherence to 
national standards of care. Outcomes will be stratified by clinical presentation and patient 
management. Accurate, up to date information about the presentation, management, and outcome 
of patients with cauda equina syndrome will inform standards of service design and delivery for this 
important but infrequent condition. 
Ethics and Dissemination 
UCES received a favourable ethical opinion from the South East Scotland Research Ethics Committee 
02 (Reference: 18/SS/0047; IRAS ID: 233515). All spinal centres managing patients with CES in the UK 
will be encouraged to participate in UCES. Study results will be published in medical journals and 
shared with local participating sites.  
Registration Details 
UCES is sponsored by NHS Lothian (Reference: AC18017). UCES is registered at ClinicalTrials.gov 







Strengths and Limitations of this Study 
 
● This UK wide study will be the largest prospectively established cohort of patients with CES. 
● The collection of detailed clinical data will describe the range of presentations treated as CES 
in the UK in current practice and allow stratification of findings by clinical presentation. 
● Validated outcome measures will be used to assess pain, disability, and bladder, bowel, and 
sexual function one year after treatment. 
● Participant identification and recruitment will be efficiently carried out using trainee research 
networks to identify participants when referred urgently to specialist spinal centres. 
● The relationship of timing of investigation and decompression to patient outcome will be 








Cauda equina syndrome (CES) is a rare but potentially devastating condition caused by compression 
of the cauda equina nerve roots. This most commonly occurs due to a prolapsed intervertebral disc. 
The clinical syndrome includes any of bilateral sciatica, saddle anaesthesia, bladder, bowel, or sexual 
dysfunction.[1-3] The disabling nature of these symptoms causes significant medical and social 
morbidity and high health and social care costs. In addition, litigation related to the management of 
CES leads to significant medico-legal workload and costs.[1,4,5]  
 
Due to the consequences of CES for patients and society, several groups have issued clinical guidance 
or standards of care for CES.[1,6-8] However, the evidence base for current clinical guidance consists 
of small retrospective single centre case series.[1,9,10] Even systematic reviews of outcomes in CES 
have included relatively few patients, with the largest including 464 patients.[9,11] Lack of a clear 
definition of CES has hampered comparative analysis of historic studies, and different interpretations 
of the available evidence have been offered.[10,12] A diagnosis of CES encompasses patients 
presenting with mild to severe urinary and bowel symptoms, perineal or perianal numbness, sexual 
function disturbance, or bilateral sciatica, and patients may also experience lower limb weakness, 
numbness, or unilateral sciatica.[2,3,13] Outcomes for different presentations vary, and accurate 
division by presentation may help to clarify the understanding of outcome studies and develop care 
standards appropriate to the presentation.[1,14]  
 
Retrospective case series in the United Kingdom (UK) have identified approximately 15-31 patients 
per year per specialist neurosurgical or spinal centre with confirmed CES.[3,13,15,16] Published 
estimates of the incidence of CES are fewer than one case per 100,000 population.[17,18] However, 
in 2010-2011 in England, 981 surgical decompressions were performed for CES,[19] and the 
population was estimated at 52,234,000,[20] giving an incidence of 1.9 per 100,000. Therefore, there 
may be over 1000 patients managed for CES in the UK each year. Accurate data on the presentation 
and management of these patients would establish current management plus adherence to and 
feasibility of care quality statements as well as potentially informing the revision of guidance based on 
accurate and current data.  
 
The British Neurosurgical Trainee Research Collaborative (BNTRC) has previously successfully used a 





systems in conditions such as chronic subdural haematoma.[21] As CES is managed in the UK by 
specialist spinal services, similar case ascertainment via specialist referral systems to neurosurgical, 
orthopaedic, or joint spinal services provides a method of accurately identifying patients with CES 
during hospital admission. We propose to carry out the first national cohort study of the presentation 
and management of CES in the UK and establish the largest prospective series of patients with CES. 
This will provide data on CES incidence, epidemiology, presentation, management, and outcomes. 
This will inform the development of clinical guidance and identify areas for future research in CES.  
 
This prospective observational cohort study aims to: 
• Identify the number of cases of CES in the UK in all collaborating centres 
• Describe the presenting symptoms and signs in patients with CES 
• Describe the pathways of presentation to specialist spinal services for patients with CES in the 
UK 
• Describe the type, timing, and findings of investigations in patients with CES  
• Describe the medical and surgical management of CES 
• Compare current practice to standards of care for CES  
• Describe clinical outcomes for patients with CES using validated patient reported outcome 
measures, stratified by presentation, investigation findings, and management 
• Demonstrate the ability of neurosurgical and orthopaedic surgical trainee networks to 
collaborate successfully on a prospective cohort study 
 
METHODS AND ANALYSIS 
Understanding Cauda Equina Syndrome (UCES) is a prospective cohort study of patients with 
confirmed CES managed at specialist spinal centres in the UK. Cases will be identified by neurosurgical 
or orthopaedic trainees in each specialist centre through daily screening of tertiary referrals and 
admissions to specialist spinal services. All patients managed as CES by the treating team will be 
included in this study.  
 
Data regarding timing and type of symptom onset, referral, investigation, management, and outcome 
will be recorded anonymously on a secure database by the local trainee investigator during the 





data and patients will be asked to complete patient reported outcome measures representing their 
condition before surgery and up to one year after surgery. Imaging at presentation will also be 
collected. This data will be compared with care quality statements and published outcome data for 
CES. This is an observational study. No changes to routine patient care will occur during this study. 
 
Participant Selection 
The study will recruit for one year. Cases will be identified from admissions to spinal units between 1st 
June 2018 until 31st May 2019. The last one year follow up assessments will be sent to participants on 
31st May 2020.  
 
For inclusion in this study, the patient must: 
• be over 18 years old; 
• be admitted to a specialist spinal service in the UK between 1st June 2018 and 31st May 2019; 
• have capacity to provide informed consent for participation in this study; and 
• have a diagnosis of clinical CES and structural compression of the cauda equina on imaging as 
determined by the treating clinician. 
o Clinical CES includes any of: altered saddle sensation; bladder dysfunction; bowel 
dysfunction; sexual dysfunction; or bilateral sciatica. This should be associated with 
radiological compression of the cauda equina. The cauda equina compression can be 
due to any cause, including, but not limited to, disc, tumour, infection, etc.  
 
There is no upper age limit as we aim to establish the demographics of those presenting with CES. 
 
The exclusion criteria are: 
• Children under 18 years old. 
• Patients undergoing emergent decompression for unilateral motor or sensory symptoms 
(such as foot drop), without clinical evidence of CES. 
• Patients referred with suspected CES where the diagnosis is not confirmed, for example 
patients with the clinical symptoms and signs of CES without radiological evidence of cauda 
equina compression. 





• Patients admitted to a participating spinal centre before 1st June 2018 or after 31st May 2019. 
• Patients who are unable to provide informed consent for participation in this study. 
 
Capture-recapture methods will be used to ensure complete case ascertainment. In December 2018, 
June 2019, and December 2019 all local investigators will check their case ascertainment by asking 
their local coding departments for all discharges coded as CES using the diagnostic code ICD-10 G83.4. 




Data relating to presentation, hospital admission, investigations, and follow up will be collected by the 
local trainee investigator. Data will be collected from the patient’s notes, through routine interaction 
with the patient as part of clinical care, and through interaction with other staff members caring for 
the patient. All clinical and demographic information collected for this study by the local investigators 
is collected routinely. No extra assessments will be performed.  
 
Study participants who have consented to participate will also be asked to fill out details about their 
patient journey, their symptoms, patient reported outcome measures, and service usage. These will 
be collected electronically anonymously via the electronic database and linked to the patient record. 
Patient reported outcome measures will include visual analogue scores for back and leg pain plus the 
relevant sections of the Oswestry Disability Index,[22] the neurogenic bowel dysfunction score,[23] 
the short form incontinence questionnaire,[24] and the Arizona sexual experiences scale.[25]  
 
All patients who are eligible for inclusion in the study will have basic anonymous clinical data collected 
as part of the screening log to establish participation rates and incidence at each centre. This will 
allow accurate assessment of the incidence of CES. Patients who do not wish to participate in the 
study will not be contacted further for the completion of patient reported outcome measures.  
 
The timing and type of clinician reported and patient reported data that will be collected for UCES is 






Clinician entered data will be entered directly into the database using the participant’s unique study 
number. Imaging will be reviewed on local PACS systems and transferred to the study team for 
review. Participant questionnaires will be sent out by email using unique links for each participant. If 
participants do not have an email address or prefer to fill out questionnaires on paper, paper or 
telephone versions of the questionnaires will be used. If participants do not respond to the email 
invitations, they will be contacted to find out whether they wish to continue with the study and to 
complete the questionnaires when willing. Where patient data is routinely entered into spinal 
databases, surgical and outcome data from those databases will be linked anonymously to the patient 
record by the clinical team using the patient’s unique identifier for that database or registry.  
 
Data Analysis 
This study aims to establish the number of patients presenting with CES in the UK over one year. We 
expect approximately 20 patients per spinal centre per year depending on the population served, and 
a total of approximately 600-1000 patients in one year across the UK. The incidence of CES will be 
established based on the number of patients identified at each unit and the catchment population of 
that unit. If all units in the UK participate, incidence will be calculated based on UK population 
estimates. Incidence will be calculated from all patients identified as being eligible for the study from 
referral screening and local coding departments even if they do not consent for further participation. 
 
A descriptive analysis of the clinical and demographic characteristics of presenting symptoms, signs, 
and outcomes of patients with CES will be performed. This will be determined from both clinician 
reported and patient reported data. CES incidence and characteristics will be broken down into 
categories such as suspected (CESS), incomplete (CESI), with retention (CESR), and early (CESE) based 
on the clinical data. The categorical and quantitative findings on imaging will also be described. 
Methods of patient presentation to specialist services will be described. Type, timings, and findings of 
investigations in patients presenting via different routes will be compared. The investigation and 
management of patients with CES will be described and compared to that laid out in current care 
quality standards. Proportions meeting the standards will be reported. Patient outcomes will be 
assessed and analysed using both clinician and patient reported outcome measures at six months and 
one year. Patient outcomes will be stratified by demographics, presenting features, causative 





healthcare services over the year following diagnosis and management of CES will be assessed using 
both patient reported service usage and electronic records.  
 
Patient and Public Involvement 
The design and aims of this study were discussed with current patients being investigated for CES and 
those who had previously been treated for CES. Patients trialled the questionnaires and provided 
feedback on the questionnaires and patient information leaflet. The length and content of the 
questionnaires and information leaflet were altered in response to patient feedback. All participants 
will receive a summary of the results of this study. Patients are not involved in recruitment to this 
study as this occurs during or after emergency admission to hospital with CES.  
 
ETHICS AND DISSEMINATION 
Patient Consent 
Once patients have been identified as being eligible to participate in the study, they will be asked by a 
member of their clinical team whether they would be willing to receive further information about the 
study. For the majority of patients this will occur during their admission to the spinal unit, and the 
approach will be made by a member of ward medical or nursing staff. Once verbal consent has been 
gained to give further information about the study, patients will be provided with the information 
leaflet for the study. Patients who indicate that they are happy to have further discussions regarding 
the study will be visited in hospital by a member of their clinical team to complete the written 
consent process. The person undertaking written consent will be adequately trained to do so, and 
have a good knowledge of the study protocol, aims, and processes. The participant will be informed 
about and consent to their medical records being inspected by regulatory authorities and 
representatives of the sponsor.  Both the participant and the person undertaking consent will sign 
and date the informed consent form to confirm that consent has been obtained. The participant will 
receive a copy of this document and a copy will be filed in the Investigator Site File. 
 
Decompression surgery for CES takes place as an emergency, and admissions occur at all times of day 
and night throughout the week and weekend. Following decompression the length of stay in hospital 
wards may be as short as one to two days, or may be longer than a week when there are ongoing 
bladder or bowel problems. All patients will be given adequate time to read the information leaflet 





being eligible for the study. These patients will be contacted by telephone by a member of the clinical 
team and asked if they would be willing to receive information about the study by post or email. If 
they agree, the information leaflet and consent form will be sent to them, and they will be re-
contacted to go through the consent process over the telephone at least 24 hours after receiving the 
information.  
 
When participants prefer to fill out paper questionnaires or do not respond to the email link, their 
contact details (name, address, telephone number) will be passed to the central study team at NHS 
Lothian using the NHS email system with the consent of the patient. The central study team will 
contact the participants to find out whether they still wish to take part in the study. Those who wish 
to continue with the study will be sent the questionnaires by email, by post, or they can be completed 
over the telephone with a member of the central study team depending on the preference of the 
participant. If participants do not wish to continue with the study, they will not be contacted further.  
 
Participants are free to withdraw from the study at any point. If withdrawal occurs, the primary 
reason for withdrawal will be documented in the participant’s electronic case report form. The 
participant will not be contacted any further for outcome measures but their basic anonymous clinical 
details will be retained to allow accurate epidemiological assessment of the incidence of CES. If a 
patient loses capacity to consent for ongoing participation during the course of the study, the data 
they have already submitted or has already been submitted by their clinical team with their consent 
will continue to be used in the study, but they will not be contacted with further questionnaires.  
 
Data Protection 
All Investigators and study site staff involved with this study will comply with the requirements of the 
Data Protection Act 1998 with regard to the collection, storage, processing and disclosure of personal 
information and will uphold the Act’s core principles. Access to collated participant data will be 
restricted to individuals from the research team treating the participants, representatives of the 
sponsor and representatives of regulatory authorities. Computers used to collate the data will have 
limited access measures via user names and passwords. Published results will not contain any 






All clinical details will be entered into a database hosted by Castor EDC. Castor EDC complies with all 
applicable laws and regulations: Good Clinical Practice (GCP), European Union (EU) Annex 11, and the 
European Data Protection Directive. Clinician entered data will be entered directly into the database 
using the participant’s unique study number. The clinical team can only view the records of patients 
from their own centre. Once a participant has consented for their email address to be stored, this will 
be entered into the Castor database by the local clinical team. The email address field is stored 
securely and is encrypted and cannot be viewed by anyone outside of the patient’s local centre.  
 
All local investigators will store a copy of the link between the patient’s unique study number and 
their contact details, National Health Service (NHS) number, hospital number, Community Health 
Index (CHI) number, unique identifiers for spinal databases or registries, or other identifying details on 
a secure password protected NHS computer. Consent forms and paper completed questionnaires will 
be stored securely in a locked NHS office. No identifying information will be entered into the secure 
database except the email address.  
 
All identifiable scans will be stored and transferred within the NHS PACS network. Only anonymised 
scans will be processed outside the NHS PACS network. Anonymised imaging data will be labelled only 
with the study number and stored on anonymised CDs or on encrypted hard drives.  
 
Data Retention 
All study documentation will be kept for a minimum of 5 years from the end of the study. When the 
minimum retention period has elapsed, study documentation will not be destroyed without 
permission from the sponsor. The end of the study is 18 months after the enrolment of the last 
participant.  
 
Insurance and Indemnity 
Sites participating in the study will be liable for clinical negligence and other negligent harm to 
individuals taking part in the study and covered by the duty of care owed to them by the sites 
concerned.  The sponsor requires individual sites participating in the study to arrange for their own 
insurance or indemnity in respect of these liabilities. Sites which are part of the United Kingdom's 







The study will be conducted in accordance with the principles of the International Conference on 
Harmonisation Tripartite Guideline for Good Clinical Practice (GCP). All researchers are encouraged to 
undertake GCP training in order to understand the principles of GCP. However, this is not a 
mandatory requirement. GCP training status for all investigators should be indicated in their 
respective CVs.  
 
UCES received a favourable ethical opinion from the South East Scotland Research Ethics Committee 
(REC) 02 (reference 18/SS/0047, IRAS reference: 233515, sponsor reference: AC18017). Local 
management approvals must be in place at each site prior to recruitment of patients to this study. 
This study is registered with ClinicalTrials.gov (160318) and at ISRCTN (ISRCTN16828522). The most 
recent version of the protocol will be available on the website of the BNTRC at www.bntrc.org.uk. This 
study is sponsored by NHS Lothian. 
 
Peer Review 
The concept for this study was selected by a panel of judges in an open competition for support from 
the BNTRC. The protocol has been reviewed and approved by the steering committee for this study 
and reviewed by the British Orthopaedic Trainees’ Association, the British Association of Spine 
Surgeons, and the BNTRC committee.  
 
Publication 
Ownership of the complete dataset arising from this study resides with the steering committee and 
the BNTRC. On completion of the study, the data will be analysed and tabulated, and a report will be 
prepared. A summary report of the study will be provided to the REC within one year of the end of 
the study. Local data collected as part of this study belongs to the local team collecting that data. The 
study report will be used for publication and presentation at scientific meetings. Summaries of results 
will also be made available to local investigators. Following the initial analysis and publication, study 
data will be made available to those who submit successful peer-reviewed proposals for use of the 





All local investigators who enter data for at least one case will be named as contributors on 
publications arising from this study and will receive a certificate of collaboration in this study. 
Authorship of publications arising from this study will be determined in accordance with the 
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Purpose: Cauda equina syndrome (CES) is a spinal emergency with clinical symptoms and signs that 
have low diagnostic accuracy. National guidelines in the United Kingdom (UK) state all patients should 
undergo an MRI prior to referral to specialist spinal units and surgery should be performed at the 
earliest opportunity. We aimed to evaluate the current practice of investigating and treating 
suspected CES in the UK. 
 
Methods: A retrospective, multicentre observational study of the investigation and management of 
patients with suspected CES was conducted across the UK, including all patients referred to a spinal 
unit over 6 months between 1st October 2016 and 31st March 2017. 
 
Results: A total of 28 UK spinal units submitted data on 4441 referrals. Over half of referrals were 
made without any previous imaging (n=2572, 57.9%). Of all referrals, 695 underwent surgical 
decompression (15.6%). The majority of referrals were made out-of-hours (n=2229/3517, 63.4%). 
Patient location and pre-referral imaging were not associated with time intervals from symptom onset 
or presentation to decompression. Patients investigated outside of the spinal unit experienced longer 
time intervals from referral to undergoing the MRI scan. 
  
Conclusions: This is the largest known study of the investigation and management of suspected CES. 
We found that the majority of referrals were made without adequate investigations. Most patients 
were referred out-of-hours and many were transferred for an MRI without subsequently requiring 
surgery. Adherence to guidelines would reduce the number of referrals to spinal services by 72% and 







Cauda equina syndrome (CES) occurs due to compression of the lumbosacral nerve roots that can lead 
to a constellation of symptoms including sphincter disturbance alongside lower limb motor and 
sensory deficits [1]. It is a common neurosurgical emergency with an incidence of approximately 0.3-
0.5 per 100,000 per year [2–4]. Clinical features of CES have low sensitivity and specificity necessitating 
imaging early in the diagnostic pathway [5–8]. 
 
Compounding these challenges is the current lack of consensus on how urgently decompressive 
surgery should be performed. There is no class I evidence to support emergency decompression at 
any time point. Meta-analyses have separately demonstrated statistically significant benefits of 
surgery within 24 hours [9–11],  within 48 hours [12], and within 72 hours when treated as 
dichotomous variables [11]. Areas of contention leading to conflicting evidence include from what 
starting point the “time to surgery” should be determined [13], and whether patients experiencing a 
complete injury with retention and overflow incontinence should be considered for emergency 
decompression [9–11]. 
 
In the United Kingdom (UK) guidelines from the Society of British Neurological Surgeons (SBNS) and 
British Association of Spinal Surgeons (BASS) advise that patients presenting with acute back and/or 
leg pain with any bladder or bowel disturbance and with or without saddle sensory disturbance should 
be suspected of having CES. There should be a low threshold for investigation with emergency MRI at 
the hospital receiving the patient prior to referral to ensure timely diagnosis, referral and transfer to 
a specialist spinal unit where appropriate. Spinal units should not be considered a scanning service 
and out-of-hours MRI scanning should be considered routine practice to prevent needless and 
potentially harmful transport of patients for diagnostic imaging. If cauda equina compression is 
confirmed, guidance is that decompressive surgery be performed at the earliest opportunity [14–17]. 
 
There is a paucity of literature regarding current service delivery against these standards. 
Consequently, we sought to investigate the current service provision for the diagnosis and 
management of CES across specialist units in the UK. 
 
MATERIALS AND METHODS 
A retrospective, multicentre observational study of the investigation and management of patients 
with suspected CES was conducted across neurosurgical units in the UK. Departments at each 
neurosurgical unit providing emergency spinal surgery (whether neurosurgery, dedicated spinal 





with suspected CES referred within the six-month data collection period of 1st October 2016 to 31st 
March 2017 were included. The study protocol was approved by the audit and clinical governance 
committee of each participating hospital where required, the SBNS, and published on the website of 
the British Neurosurgical Trainee Research Collaborative (BNTRC) [18]. Patient consent was not 
required due to the fully anonymised collection of data without any patient-identifiable information. 
The manuscript was prepared in accordance with the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines. 
 
Data collection 
Data were collected in each spinal unit using a standardised proforma by teams consisting of 
consultant surgeons, trainees, junior doctors, and medical students. Data were entered electronically 
into Castor EDC (Castor EDC, Amsterdam, Netherlands), which complies with all applicable laws and 
regulations (Supplementary Material Figure S1). 
 
Demographic data included the spinal unit, age, gender, source of referral and presentation 
categorised as incomplete CES (CESI) or CES with retention (CESR) (Table 1) [19], or “Other”. Referrals 
for patients with isolated back pain or unilateral leg symptoms were subsequently excluded from 
calculation of referral timings. Imaging modality, imaging findings, imaging availability, purpose of 
referral, outcome of referral, patient transfers, surgical decompression, length of stay, and discharge 
destination were also recorded. Date and time information was collected for each step in the referral 
pathway (onset of symptoms, presentation to healthcare professional, referral to the spinal unit, MRI 
before or after referral, transfer, decompression and discharge including discharge destination). For 
the purposes of evaluating out-of-hours service provision, out-of-hours was defined as outside the 
hours of 9am-5pm Monday-Friday. 
 
Statistical analysis 
Categorical comparisons on pair-wise data were undertaken using Fisher’s Exact testing. Continuous 
data excluding time intervals were analysed using Kruskal-Wallis testing. Time interval data were 
analysed using generalised linear modelling with logarithmic transformation of the timing variables 
following visual inspection of Q-Q plots. Univariable analyses were performed based on referral 
pathways. Multivariable analyses were performed including age, gender, presentation, timing of 
referral (dichotomised into in-hours and out-of-hours), pre-referral imaging and the referrer. Length 
of stay was calculated based on time from MRI to discharge if transferred to the spinal unit for an MRI, 





those transferred for an MRI included age, gender, presentation, timing of referral, the referrer, 
whether or not the patient underwent decompression after the MRI, and discharge location. Cases 
with specified dates and times were used to analyse time intervals in hours, while all cases with dates 
submitted were included to analyse time intervals in days. Bonferroni correction was implemented to 
account for the multiple time points tested in the referral pathway, with a resultant threshold p-value 
of 0.007 (0.05/7) used to denote statistical significance. All statistical analyses were performed in R 
version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria). 
 
RESULTS 
A total of 4441 referrals across 28 UK spinal units (coverage 93%) were included in the study during 
the six-month period. Median patient age at referral was 47 years (IQR 36-61). The majority of 
referrals were for female patients, and from a hospital other than the spinal unit (Table 2). Nearly half 
of the patients presented with CESI, and of those submitted as presenting with “other” symptoms, 
lower back pain was the most common (Supplementary Material Figure S2). Of all referrals, 3679 
(82.8%) were made on a weekday. For referrals where time of referral were submitted, the majority 
were made out-of-hours (n=2229/3517, 63.4%). This is in contrast to the time of presentation where 
available where less than half of patients presented out-of-hours (n=622/1261, 49.3%) (Figure 1). 
 
Referral and Treatment Characteristics 
In total, 1628 referrals (36.6%) were made with an MRI completed prior to referral. Twenty percent 
of patients were referred with reported MRI evidence of cauda equina compression (n=918/4441, 
20.7%). Of the 878 cases with an MRI report, the most common causes included disc prolapse 
(n=470/878, 53.5%), spinal stenosis (n=205/878, 23.3%) and spinal metastases (n=78/878, 8.9%).  
 
When referrals were made without an MRI, the purpose of the referral was for imaging advice 
(n=1564/2813, 55.6%), the lack of availability of an MRI scanner out-of-hours (n=551/2813, 19.6%) 
and the absence of an available MRI scanner to the referrer (n=265/2813, 9.4%). Referrals from other 
hospitals were more likely to be made with a completed MRI (n=1033/2485, 41.6%) than referrals 
from other specialties on the same site as the spinal unit (n=436/1194, 36.5%, p<0.001), or referrals 
from primary care (n=153/715, 21.4%, p<0.001) (Supplementary Material Figure S3 and Table S1). 
 
Graphical depiction of the outcome of referrals is shown in Figure 2, demonstrating the pathways for 
patients with suspected cauda equina syndrome. Of the 2813 referrals made without an MRI, in 2336 





underwent surgical decompression (15.6%). Of the patients referred with an MRI, 474/1628 (29.1%) 
underwent decompression. A significantly smaller proportion of referrals made without an MRI 
resulted in surgical decompression (n=221/2336, 9.5%, p<0.001). Causes were not significantly 
different between cohorts undergoing decompression with an MRI before or after referral which was 
performed most commonly for a disc prolapse (n=532/695, 76.6%), spinal stenosis (n=96/695, 13.8%), 
and infection (17/695, 2.4%).  
 
Out-of-hours Service Provision in Other Hospitals 
In other hospitals receiving patients with suspected cauda equina syndrome, the majority of referrals 
to the spinal unit were made out-of-hours (n=1529/2485, 72.7%, Supplementary Material Table S1). 
Out-of-hours referrals were more likely to be made without a completed MRI scan (out-of-hours 
n=991/1529, 64.8%, vs. in-hours n=202/575, 35.1%, p<0.001, Figure 3). Of the referrals made without 
an MRI scan, referrals out-of-hours were more likely to result in the transfer of the patient for an MRI 
scan (out-of-hours n=370/991, 37.3%, vs. in-hours n=38/202, 18.8%, p<0.001). Overall 2.9% of all out-




Time intervals were available for 3168 (71.3%) of referrals (Table 2) with analysis based on the 
pathways outlined in Figure 2. Comparisons were made for each stage in the referral process with 
each pathway relative to the most common (MRI not done, MRI at other hospital) (Figure 4, Figure 5). 
Full results including effect sizes and confidence intervals can be found in the Supplementry Material 
(Table S2).  
 
There was a significantly longer time interval from presentation to referral for patients undergoing an 
MRI prior to referral (median 6.1 vs. 1.5 hours, p<0.001). Conversely, the time interval from 
presentation to MRI for patients referred with an MRI was significantly shorter than patients referred 
before an MRI (median 3.1 vs. 13.9 hours, p<0.001). Of those cases referred before an MRI was 
completed, the time interval from referral to MRI was significantly shorter if the patient underwent 
the MRI at the spinal unit even if transferred from another hospital (median 7.2 vs. 13.3 hours, 
p<0.001). Moreover, for patients referred from another hospital, the time interval from MRI to 
decompression was significantly longer in patients referred with an MRI compared to if referred 
before an MRI was completed (median 23.2 vs. 9.7 hours, p=0.003). These results were consistent 






Full multivariable results are shown in Supplementary Table S3. Cases submitted with an MRI prior to 
referral reported a significantly longer time interval from presentation to referral and shorter time 
from presentation to MRI than cases referred without imaging. Referrals in-hours were associated 
with a shorter time from presentation to MRI, while patients presenting to primary care (GP) were 
referred earlier than patients from hospitals other than the spinal unit. Cases referred from the 
hospital in the same site as the spinal unit reported a significantly shorter time interval from 
presentation to MRI and presentation to decompression. Increasing age was associated with a longer 
time interval from MRI to decompression and referral to decompression. These results were 
consistent when analysing time intervals expressed in days (Supplementary Material Table S5). 
 
Length of Stay 
Median length of stay for patients transferred for an MRI was 17.9 (IQR 4.5-70.3) hours. Median length 
of stay for patients transferred not requiring surgery was 11.1 (IQR 3.6-48.6) hours compared to 75.6 
(41.9-116.5) hours for those requiring decompressive surgery. A quarter of patients transferred for an 
MRI scan not requiring surgery were admitted for over 24 hours (n=78/330, 23.6%). Length of stay 
was significantly shorter if patients not requiring surgical decompression were transferred back to 
their referring provider (median 7.2 (IQR 3.0-15.4) hours) rather than their original place of residence 
(median 16.8 (IQR 4.0-59.9) hours, p<0.001). For all patients undergoing surgical decompression, 
multivariable analysis demonstrated a longer admission was associated with increasing age (Wald Z = 
2.94, p=0.003), and diagnosis of an infection (Wald Z=2.86, p=0.004) or spinal stenosis (Wald Z=3.03, 
p=0.003). A shorter admission was associated with referrals from primary care compared to other 
hospitals (Wald Z=-2.35, p=0.019, Supplementary Material Table S7). 
 
DISCUSSION 
In this retrospective multi-centre study of 4441 referrals for suspected CES, substantial deviations 
from UK guidelines were identified. While the SBNS and BASS recommend that local hospitals should 
investigate patients thoroughly prior to referral to spinal services, in this study only a minority of cases 
were referred with diagnostic imaging completed (n=1628/4441). Guidelines also state that spinal 
units should not be considered a scanning service, but due to the majority of referrals being made 
out-of-hours (n=1529/2104, 72.7%) a proportion of patients were transferred to the spinal unit for an 
MRI scan (n=370/1529, 24.2%). Importantly, of these referrals a fraction required surgical 







Referrals made without an MRI were most commonly made for advice on whether an MRI was 
indicated. Existing guidelines already include specific signs and symptoms suggestive of CES available 
for all practising physicians that should prompt an emergency MRI. A proposed diagram based on 
these guidelines is shown in Figure 6, including where the MRI should be performed and what MRI 
findings require an emergency referral to spinal services. Based on a six-month period, implementing 
this pathway would reduce the number of referrals to spinal services by 72% (4441 to 1224) and 
reduce the number of patient transfers by 79% (739 to 156). This pathway should be incorporated into 
local and regional protocols with dissemination in key departments particularly Emergency 
Departments. Due to the possibility of self-referral, direct-to-patient education leveraging existing 
organisations such as Cauda Equina UK could also be made to improve detection of red flag symptoms 
early on in the disease [20]. Given that the majority of patients presented in-hours and were only 
referred out-of-hours, work to improve triage of these patients will also improve the burden of 
undertaking diagnostic imaging for these patients out-of-hours. 
 
In other countries, guidelines are less specific on when and where an MRI should be undertaken. In 
the Netherlands, referral to specialists should be considered when the general practitioner is not sure 
about the diagnosis or considers surgical intervention.[21] In Norway and Denmark, guidelines for 
degenerative spinal conditions recommend referral to neurosurgery after an MRI is completed, but in 
the case of suspected CES early referral is recommended without specific guidance on where 
diagnostic imaging should be performed.[22, 23] In Germany, acute inpatient admission is required in 
patients with “red-flag” symptoms but again no specific guidance on location for diagnostic imaging is 
given.[24] Overall, no study of referral patterns or pathways for suspected CES in other countries was 
identified. 
 
Diagnostic Imaging Availability 
Part of the problem with implementing the pathway outlined in Figure 6 lies in the availability of 
diagnostic imaging. Numerous national guidelines and protocols recommend that emergency MRI 
scanning is available 24/7 in all UK district general hospitals [25–27] and yet UK survey data showed 
only 14% of hospitals providing access to MRI 24 hours a day [28]. Although costs and staffing levels 
are often cited as the challenge, there are examples of cost neutral solutions without increased 
staffing, such as arranging out-of-hours CT radiographer training in basic brain and spine MRI scanning 






Any associated cost increase will have to be balanced against two current significant cost burdens. 
First, the costs associated with the transfer of patients for an MRI scan which one hospital estimated 
at £6,000 per referral. Such is the cost that if only two referrals were made from one district general 
hospital it would be more cost effective for the trust to have their own dedicated radiographer on call 
[29]. Second, the clinical and financial implications of inadequate investigation and management of 
CES are an important consideration [30]. Around 10% of CES cases involve litigation [1]. Average claims 
range from £117,331, to £211,758 per case and a highest settlement of £2,041,000 [31]. 
 
Timing of Surgery 
Although the decision to perform decompressive surgery for confirmed CES is a recognised 
emergency, the decision as to how quickly this should be performed is unclear. Guidelines are based 
on balancing the duration and clinical course of symptoms and signs alongside potentially greater risks 
of operating out-of-hours. No specific standards on time intervals have been published due to the 
absence of consistent results in published studies. The literature is also unclear with regards to the 
defined starting points used to calculate “time to surgery”, with studies reporting the time from the 
first urinary symptom, time from bladder paralysis, or the time from admission to hospital [13]. 
 
This study revealed no significant differences between referral pathways and the time of onset of 
symptoms or presentation to decompression. However, pathways of patients referred outside the 
spinal unit were associated with significantly longer time intervals from referral to MRI if undergoing 
the MRI outside the spinal unit after referral. Furthermore, time intervals from MRI to decompression 
were significantly longer for patients with a confirmed CES undergoing an MRI before referral. Both 
represent the proposed pathway for managing patients with suspected CES in the UK. These results 
therefore have important implications for service delivery, particularly with efforts to increase the 
proportion of patients investigated through this pathway. Any policy changes to reduce the referral 
burden on specialist spinal units will need to ensure this does not result in an increase in the length of 
time patients with suspected cauda equina syndrome are being investigated and treated. 
 
Future Directions 
The comparative epidemiology and referral patterns between countries for suspected CES requires 
further investigation. The Getting It Right First Time (GIRFT) is a programme delivered in the United 
Kingdom to improve the quality of care within the National Health Service by reducing unwarranted 
variations. Data from this study will inform work to review local policies related to out-of-hours 





hour local MRI scanning [29]. This study has also informed an ongoing large prospective study of the 
investigation, management and outcome of patients with confirmed CES in the UK (Understanding 
Cauda Equina Syndrome or UCES) where comprehensive presenting symptomatology, timings, and 
outcome data will be collected [32]. The results of UCES will contribute to existing work developing 
tools to improve the clinical assessment and investigation of patients with suspected CES. [26, 33].  
 
LIMITATIONS 
This study covered a large number of referrals to spinal centres within the UK over the six-month study 
period and 28 out of the 30 UK neurosurgical centres participated. However, the absence of two 
neurosurgical centres and smaller orthopaedic centres that did not participate, means that this does 
not cover the whole population of the UK. Despite these limitations, we think that the large number 
of cases in this study should be representative of those referred across the UK. There may be a 
variability in data collection between centres which could not be centrally verified by the primary 
investigators due to the anonymous nature of data collection. This study only addressed cases which 
were referred to a spinal unit, missing patients who were managed without an MRI or who underwent 
MRI scanning locally which was normal without referral to the spinal unit. Outcome data was not 
collected in this study; the aforementioned future prospective study of confirmed CES in the UK (UCES) 
will collect outcome data and its relationship to presenting symptoms and the referral pathway 
including timings will be identified [32]. 
 
CONCLUSION 
Guidelines in the UK for the investigation and management of patients with suspected cauda equina 
syndrome emphasise the importance of thorough investigation in the receiving hospital prior to 
referral to specialist units. This national retrospective multi-centre study of 4441 referrals has 
identified deviation from national guidelines. Currently the vast majority of referrals for suspected CES 
are made without an MRI out-of-hours with specialists subsequently recommending an emergency 
MRI that in a proportion requires a transfer to the spinal unit. Adherence to guidelines would reduce 
the number of referrals to spinal services by 72% (4441 to 1224) and reduce the number of patient 
transfers by 79% (739 to 156). Changes required to adhere to guidelines will need to acknowledge the 
identified longer time intervals for diagnostic imaging if patients are investigated locally without 
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Background Data regarding long-term outcomes following surgery for cauda equina syndrome (CES) 
is scarce. In addition, these studies rely on patient descriptions of the presence or absence of 
symptoms, with no gradation of severity. This study aimed to assess long-term bladder, bowel, 
sexual and physical function using validated questionnaires in a CES cohort.  
 
Methods A pre-existing ethically approved database was used to identify patients who had 
undergone surgery for CES between August 2013-November 2014. Patients were contacted over a 
one-month period between August – September 2017 and completed validated questionnaires via 
telephone, assessing bladder (Urinary Symptom Profile), bowel (Neurogenic Bowel Dysfunction 
Score), sexual dysfunction (Arizona Sexual Experiences Scale) and physical function (Physical 
Component Summary of SF-12 Questionnaire). Patients were also asked which of their symptoms 
currently they would most value treatment for and what healthcare services they had accessed post-
operatively. 
 
Results Forty-six of 77 patients (response rate 72%, inclusion rate 60%) with a mean age of 45 years 
(21-83) and mean time since admission of 43 months (range 36-60) took part in the follow up study. 
The prevalence of bladder dysfunction was 76%, bowel dysfunction 13%, sexual dysfunction 39% 
and physical dysfunction 48%. Pain was chosen as the symptom patients would most value 
treatment for by 57%, but only 7% reported post-operative pain-management referral. 
 
Conclusions With a mean follow up time of 43 months, these findings confirm the high prevalence of 
long-term bladder, sexual and physical dysfunction in CES patients and provide useful data to guide 







Cauda Equina Syndrome (CES) is a neurosurgical and spinal orthopaedic emergency with potentially 
significant clinical and medicolegal consequences for both the patient and the medical team 
managing the condition. It is a relatively rare occurrence with an incidence of 0.3-1/100,000 in the 
general population and accounts for 2-6% of lumbar spine procedures [7]. However, it is difficult to 
establish the true incidence of the condition due to a lack of consensus on an exact definition of the 
syndrome and its sub-classes [6]. 
CES involves compression of the nerves of the cauda equina, most commonly caused by the 
herniation of an intervertebral disc [6]. This results in a constellation of symptoms related to a loss of 
cauda equina neural function including bladder, bowel and/or sexual dysfunction along with loss of 
saddle sensation, motor control or reflexes of the lower limbs [6]. The aim of surgical management is 
to restore normality of function by urgent decompression of the cauda equina nerve roots, but there 
is a risk that recovery may be only partial or absent entirely. It is these debilitating residual 
symptoms that contribute to the serious physical and socioeconomic consequences that can arise 
following CES. 
The main body of research into CES has attempted to elucidate factors affecting post-
operative outcomes, such as presentation characteristics and time to decompression[5, 8, 11, 14, 
20]. Individual studies are largely equivocal, but meta-analyses conclude that earlier surgical 
decompression is beneficial for the patient, and that patients with urinary retention and overflow 
incontinence have poorer outcomes than those without [1, 3]. However, because the main area of 
investigation is prognostic factors prior to surgery, outcomes following surgery are understudied.  
The few studies that do assess outcomes generally focus on mobility, pain or bladder 
function, with bowel or sexual function rarely investigated. Furthermore, they tend to be short term 
in design, with data collection limited to the first routine follow-up appointment, leading to a paucity 
of data regarding the long-term outcomes following CES surgery. For example, Srikandajarah et al 
assess bladder outcome but only at around 3 months, with Korse et al (2017a) investigating bladder, 
bowel and sexual function but only at 6 weeks [12, 23]. This is a short time into the patients’ 
recovery journey and means that both clinicians and patients have little data on which to base long-
term recovery expectations. 
When long-term bladder, bowel and sexual function are measured, such as Korse et al 
(2017b), studies rely on patient reported data, with outcomes often not defined or measured using 





with no gradation of severity and means the data may not reflect the diverse range of residual 




This study used validated questionnaires to objectively assess a range of long-term outcomes 
following CES surgery. The primary aim was to assess the patients’ current bladder, bowel and sexual 
function. Secondary aims assessed quality of life related to physical function, ability to return to 
work, what symptom patients would most value treatment for currently, and long-term healthcare 
service use as reported by the patient. 
 
 
Materials and Methods 
 
Participants and procedures 
 
Seventy-seven patients who had attended the regional neurosurgical centre of the Western General 
Hospital, Edinburgh, between August 2013 and November 2014 were identified from a pre-existing 
ethically approved database of patients with suspected CES. After University of Edinburgh ethical 
review, the participants were contacted via telephone, gave informed consent and completed the 
questionnaire delivered by the author (JEH). Patients were included in CES caused by degenerative 
disc disease and excluded in cases of CES secondary to intradural or extradural tumours or if unable 
to complete the questionnaire due to death, insufficient English or untraceable contact details 
(Figure 1).  
Following completion of the questionnaire, electronic records were used to confirm age and gender, 
and to assess whether the patient had incomplete CES (CES-I), with altered urinary sensation or loss 










The questionnaire contained two sections; validated and unvalidated.  In the validated section, 
bladder dysfunction was assessed using the Urinary Symptom Profile (USP) with dysfunction defined 
by a score ≥1. This allows the breakdown of urinary symptoms into 3 domains of stress incontinence, 
overactive bladder (OAB) and low stream.  Increasing scores indicate worsening dysfunction [9]. 
Bowel dysfunction was assessed using the Neurogenic Bowel Dysfunction (NBD) Score, which 
categorises bowel dysfunction into “very minor” (score 0-6), “minor” (7-9), “moderate” (10-13) and 
“severe” (14+), and rates overall bowel satisfaction out of 10 [15]. Sexual dysfunction was assessed 
using the Arizona Sexual Experiences (ASEX) Scale, where dysfunction is described by an overall score 
of ≥19, one domain ≥5 or 3 domains ≥4 [17]. Lastly, physical functioning was assessed using the 
Physical Component Summary (PCS) of the Short-Form 12 (SF-12) questionnaire with scores 
compared to the Scottish adult average data [26].   
The unvalidated section was a semi-structured interview conducted by JEH.  This assessed 
occupation status prior to CES; return to work following surgery; current status including any 
residual weakness/numbness/pain; whether pain prevents them from doing daily activities; use of 
any mobility aids; which of their symptoms they would most value relief from, and healthcare 
service use.   
 
Statistical analysis  
 
Statistical analysis was performed using SPSS version 22 for Mac OS X (SPSS inc., Chicago, IL). 
Independent T-tests were used to analyse mean differences between the CES-I and CES-R, with 










Overall 46/77 participants completed the study, generating a response rate of 72% and an inclusion 
rate of 60% (Figure 1). The group comprised of 19 males and 27 females with a mean age of 45.4 
years (range 21-83) and mean time since admission of 43.4 months (range 36-50). In total, 83% 
(n=38) of participants had (CES-I) and 17% (n=8) had CES-R. This proportion is similar to that of the 
intial cohort of 74 patients, which had 81% with CES-I and so is representative. 
 
 
** Figure 1 here** 
 
Bladder function 
On follow-up, 76% (n=35) of patients suffered bladder dysfunction as defined by the USP (Table 1). 
Overactive bladder was the most frequently described symptom (72%), with stress incontinence 
(39%) and low stream (41%) affected at similar rates. The mean total USP score for all participants 
was 7.15 (±7.17), with breakdown mean scores of Overactive Bladder 4.37 (±4.72), Low Stream 1.59 
(±2.70) and Stress Incontinence 1.20 (±2.07). Patients with CES-R demonstrated significantly more 
dysfunctional Low Stream scores (+2.77, p=0.007), with no significant differences in the other USP 
domains. 
 
**Table 1 here** 
 
Bowel function 
On follow-up, 13% (n=6) of participants reported bowel dysfunction with a severity of “minor” or 
greater as defined by the NBDS. The mean score for satisfaction was 7.7/10, the median 9/10, and 
the mode 10/10. Bowel function was significantly worse in patients with CES-R, with a mean 
difference of +4.13 compared to those with CES-I (p=0.012). 
 
Sexual Function 





questionnaire. Patients were most commonly dysfunctional in the domains of sex drive (35% n=16), 
ease (37% n= 17) and maintenance (35% n=16) of arousal and ease of orgasm (39% n=18) with 
orgasm satisfaction less affected (23% n=11). Patients with CES-R had significantly worse sexual 
function, with a mean difference of +6.76 (p=0.009)  
 
Physical function and Employment 
The SF-12 demonstrated 48% (n=22) of patients to have statistically significant poorer physical 
function than the Scottish adult average of 49 (±10.3) and the group mean Physical Component 
Score of 39.2 (±11.3) to be markedly lower than this too (Figure 2). Prior to admission 74% (n=34) 
patients were in employment, with 15% (n=7) unemployed and 11% (n=5) retired. At follow-up, 71% 
(n=29) of those of a working age were able to return to full employment, with 15% (n=6) returning in 
a reduced capacity and 15% (n=6) unable to work. The number of retired patients remained n=5. 
There was no significant difference between CES-I and CES-R in the Physical Component Summary. 
 
**Figure 2 here** 
 
Semi-structured interview 
Residual symptoms were present in many with 70% (n=32) reporting areas of sensory loss and 44% 
(n=20) reporting current leg weakness, including 13% (n=6) requiring walking aids to mobilise. 
Additionally, 70% (n=32) of patients described themselves as suffering pain, of which the majority was 
back pain (35%, n=16). This pain represents a significant barrier in 57% (n=26) who state that pain 
prevents them from doing things in their daily lives. 
Despite a variety of residual symptoms, the majority of patients chose pain as the symptom 
that they would most value treatment for (57% n=26). Back pain was highlighted as more important 
than leg pain with 35% (n=16) stating it to be the symptom that they would most like to remove 
(Figure 3). 
 
**Figure 3 here** 
 





Following hospital discharge, 85% (n=39) of patients reported having contact with the healthcare 
service, the most common being community-based physiotherapy (76% n=35). Fewer patients, 20% 
(n=9) stated they had been referred to specialist urology services and fewer still 7% (n=3) had been 
referred to the pain management team (Figure 4). 
 




This study aimed to assess the long-term outcomes following CES surgery by using validated 
questionnaires to quantify the symptoms currently experienced by a cohort of previous CES patients. 
Results demonstrated bladder, bowel and sexual dysfunction to be common problems within this 
population. Physical function was also shown to be significantly reduced in a large proportion of the 
patients, with many reporting persistent pain, sensory loss or weakness. Patients who had CES-R had 
significantly more stream-related bladder dysfunction, bowel dysfunction and sexual dysfunction, 
but no difference in physical functioning. Service use was assessed through semi-structured 
interview, with the majority of patients obtaining post-discharge physiotherapy, but few accessing 
urology or pain management services.  
The main limitation of this study is the relatively small sample size (n=46) and the risk of 
selection bias and social desirability bias when sourcing data from voluntarily responding patients. 
However, we achieved a follow-up rate of 71% using telephone interviews and attempted to 
minimise social desirability bias through a semi-structured interview approach. We feel our sample 
size to be satisfactory, since the median number of participants in CES studies is n=14, and consider 
our inclusion rate to be adequate give the personal and invasive nature of the questionnaires [24]. 
Whilst the USP is useful for determining the number of patients affected by bladder symptoms and 
in what way, it does not provide a scale to assess the impact of the symptoms on quality of life. As 
such, future studies could assess this through combining the USP with the recently validated SF-
Qualiveen [13, 21]. Use of services post discharge was patient reported. This was impossible to 
confirm due to patients coming from many regions with differing online record systems which may 
have impacted on the figures. However, urological and pain management interventions are often 
quite invasive or time intensive and the high rates of reported physiotherapy usage gives us 





In highlighting the large burden of disease present in this patient population, our results 
broadly agree with previous literature in this area. However, the proportions of patients with 
residual symptoms differ in some categories. 
Our study noted a much higher rate of bladder dysfunction (76%) than previous 
investigations, with Mccarthy et al finding 43% of patients to have bladder dysfunction at 5 years 
and Korse reporting 47% reducing to 41% on long term follow-up [13, 16]. We hypothesise that this 
difference may be explained by the use of the objective USP score which is known to have a high 
sensitivity to a range of urological symptoms and patients would often report a symptom-free 
bladder, only to show dysfunction on the USP [27]. This conjecture is supported by the findings of 
Hellström et al who describe how although only 41% of CES patients complained of bladder 
dysfunction, urodynamic findings were abnormal in 76% [10]. This potentially demonstrates an 
opportunity to improve symptoms in patients who are not aware of the possibility. The majority of 
bladder dysfunction was in the overactive bladder domain (72%), with less dysfunction related to 
stress incontinence or low stream. This is likely due to the neural damage sustained in CES that 
would preferentially affect detrusor innervation and function over pelvic floor strength or urethral 
patency [2].  
Bowel dysfunction is the symptom with the greatest variation of reported prevalence in the 
literature and the results from this study continued this trend, describing a much lower rate than 
previously reported. Korse et al describe a higher prevalence of 47% on initial follow-up, reducing to 
43% over 13 years [13]. The rates reported by McCarthy et al. were higher still with 60% reporting 
“bowel disturbance” as they were by Podnar, however this study did not use validated 
questionnaires in data gathering [16, 19]. Using the neurogenic bowel dysfunction score allowed us 
to assess the degree of dysfunction present. Results showed that although the literature describes 
patients who complain of bowel disturbance following CES, few are affected to a quality-of-life-
reducing level when investigated using validated methods. This is further supported by the high 
median and mode average in “bowel satisfaction” with a lower mean value. 
In regards to sexual function our results demonstrated a lower prevalence of dysfunction 
(39%) compared to prior research, again likely caused by the method of outcome measurement. 
Mccarthy et al reported that 50% of patients had some degree of dysfunction, with Korse et al 
finding dysfunction prevalence to be 56% at 2 months, marginally improving to 53% at 13 years [13, 
16]. However, Mccarthy et al used different questionnaires to assess outcomes in males and females 
including the unvalidated Female Pelvic Floor Questionnaire. In Korse et al, the outcome was patient 





specified”. Whilst this may represent abnormal sexual function it does not necessarily imply 
dysfunction and may lead to an inflated prevalence. 
Physical function is rarely objectively assessed in CES patients, but previous research agrees 
that the majority of patients score lower than the population average. McCarthy et al assessed 
physical function using the Short-Form 36 questionnaire, a longer questionnaire from which the SF-
12 was adapted and found CES patients to have significantly reduced function in the “Physical” and 
“Role Physical” domains [16]. 
Patients with CES-R demonstrated significantly poorer Low Stream bladder function, bowel 
function and sexual function in comparison to those with CES-I. This is likely due to the more serious 
nature of CES-R, which indicates compression and damage to nerves of the lumbo-sacral plexus and 
therefore more likely subsequent permanent damage the nerves supplying bladder, bowel and 
sexual function as a result. Specifically, the Low Stream USP domain was worse in these patients due 
to some needing to self-catheterise as a result of CES.  Few studies directly compare long-term 
outcomes between patients with CES-I and CES-R, with none to our knowledge assessing bladder, 
bowel, sexual and physical function. Gleave and Mcfarlane feel those with CES-R often have worse 
outcomes and this is supported by Kennedy et al note that all 5 patients in a 19 patient study who 
had residual impairments at 2 years follow-up had urinary retention at presentation [8, 11]. 
However,  McCarthy et al found no significant differences between CES-I and CES-R in a range of 
outcomes [16]. A Meta-analysis was performed, but was only able to report on urinary outcomes 
due to a lack of data present for other functions. This showed that patients with CES-R had relative 
risk of 2.58 of having bladder dysfunction, although this result was not significant (95%CI 0.59-
11.31)[4] 
 
In a holistic approach we also assessed function through the patients’ occupation status, 
symptom they would most value treatment for, and NHS service use post-discharge. In patients of 
working age we found 71% were able to return to full employment, roughly matching the data from 
previous studies regarding spinal surgery which found 67% patients were able to return to work over 
a 3-month to 5-year follow-up [25]. 
Overall, 70% of patients declared that they suffered pain on follow-up, with 57% (n=26) 
stating that it stops them from doing things in their daily lives. Furthermore, when asked to decide 
which symptom they would most value treatment for, the most commonly chosen option was pain, 





expected, given that the proportion of patients reporting leg or back pain 2 or more after discectomy 
for radiculopathy 17% [18]. Furthermore, little literature has assessed the prevalence of pain as a 
long-term outcome, preferring to focus on other functions. However, a small study of 14 CES 
patients by Shapiro found that 28% suffered from chronic pain at 6-60 months follow-up [22]. 
The patient-selected most important symptoms did not correlate with the patients’ stated 
use of NHS services. Despite 57% of this population describing their lives to be limited by pain and it 
being their chosen symptom for treatment, only 7% (n=3) reported contact with the pain 
management team post-discharge suggesting that greater utilisation of this service could benefit this 
population.   
Future studies should continue to follow this cohort and reassess for any future 
improvement in bladder, bowel, sexual or physical function using the questionnaires utilised by this 






This long-term outcomes investigation of CES post-surgery patients has identified continued 
abnormal bladder, bowel, sexual and physical dysfunction in patients at a mean follow-up of 43 
months. Almost three quarters of patients continued to have bladder symptoms at long term follow 
up and almost 40% had sexual dysfunction.  Bowel dysfunction was found to have less of an impact 
than previously suspected, and pain was identified as the symptom patients would most value 
treatment for. However, referrals for pain management did not correlate with the importance given 
to this symptom, highlighting the necessity of global assessment and management in this complex 
patient group.  
We believe this to be the largest cohort of patients with CES investigated for long-term 
outcomes using validated questionnaires and, although a relatively small sample, we hope this will 
provide some much needed data to guide the expectations of clinicians and patients throughout 
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Fig 2 Histogram of patient SF-12 PCS distribution 
Table 1. Patient Characteristics at follow up 
  
Measure n = % Mean Score (±SD) 
Urinary Symptoms Profile 
Overall Urinary Dysfunction Score 35 76 7.15 (±7.17) 
Stress incontinence 18 39 1.20 (±2.07) 
Overactive Bladder 33 72 4.37 (±4.72) 
Low Stream 19 41 1.59 (±2.70) 
Neurogenic Bowel Dysfunction Score 
Very minor 40  87 
Minor 4 9 
Moderate 0 0 
Severe 2 4 
Arizona Sexual Experiences Questionnaire 
Sexual dysfunction 18 39 
Physical Function 
Working 29 63 
Working in a reduced capacity 6 13 
Not working 6 13 
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ABSTRACT   
OBJECTIVE 
In their 1973 BMJ paper ‘ Cryptogenic Drop Attacks’, Stevens and Matthews described 40, mostly 
middle aged, female patients with drop attacks of unknown cause. Although clinically common, 
there has been little on this topic since. We aimed to determine clinical features, comorbidity and 
outcome of patients with drop attacks. 
METHODS 
We carried out a retrospective review of patients with cryptogenic drop attacks seen consecutively 
by one clinician (JS) between 2006 and 2016. Demographics, phenomenology, duration and 
frequency of attacks, attack description and comorbid diagnoses were recorded.  Patients were 
followed up with a notes review. 
RESULTS 
83 patients with cryptogenic drop attacks were predominantly female (89%,n=79) mean age 44yrs.  
The majority (93%,n=77) could not remember the fall itself and almost half (43%, n=36) experienced 
prodromal dissociative symptoms. Mechanical trips or syncope preceded drop attacks, historically, in 
24% (n=20) of cases.  Persistent fatigue (73%,n=61), chronic pain (40%,n=33), functional limb 
weakness (31%,n=26) and dissociative (non-epileptic) attacks 28% (n=23) were common, with the 
latter usually preceding or emerging from drop attacks.  At follow-up (88%,mean 38 months), 28% 
(n=23) had resolution of their drop attacks.  Predisposing (but non-causative) disease comorbidity 
was found at baseline (n=12) and follow up (n=5). 
CONCLUSIONS 
Cryptogenic drop attacks are associated with high frequency of comorbid functional somatic and 
functional neurological disorders.  Patients commonly have prodromal dissociative symptoms and in 
some there was a clear relationship with prior or subsequent dissociative (non-epileptic) attacks.  
Some cryptogenic drop attacks may be best understood as phenomena on the spectrum of 
dissociative attacks. 





Cryptogenic drop attacks were defined in a seminal paper by Stevens and Matthews in 1973 as falls 
without warning, without clear cause of loss of consciousness, ‘vertigo or other cephalic sensation’ 
and with rapid recovery, occurring predominantly in middle- aged women[1].  Drop attacks due to 
various disorders including cardiac, cerebrovascular causes, vestibular or, most commonly in 
children, seizure disorders[2–5] have been described since the early 1900s[4,6–12]. 
 In their study of 40 patients with drop attacks Stevens and Matthews considered various 
mechanisms but concluded that this ‘cryptogenic’ presentation was the most common. Despite their 
prevalence, estimated at 3.5% of falls in adult women[1], and their potential to be both 
embarrassing and fear inducing, no consecutive series of cryptogenic drop attacks in a 
predominantly middle age cohort has been undertaken since 1973[6].   
Several clinical observations in a series of patients with drop attacks led us to wonder whether some 
of them, especially in younger patients, may be considered a subtype of functional (psychogenic) 
neurological disorder. We hypothesize that a brief moment of dissociation, akin to that seen in 
dissociative (non-epileptic) attacks and/or sudden functional leg weakness, could be elicited as a 
conditioned response bound to the experience and subsequent fear of falling. 
We studied the clinical features and outcome of a retrospective consecutive series of patients with 
drop attacks to investigate this idea further. 
 
MATERIALS AND METHODS 
We searched consecutive outpatient clinic letters for patients with ‘drop attacks’ from one 
neurologist (JS) with experience in the diagnosis of dissociative (non-epileptic) attacks, syncope, 
seizures and other causes of falls. All patients were referred to the Department of Clinical 
Neurosciences, Edinburgh, UK between 2007 and 2016 from one of three sources: an unselected 
primary care referral to a general neurology clinic which was randomly assigned to all general 
neurologists in the department; a clinic designed for the assessment of patients with functional 
disorders; or referred from colleagues due to a known research interest in patients with drop 
attacks. 
Patients were included in the study by the authors (other than JS), if they met a modified version of 
Stevens and Matthews’ definition of cryptogenic drop attacks: sudden fall to the ground, not caused 
by persistent leg weakness, change in posture or head position, nor accompanied by any vertiginous 




symptoms.  Our modification was to include patients with intermittent functional leg weakness. We 
included those who could not remember the fall itself or who described finding themselves suddenly 
on the ground but not those who had a witnessed or perceived loss of consciousness.  We included 
patients who had drop attacks even if it was not their primary neurological complaint.   
We excluded patients with prolonged loss of consciousness or responsiveness and cases when there 
was insufficient description of the attack itself.  Dissociative (non-epileptic) seizures, including 
hypokinetic episodes (psychogenic pseudosyncope) and hyperkinetic episodes, were differentiated 
from drop attacks by the presence of reported or witnessed loss of consciousness or responsiveness 
with typical positive clinical features seen in those diagnoses[13]. We also excluded patients whose 
drop attacks were not cryptogenic, but included patients where comorbid medical diagnoses may 
have been contributing to the clinical picture but did not fully explain it. Drop attacks referred to in 
this study will refer to this definition unless otherwise specified. 
We retrospectively recorded data on age, gender, duration and frequency of attacks, and attack 
description including place, contextual use of medication, alcohol and drugs which may have caused 
the drop attack, injury, comorbid diagnoses including structural pathophysiological, functional 
somatic, functional neurological and psychiatric disorders from the medical notes and from JS’s 
review.  Particular attention was paid to the presence of dissociative symptoms (such as 
depersonalisation and derealisation), situational triggers, the circumstances of the first attack and 
whether attacks changed over time.  Comorbid symptoms and diagnoses were recorded as were 
radiological and cardiac investigations performed by the neurologists or other health professionals.  
We recorded the outcome of attacks and the development during follow-up of other conditions that, 
with the benefit of hindsight, might have explained the drop attacks.  Follow up was based on 
electronic medical records in the host healthcare board, NHS Lothian, and five additional health 
boards in surrounding areas.  A UK healthcare board is a connected set of hospitals and outpatient 
facilities where patients receive secondary level care.  For patients from outside the host healthcare 
board and surrounding area, we attempted follow up via an additional, more limited, online health 
record system.  Characteristics of patients referred to specialist or general clinics with drop attacks 
were compared using two-sided Chi-squared and t-testing. 
  
RESULTS 
Participants and Demographics 




91 patients with drop attacks were diagnosed and seen by JS between January 2007-July 2016.  Eight 
were excluded (drop attacks due to other causes (n=2), insufficient description of attacks (n=6)). For 
the remaining 83 patients, medical records were available for detailed review.  Full electronic patient 
records documenting all hospital attendances were available for 67 patients who were referred from 
within NHS Lothian.  Sixteen patients, referred from outside NHS Lothian underwent more limited 
notes review.   
Of 83 patients, the majority (n= 74, 89%) were female and mean age was 44yrs old (range 12-78yrs).  
Almost half of the patients (n=37, 44 %) were unselected referrals to a general neurology clinic (i.e. 
not specifically to JS), with the others divided almost equally between the functional disorders clinic 
(n=20) and those referred by other neurologists (n=26).  
 
Clinical features of attacks.   
Some of the key clinical features and their frequency is shown in Table 1 
Description of attack.  Drop attacks, by definition, occurred suddenly, from standing or whilst 
walking.   According to their records, the vast majority of patients (93%) could not remember the fall 
itself.  Patients typically described finding themselves suddenly on the ground.  All patients initially 
stated they had no warning. However, when asked specifically about symptoms of dissociation or 
panic 43% (n=36) of patients described a brief prodrome.  This commonly consisted of 
depersonalisation and derealisation such as feeling “unplugged”, “floating” or a feeling of one of 
their legs not really belonging to them for only a second or two before the fall.    
Twenty-four (29%) patients had soft tissue injuries documented from the falls.  More than half the 
patients with soft tissue injury had recurrent facial injuries indicating that they did not put their arms 
out to protect themselves (n=17).  Injuries were also common to the knees (n=12).  Eight patients 
(9%) had fracture of either a finger (n=3), ribs (n=2), an elbow, toe or wrist (all n=1). Unless they 
were injured, subjects were typically able to get up quickly but often reported being very 
embarrassed and worrying about future attacks. 
Frequency and duration.  The mean duration of drop attacks when first seen at outpatient clinic was 
56 months (range 2-388 months).  There were three patterns of attacks: regular attacks occurring 
between ten times per day to once per month (n=34), clusters of attacks with freedom from attacks 
between clusters (n=6) and infrequent or solitary attacks (n=17). 




History of onset of attacks. In almost a quarter of patients (n=20, 24%) the first fall was reported as 
different from the subsequent drop attacks and was more likely a simple trip (n=11), vasovagal 
syncope (n=4), or associated with feeling generally unwell or dissociation (n=5). 
Triggers. 35% (n= 29) of patients noted drop attacks that were more likely to occur in certain 
situations or at certain times.  These associations could be with places where they worried 
excessively about falling, such as on the stairs, in the bathroom or kitchen or only occurring outside, 
in the context of excessive noise or bright lights or when unaccompanied. In two cases the timing of 
the falls could be isolated to a short daily period (only occurring between 3-6pm in one patient and 
between 12-2am in another). Patients frequently expressed constant background concerns about 
falling with persistent and significant fear of injury and embarrassment. Seven patients with regular 
attacks described transient feelings of relief, or a feeling that, following an attack, they would be 
very unlikely to get another one for a few days, and indeed that prediction would usually be true. 
 
Comorbidities 
Comorbid defined pathophysiological diseases at baseline: 
 At baseline 12 patients (14%) had a potentially relevant comorbidity which may have increased their 
vulnerability to drop attacks, by either providing an initial or an ongoing physiological trigger for the 
attacks (epilepsy n=4, vertigo n=2, and one each of: asymptomatic pineal cyst with prior 
hydrocephalus and static neuroimaging >6years, Chiari malformation with foramen magnum 
decompression, basilar tip aneurysm coiling without evidence of clinical or radiological brainstem 
damage, left lacunar stroke which caused right sided weakness, type 1 diabetes but no evidence of 
hypoglyacemic events, hereditary hemorrhagic telangiectasia with pulmonary arteriovenous 
malformation).  
Comorbid functional and/or psychological disorders:  
Seventy-five patients (90%) had comorbid functional somatic disorder (n=68, 82%) or functional 
neurological symptom disorder (n=48, 51%) which typically overlapped.  Somatic symptoms 
included: persistent fatigue (n=61, 73%), chronic pain (n= 33, 40%) and irritable bowel syndrome 
(n=12, 14%).  58% (n=48) of patients had a comorbid functional neurological symptom disorder: 
functional limb weakness (n=26, 31%), dissociative (non-epileptic) seizures (n=23, 28%), functional 
movement disorders (n=11, 13%) and other functional neurological symptoms affecting speech, 
vision or cognition (n=20, 24%). 23% (n=19) had episodes of dissociation without loss of 
consciousness, (i.e. episodes of gradual zoning out lasting several minutes with interruptibility). 74% 




of patients with comorbid dissociative (non-epileptic) seizures had them before the drop attacks and 
in 26% they developed after the drop attacks. 
Perhaps unsurprisingly, given the unpleasant and random nature of drop attacks, 43% (n= 36) of 
patients had a record of anxiety (n=23) or agoraphobia (n=13).  Fifteen patients had depression 
(18%), three had bipolar affective disorder (one with comorbid schizoaffective disorder) and one 
patient had a diagnosis of post-traumatic stress disorder.  
We analysed referral bias as an explanation for comorbidity. Patients with drop attacks referred to 
an unselected general neurology service (i.e. not referred specifically to JS) had similarly high levels 
of functional somatic and functional neurological symptom disorders to those referred to a 
functional disorders clinic run by JS (Supplementary Table 1).   
 
Investigations 
86% (n=71) of patients had cardiac investigations, 77% (n=64) of patients had CT or MRI brain 
imaging and 23% (n=19) of patients had an EEG (Supplementary Table 2).  Three patients had left 
their general practitioners and their cardiac investigations were impossible to trace.  Of the 71 
patients who had documented cardiac investigations, 34 were referred from either cardiology (n=15) 
or after normal 24-hour tape (n=19).  Others had a mixture of investigations for cardiac causes of 
loss of consciousness including ECG plus a mixture of 24-hour blood pressure monitoring, 
echocardiography, tilt table testing (n=3) and implantable loop recorder (n=1). Six patients had their 
typical drop attacks during cardiac monitoring (n=4 telemetry, n= 1 implantable loop recorder, n=1 
pacemaker) without cardiac abnormality.  Three patients (4%) had neuroimaging abnormalities (n=1 
cerebrovascular disease and atrophy in a patient subsequently diagnosed with frontotemporal 
dementia (FTD), n=1 previous posterior fossa craniectomy for Chiari malformation, n=1 small vessel 
ischaemic changes thought to be non-specific by consultant neuroradiologist). 
Prognosis and Treatment 
88% (n=73) patients had documented follow up with a mean duration of 38 months (median 29 
months, range 0-115months).   
During follow up, until the end of July 2016, five patients developed a potentially relevant disease; 
dementia n=3 (FTD n=2, Alzheimer’s n=1), ischemic heart disease n=2, prolonged QTc n=1. 
Half of patients’ reported that their drop attacks (n=42, 51%) had either resolved (n=23, no attacks 
for at least 6 months) or reduced in frequency by the end of follow up.  Almost a quarter had a static 




rate of attacks (n=18, 22%), 5% (n=4) were worse and 11% (n=9) had evolved into dissociative (non-
epileptic) seizures.   
Only naturalistic data was available on treatment. Ten patients appeared to be treated effectively 
for their drop attacks, on the basis of episodes which resolved with distraction techniques and 
treatment based on a formulation of their symptoms as a conditioned response (see below).   
Patients without functional comorbidity  
Of the eight people without any functional disorder three were male, four had defined 
pathophysiological comorbidity (n=1 epilepsy and n=2 FTD, n=1 Hereditary hemorrhagic 
telangiectasisa with pulmonary arteriovenous malformation), and one man had events in the 
context of alcohol and nicotine excess.  Four patients had resolution of drop attacks on follow up. 
 
DISCUSSION 
There are many clearly established causes of sudden falls with preserved consciousness including 
simple trips, knee instability, presyncope (and brief vasovagal syncope), arrhythmia and carotid sinus 
hypersensitivity, vertigo, cataplexy and colloid cyst of the third ventricle.  The clinical features of 
alternate causes of drop attacks are addressed in other articles and summarized in Table 2 [14–35]. 
The consideration that cryptogenic drop attacks in the majority of patients may be due to a 
pathophysiological disorder causing brief loss of consciousness is warranted [36,37].  Syncope can 
present without prodrome or with amnesia for the event. Although any type of syncope can occur 
without prodrome, arrhythmic cardiac syncope and cardioinhibitory reflex syncope are perhaps 
most likely to be associated with a rapid onset of unconsciousness and are the main 
pathophysiological differential diagnosis for cryptogenic drop attacks[14,38].  In patients with 
syncope, amnesia for the loss of consciousness can be present, occurring in 25- 28% of 
predominantly older patients (>60yrs) [39]. Additionally, some patients with provoked syncope may 
describe dissociative symptoms including an ‘out of body’ experience (9%). However, we propose 
that the very brief duration of cryptogenic drop attacks is the key distinguishing feature.  Patients 
with cryptogenic drop attacks are alert until the start of the fall and immediately again on hitting the 
ground, meaning any loss of consciousness or awareness in drop attacks must be less only a second 
or two.  In any cardiac induced loss of consciousness it usually takes seconds to lose consciousness 
and also seconds to regain it[40,41]. We suggest that the very brief loss of awareness in cryptogenic 
drop attacks is too short to be due to cerebral hypoperfusion, whilst accepting that it could be in the 
realms of a complicated pre-syncopal episode. 




Functional neurological disorders are defined as those in which patients have motor or sensory 
symptoms which can be clearly identified as internally inconsistent or incongruous with disease on 
the basis of positive signs such as Hoover’s sign or tremor entrainment test[42]. These highlight the 
fact that functional motor symptoms are normally maintained by excessive attention paid to the 
limb which in turn interferes with normal voluntary movement [43–45]. The symptoms are 
experienced as involuntary and may or may not be associated with psychological comorbidity or 
prior psychosocial stress.  
Research on functional/psychogenic causes of brief loss of consciousness such as psychogenic 
pseudosyncope and dissociative (non-epileptic) seizures highlight evidence that many patients 
experience dissociative responses as a conditioned response to autonomic arousal that occurs 
suddenly and briefly prior to their events [36,37,46]. We have found some features in our case series 
to support a hypothesis that cryptogenic drop attacks may, in many cases, be a functional rather 
than defined pathophysiological disorder of the nervous system, on a spectrum of transient 
dissociation which includes psychogenic pseudosyncope and dissociative (non-epileptic) seizures 
(Table 2, Table 3, Figure 1).  Features of cryptogenic drop attacks supporting this hypothesis include: 
1) cryptogenic drop attacks are inconsistent with most types of falls in adults in which the fall is 
usually recalled [47], 2) a period of loss of awareness too short to represent syncope and only 
compatible with dissociation, 3) Brief dissociative symptoms just before or after the event in 43%, 4) 
the co-occurrence of clear dissociative (non-epileptic) seizures either before or after drop attack 
(28%) or functional limb weakness (31%); 5) Attack clustering and situational attacks in 35%; 6) high 
comorbidity of fatigue, pain and other symptoms seen in functional neurological disorders such as 
dissociative (non-epileptic) seizures[48], 7) Successful treatment in some patients based on 
distraction techniques during the prodrome (12%). 
Specifically, we propose that in some individuals with cryptogenic drop attacks, the disorder is best 
considered a form of brief dissociative attack which then becomes established as a patterned and 
conditioned response generated by a fear of falling, either with or without situational triggers (Table 
2 and Figure 1).  We hypothesise that patients with a biological or biopsychosocial vulnerability to 
drop attacks typically have a triggering event such a simple fall, trip, syncope or episode of 
dissociation.  Excessive worry about further falls, particular in inopportune settings, leads to a 
cognitive representation of the attacks which drives abnormal self-directed attention and 
rumination about the possibility of falling. The idea of a cognitive representation can be conceived 
both as a consciously processed illness model and in terms of Bayesian predictive coding, an idea 
that has been explored in depth in more recent models of dissociative (non-epileptic) 
attacks[45],[49],[46]. Our hypothesis is that drop attacks are at one end of a spectrum of dissociative 




attacks that includes brief dissociative episodes with staring and “zoning out”,  more prolonged 
motionless unresponsiveness (psychogenic pseudosyncope) and episodes with hyperkinetic 
movements (dissociative seizures) (Table 3). 
We propose that falls occur due to brief loss of awareness secondary to episodes of dissociation.  
We hypothesise that this becomes a classically conditioned response and patients’ falls become 
associated, in some cases, with situational triggers and in some cases reinforced by a feeling of relief 
after the fall is over. Some patients’ drop attacks may develop through operant conditioning with 
conscious avoidance of stimuli associated with the drop attacks.  This worry about falling can 
generalize to anxiety or agoraphobia through the process of ‘chaining’ where more background 
stimuli are associated with the drop attack.  Neurological disease in general is a significant risk factor 
for functional disorder, being a potent cause of distortion of sensori-motor experience, cognition 
and anxiety[50,51]. We propose that some of the neurological comorbidities described in our series 
have increased the risk of functional disorder rather than offering an alternate pathophysiological 
explanation in our patients. 
Table Two: Features of cryptogenic drop attacks in keeping with a functional disorder 











1. Inability of patients to recall falling  7
7 
93 
     
2. Brief dissociative or panic symptoms just 




     
3. Dissociative (non-epileptic) seizures 
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     
5. Long duration of intermittent falls 





     
6. Co-occurrence with persistent fatigue  6
1 
73 
     
7. Co-occurrence with functional weakness 2
6 
31 
     




8. Attack clustering and situational attacks 
in some patients (in agoraphobic 





     
9. Feelings of ‘relief’ once the drop attack 
had occurred, akin to relief seen after some 




     
10. Successful treatment of attacks using a 
model of distraction developed for the 






     
11.Resolution of attacks in patients 2
3 
28 




     
=possible =likely = very likely 
 




Table Three: The proposed spectrum of functional (dissociative) attacks or seizures 
















Peak age of 
onset 













suddenly on the 
ground without 
apparent loss of 
consciousness 
Long duration 
episodes of ‘fall 
down lie still’ (i.e.> 
two minutes), 
typically with eyes 
closed  [40] 
 
Episodes of 
generalized or focal 
limb shaking, 
typically with eyes 
closed and other 
positive 
features[15] 
Episodes of being 
relatively 
unresponsive or 
staring, with or 
without experience 
of unawareness or 
dissociation 
Prodrome and  
proposed 
Mechanism 
Prodromal dissociative symptoms and arousal in many patients 
Fearful anticipation increases likelihood of events and attacks may cluster situationally 
in some 
Trigger All may apparently be triggered by initial fall, vasovagal syncope or panic attacks 
which are different from subsequent drop attacks[16,51] 
 
In our series, recurrent facial soft tissue injuries were more common than the bruised knees from 
which drop attacks gain their French name ‘la maladie des genoux bleus’.  Injuries have long been 
associated with dissociative seizures occurring in 30-40% of case series [52,53].  Drop attacks are not 
a benign condition either and many of our patients gave up work or had substantial social and 
occupational impairment.  Comorbid functional neurological disorders have not been previously 
described in patients with cryptogenic drop attacks including in Steven’s and Matthew’s paper.  
Given that one third of our patients were unselected referrals to a general neurology service this 
suggests a genuine association.  The absence of comorbid functional disorders in reported literature 
may be due to lack of expertise in identifying functional disorders by non-neurologists seeing these 
patients or lack of confidence in making a diagnosis by neurologists.  Similar underreporting of 
psychogenic pseudosyncope is seen in large cohort studies of syncope [54].  The lack of any in-depth 
studies of younger patients with cryptogenic drop attacks since 1973 may also play a role.  
Even if the majority of patients with cryptogenic drop attacks can be thought of as attacks within the 
spectrum a functional neurological disorder, there are patients in our study in whom the aetiology of 
their drop attacks remains cryptogenic.  Men were entirely absent from the Stevens and Matthews 




series.  They represented 11% of our cohort and are under-represented even in older drop attack 
populations [5].  In our study the comorbid defined pathophysiological risk factors at baseline or 
follow up was over three times that in men than women (55% vs. 15%), raising the possibility that 
mechanisms of drop attacks in men may have some differences to women.  The absence of a 
comorbid functional disorder should also signal a warning flag for underlying pathophysiological 
disorders given the high proportion (50%) in our eight patients. 
We acknowledge significant limitations in this data which we present as hypothesis generating. This 
was a retrospective study of consecutive cases seen in routine clinical care and clinical variables 
were chosen from this material.  There are many variables, including adverse childhood experience, 
that we did not collect. 
. Importantly, not all patients were subject to neuroimaging or cardiac investigation such as 24 hour 
ECG or EEG. More detailed investigations such as tilt table testing and specific measures of balance 
were not applied[55]. It remains the case, that some of these patients may have alternative 
diagnoses, particularly syncope. A comparison group with a paroxysmal condition such as 
neurocardiogenic syncope would have helped to examine the specificity of some of the proposed 
associations. JS’s clinical interest in functional disorders may have biased frequency of comorbidity, 
although similar frequencies were seen in unselected referrals to a general neurology clinic.  
Because our patients were seen clinically rather than in a research study, physiological and structural 
measures of falls, such as dynamic posturography, used in other studies were not routinely used in 
our patients.  Sixteen of the 83 patients were referred from outside of the health board which may 
have led to an underestimate of follow up diagnoses. Data on treatment modalities and outcomes 
was insufficient for more in-depth analysis, so was only considered anecdotally. 
Additionally, ideas solidified through the process of seeing patients and some of the questions asked 
of the 83rd patient were not the same as those asked of the first.  We have endeavored to make the 
process as uniform as possible by including only those patients who were seen by the author JS and 
excluding patients where the description of the attack could not be judged by the rest of the 
research team.    
We present our data to support a hypothesis weaved together from the stories of the patients seen 
in routine clinical practice. We suggest considering cryptogenic drop attacks in some patients as a 
subtype of functional neurological disorder. We propose that brief episodes of dissociation, often 
precipitated by a mechanical fall or faint, perpetuated by fear of falling can become habitual via a 
conditioned behavioral response.  This could lead to specific treatment techniques involving 




education, distraction techniques, overcoming avoidance and graded exposure to the conditioned 
stimuli. 
A prospective multi-centre controlled study of drop attacks in younger individuals that avoids the 
limitation of this case series including tilt-table testing and, where possible, timing of loss of 
awareness as well as multiple psychological, physiological and structural measures is warranted to 
examine the question of whether cryptogenic drop attacks overlap with functional neurological 
symptom disorders or are better thought of, and treated as, functional drop attacks. 
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Table One: Differential Diagnoses of Drop Attacks 
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Paper Five: Stone J1, Hoeritzauer I1, Tesolin L2, Carson A1,3 Functional Movement Disorders of the 
Face: A Historical Review and Case Series.  J Neurol Sci. 2018 Sep 26;395:35-40.  
 




Functional facial dystonia or spasm has, in recent years, been recognised as a relatively common 
form of functional movement disorder. We describe historical 'forgotten' neurological literature 
indicating that this was a well described phenomenon by the early part of the 20th century but 
subsequently faded from awareness. We add data from our own series of 41 patients with functional 
facial dystonia to explore the clinical features and associated comorbidities of patients with this 
movement disorder.   
The Clinical Features and Prognosis of ‘Scan Negative’ 





The last decade has seen increasing awareness of the fact that functional movement disorder may 
affect the muscles of the face. An initial report on  four patients  by Tan and Jankovic in 2001[1], was 
followed by scattered reports[2][3] prior to a seminal case series of 63 patients by Fasano et al in 
2012[4][5]. Subsequent small series[6] have all added to the characterisation of functional facial 
movement disorders which were defined by Fasano and Tinazzi as a dystonia with fixed unilateral 
facial contraction, usually involving the lower lip and often with ipsilateral orbicularis oculis and jaw 
involvement.  They are often of maximal severity at onset and display inconsistencies on clinical 
examination, such as resolution with distraction and changes in side and pattern during or between 
examination or spontaneous remissions[5].  
 
The history of the field has not been one of linear accumulating knowledge. ‘Hysteria’ was a core 
part of neurological textbooks in the 19th century but it gradually lost its popularity as a subject of 
neurological study over the course of the 20th century [7][8]. Consequently, a considerable number 
of useful but older clinical descriptions have been forgotten. Much of our apparently new knowledge 
in this field revisits clinical experience that had been documented in the past.  
 
Fasano et al noted that patients diagnosed with atypical facial movement disorders in studies going 
back to 1986 also probably fulfilled the diagnostic criteria for functional movement disorders[4]. 
From our own reading of the older literature, however, it was clear that this clinical entity had 
already been recognised much further back in the 19th century.  
 
In this article, we re-examine the historical literature on functional facial movement disorders and 
compare it, and recent work, with a new case series of 41 patients with functional facial movement 
disorders to extend the historical and clinical perspective of this clinical presentation. 
 
METHODS 
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For the historical review, we carried out a systematic search of a collection of neurological textbooks 
and books on hysteria and allied conditions published prior to 1920.  All book titles are available for 
public download from www.archive.org.  Each book was searched for the terms ‘facial’, 
‘blepharospasm’ and ‘ocular’.  In this section, we sometimes use the term hysterical since it was the 
term used in these publications.  In addition, we searched for descriptions of patients with atypical 
facial dystonia or movement disorder from 1960 until 2017 who had features in keeping a functional 
facial movement disorder.   For both the historical literature and recent search we explored 
references when relevant.  Our case series is derived from 41 patients with functional facial 
movement disorders seen consecutively in general neurology and specialist ‘functional’ clinics in the 
Department of Clinical Neurosciences, Edinburgh by one of the authors (JS) over a period of from 
2008-2013.   
 
 
REVIEW OF LITERATURE 1880s to 1960s 
 
We cannot find an earlier reference than 1887 when Charcot described unilateral hysterical facial 
spasm in the well-known patient 'Le Log' as follows[9]:  “...left labial commissure is raised and mouth 
is partly open. At first thought to be paralysis of right inferior facial...on further examination it is due 
to spasm of the muscles on the left side of the face”. 
 
Gowers at around the same time[10]  also described hysteria affecting the face: 
"In hysteria there is either tonic contracture, especially in the orbicularis, or attacks of quivering 
movement, which do not resemble true facial spasm.... The effect of the preponderant contraction in 
the orbicularis and zygomatic muscles is a curiously mixed emotional aspect, a sort of whimpering 
smile ".   Gowers, whose chapter on hysteria in that book has rarely been surpassed, also 
commented that these spasms were " usually lessened by rest, physical and mental... always 
increased by emotion, and by movement of the face, whether in speaking or chewing and ...by light 
and by cold." He noted that "The influence of light is intelligible, since the orbicularis palpebrarum is 
almost always involved, and a strong light produces reflex contraction in this muscle under normal 
circumstances".  Gowers also refer to the presence of 'wrong way' tongue deviation, in which the 
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tongue deviates to the side of facial spasm/apparent weakness, and is the opposite of what would 
be expected were the patient to have a pontomedullary lesion. 
 
Babinski and Froment summarise earlier descriptions under the term 'glosso-labial hemispasm’, 
under which it can often be found in subsequent textbooks[11]:  “In glosso-labial hemispasm, 
described by Charcot, Brissaud and P. Marie, the spasm, as its name indicates, may be limited to the 
tongue and lips but sometimes affects simultaneously the orbicularis palpebrarum, platysma and 
neck muscles. The hook-like appearance of the tongue and the intermittent spasms of the contracted 
muscles give it an almost pathognomonic appearance.”  They also reinforce the potential for 
confusion that could arise regarding whether there was paralysis or not “when there is facial 
asymmetry it will be found to be due not to muscular hypotonus but to spasm.” 
 
Dejerine commented 'as far as the face is concerned one much more frequently observes a 
glossolabial spasm than a facial paralysis properly so called[12]’. Charcot and Dercum were not 
convinced that facial muscular paralysis could occur as a hysterical symptom stating ‘in the hysteric 
the deviation of the mouth and tongue, and facial paralysis, are wanting.’[13]  Preston in 
1897,considered facial spasm to be 'not rare' but hysterical facial weakness 'very infrequent'[14].  
 
Wood, in JAMA in 1898 [15]writing about neuro-ophthalmological aspects of hysteria commented, 
“a very common and in my opinion characteristic eye-sign in hysteria is spasm of orbicularis, the so-
called blepharospasm…When this is unilateral it is almost invariably hysteric.”  Pershing discusses 
this diagnosis in 1901[16] and Oppenheim  in 1900[17]. Janet, wrote that he had seen ‘many cases of 
hysterical facial paralysis’ that were ‘typical’ [18] but he may have been describing spasm since he 
doesn’t refer specifically to weakness.   In the 1920 edition of Diagnosis of Nervous Diseases by 
Purves-Stewart there are three photographs of patients displaying functional unilateral 
blepharospasm (Fig.1)[19].  
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Figure 1: Functional facial movement disorder – historical cases. A-D[22]: (A) Bilateral ptosis with 
frontalis overactivity, cured within several weeks. (B) Right ptosis requiring frontalis overactivity to 
see. Left orbicularis overactivity with amblyopia, resolved with a one-hour treatment (right hand 
image). (C) Right orbicularis overactivity and left frontalis overactivity with ptosis and amblyopia of 
five months duration, and after a half-hour treatment (left hand image). (D) Bilateral ptosis at rest 
with right facial spasm and apparent left facial weakness; left eyelid raised to see; attempt to open 
eyes resulting in overactivity of left frontalis and spasm of the right side of the face. (E) Functional 
facial spasm and torticollis[48]. (F & G): Left ‘hemiglossolabial spasm’ associated with ipsilateral 
functional limb weakness and contracture[19].  
  
 
Also at that time Arthur Hurst, a British physician known best for his films of patients with shell 
shock[20][21],  described facial weakness and ptosis which resolved rapidly with suggestion and 
persuasion[22].  Hurst also provides some of the best images of patients with ‘hysterical’ facial 
spasm (Fig. 1).   
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There were sporadic mentions of 'hysterical' facial spasm in the 1950s,[23] and 1960s[24] but then 
the problem largely disappeared from view. 
 
From the historical review, functional facial movement disorders were positively described as 
unilateral facial spasm, most commonly presenting with unilateral orbicularis, lower face or 
platysma contraction.  They differed from other types of dystonia by the sustained nature of their 
contraction. There was general agreement that functional facial weakness, as opposed to muscle 
overactivity giving the appearance of overactivity, was very rare. 
 
PREVIOUS PUBLISHED REPORTS OF ATYPICAL FACIAL MOVEMENT LIKELY TO REPRESENT 
FUNCTIONAL FACIAL MOVEMENT DISORDERS 
With hindsight, and as previously described by Fasano et al.[4], some case reports and series of 
patients with facial dystonia from the 1980s to the early 2000s may be better classified as a 
functional movement disorder in terms of variability, associated features and response to 
treatment[25–27][28][29][30]. Four such cases from the paper by Thompson et al. [25] are shown in 
Fig.2 along with two other subsequent reported cases  mentioned by Fasano et al. Schrag[31] et al 
reported eight cases who developed cranial dystonia within hours to months following a dental 
procedure.  Two of these eight cases had fixed jaw deviating dystonia, and four had painful 
dysaesthesia which the authors suggested was similar to the limb causalgia–dystonia syndrome, now 
described as complex regional pain syndrome. The authors discussed how the fixed nature of the 
jaw deviation, lack of sensory geste antagoniste, presence of pain and long duration of symptoms 
without progression to a segmental or Meige syndrome supported the unusual nature of the 
movement disorder and left open the possibility of a functional/psychogenic movement disorder in 
these four cases. 
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Figure 2: Published cases of facial dystonia that in hindsight fit better with a diagnosis of functional 
movement disorder. Cases A-D[25] reproduced by permission of BMJ publishing group Ltd.  (A) 
Painful jaw deviation following dental extraction with normal R2 blink response latency. (B) 
Intermittent left face/tongue/jaw spasm. (C) Episodes of complex face and eye spasm with 
convergence spams of the left eye. An original diagnosis of multiple sclerosis was made, but MRI 
brain scan and CSF parameters were normal. (D) Episodes lasting 2-5 minutes as shown associated 
with hyperventilation and relieved by intravenous calcium gluconate despite normal calcium levels 
during the attacks. (E) Two of the four cases of acute lip deviation reported by Kleopa et al.[26] 
associated with ipsilateral limb weakness. Reproduced by permission of John Wiley and Sons. (F): 
One of two similar cases to Kleopa reported by Wohlgemuth et al.[27]. Reproduced by permission of 
John Wiley and Sons.    
 
 
At the time of Thompson et al.'s paper there remained a common view that 'psychogenic' 
movement disorder could only be diagnosed in patients with recent life events or with concurrent 
psychiatric abnormalities.  In addition, a diagnosis of hysteria was still seen as pejorative and 
therefore often avoided in cases where the doctor believed the patient had a genuine problem. In a 
climate in which some focal dystonias had only recently been 'rescued' from psychodynamic 
interpretations such as torticollis being a 'turning away from responsibility' it is understandable that 
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there was a desire to avoid the diagnosis of “hysteria”, although David Marsden, who led the work 
on focal dystonia was perspicacious on hysteria and made the diagnosis often[8,32]. The problems 
with diagnosis at that time can be seen, for example, in the four patients said to have psychogenic 
blepharospasm in the paper by Cavenar et al in 1978[33]. based on profound psychopathology.  All 
of these patients had features in keeping with organic blepharospasm with bilateral involvement and 
psychiatric comorbidity.  The changing view of functional movement disorders now encompasses 
movement disorders that are genuine, variable, utilise voluntary muscle pathways and have 
diagnostic features that indicate the role that attentional focus plays in the movements. A diagnosis 
of functional movement disorder no longer requires psychological causation in the latest revision of 
DSM-5, the American Psychiatric Association’s psychiatric classification[34]. 
 
 
EMERGENCE OF REPORTS OF FUNCTIONAL (PSYCHOGENIC) FACIAL MOVEMENT DISORDERS 
Keane, in 1986, noted the presence of 'wrong way tongue deviation' as a sign of  functional disorder 
and commented on the presence of ptosis in some patients[35]. Case reports of functional or 
psychogenic pseudoptosis (in fact related to orbicularis oculi contraction rather than eyelid 
drooping) appeared from 1997 onwards [36–39].  Psychogenic hemifacial spasm, involving the lower 
face, was reported by Tan & Jankovic in 2001 [n=4][1], with subsequent case series by Tarsy et al. 
[n=5][2], and a report by Stone [n=1[3]] between 2001-2010.  Patients with psychogenic 
blepharospasm were also reported in case series of other psychogenic movement disorders without 
detailed description of how the positive diagnosis had been made[40,41]. In 2011 Schwingenschuh 
and colleagues reported that the blink recovery cycle reflex was normal in patients with "presumed 
psychogenic" blepharospasm (n=9) but abnormal in essential blepharospasm [42].  More recently 
Ganos et al describe psychogenic paroxysmal movement disorders affecting the face and head in six 
and seven patients respectively[43]. The case reports of  Gozke et al [44] and illustrated case series 
of four patients with tonic lip deviation by Colosimo et al highlight the growing awareness of 
functional facial movement disorders [45]. 
 
NEW CASE SERIES IN CONTEXT 
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Data from our new case series, the second largest, are described in table one and compared to the 
other large series of patients with functional facial movement disorder described by Fasano et al[4].  
 
The presence of 41 cases collected over a 5-year period indicates a movement disorder that must be 
relatively common relative to many other disorders. The neurologist seeing these patients (JS) does 
have an interest in functional disorders but nevertheless many of these patients were seen in a 
general neurological setting and the population catchment of the centre is only 1 million persons. 
 
Patients in our case series were predominantly female (81%) and middle aged (mean age 44yrs).  
The most common signs were downward lip pulling and orbicularis oculis spasm (both 90%). 
Platysmal overactivity frequently accompanied this (85%).  It was usually unilateral (90%), without 
right or left preponderance, and 71% episodic.  Tongue deviation, exclusively towards the side of 
facial spasm, was not seen commonly (12%) and jaw deviation was much less frequently seen than 
was described by Fasano et al (22% vs. 84%).   
 
Not recorded by Fasano et al[4] but seen in our series, were facial spasms triggered by examination 
of eye movements or by asking the patients to sustain muscular contraction of the face (51%). This is 
a similar mechanism to the triggering of functional convergence spasm by sustained gaze in Kaski et 
al’s study of patients with functional eye movement disorders and likely relates to the effect of 
sustained attention in functional facial movement disorders[6].  From a clinical perspective we found 
this a good way of inducing the symptom in those patients who attended clinic with a history of 
episodic spasm but without the movement disorder at the time of assessment.  
 
In 78% patients, there was evidence of functional limb weakness. This was mostly in the ipsilateral 
limb (91% of the time when present.  Our series is also notable for a high frequency of other 
comorbid functional neurological disorders not reported by Fasano et al including convergence 
spasm of eye abduction (22%), dissociative (non-epileptic seizures) (32%) and functional dysphonia 
(12%). Other physical comorbidities including persistent fatigue (83%) and migraine (51%) were also 
common, in keeping with findings of multiple comorbidity in other functional movement disorder. 
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Migraine triggered functional facial movement disorders in 17% and 7% of patients reported 
premonitory symptoms that were abolished by paroxysmal movements. Such premonitory 
symptoms also occur in ‘organic’ forms of oromandibular dystonia and are certainly not 
diagnostic[46]. The phenomenology here was similar to patients with non-epileptic attacks who 
commonly experience an unpleasant aura that is relieved by the attack (even though the attack itself 
is also unwelcome) [47]. In the context of a functional facial movement disorder this finding could be 
used in treatment strategies during cognitive behavioural therapy. 
 
Conclusion 
Functional facial dystonia or spasm has recently been recognised as a relatively common form of 
functional (psychogenic) movement disorder with clearly identifiable clinical features. We have 
highlighted historical and 'forgotten' neurological literature dating back to 1887 indicating that it 
was a well described phenomenon at that time, although awareness of it slipped from general 
neurological awareness in the middle of the 20th century. With hindsight, many published cases of 
facial dystonia from the 1980s onwards fit best with this entity.  Our own case series of 41 patients 
from one regional centre highlights that this must be a relatively common clinical problem and 
highlights some new data, especially in relation to triggering manoeuvres during examination and 
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Table 1 Clinical features in a new series of 41 patients with functional facial movement disorder. 
Compared to other large series of Fasano et al.[4]  
 
 This Series (n=41) Fasano et al. (n=61) 
Mean Age (range) / Sex 44(19-75), 81% F 44 (19-66), 92% F 
Median Duration (range) 12 months (0-30) 6.7 years (0-30) 
Side (R:L:Both) 40% R; 50% L; 10% B 31% R; 39% L; 29% B* 
Episodic vs Fixed 93% vs 7% 73% vs 27%* 
Location 
   Eye 
   Mouth 
         (Down vs up) 
   Unilateral Platysma Contraction/ 
Jaw Deviation 















Functional Movement Disorder  
    Weakness 
         Ipsilateral limb 
         Contralateral limb 










Arm (29%), Leg (16%), 
Neck (16%) 
Movement triggered by eye 
movement or sustained facial 
muscle contraction 
51% Not recorded 
Other Functional Symptoms 
    Migraine 
    Fatigue 
    Convergence Spasm 
    Dysphonia 
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Triggering and premonitory 
symptoms 
17% Headache, 7% 
premonitory dissociation 
Not recorded 
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There have been many articles highlighting differences and similarities between complex regional pain 
syndrome and functional neurological disorders but until now the discussions have often been 
adversarial with an unhelpful focus on malingering and a view of FND as “all in the mind”.  However, 
understanding of the nature, frequency and treatment of FND has changed dramatically in the last 10-
15 years. They are no longer assumed just to be a physical “conversion” of a psychological conflict or 
trauma but are understood as a complex interplay between peripheral stimulus, expectation, learning 
and attention mediated through a Bayesian framework, with predisposing, triggering and 
perpetuation inputs which may be biological, psychological or social. Building on this new ‘whole 
brain’ perspective of FND we seek to reframe the debate about psychological versus physical triggers 
or sequalae in complex regional pain syndrome (CRPS), and to recognise how research into peripheral 
and central nervous system abnormalities and treatment in patients with CRPS may inform future 
mechanistic understanding of FND. Conversely, we review advances in FND, especially treatment, 
which could have implications for improving understanding and management of CRPS. 
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Complex regional pain syndrome (CRPS) is a disabling chronic condition following physical injury to a 
limb, that is characterized by local inflammatory and autonomic dysregulation combined with trophic 
and motor dysfunction of the affected body part1. Although its defining features (sensory, autonomic, 
motor and trophic) have been extensively studied and incorporated into validated diagnostic criteria 
("Budapest Criteria"2,3), their pathophysiological nature and the role of the incipient event remain a 
matter of debate and research1.  
 
In the debate surrounding CRPS one conceptual schism stands out as particularly polarizing and 
counterproductive: the role of psychological processes4,5. This debate has typically been characterised 
over the years as a battle between those who see CRPS as a genuine medical disorder, and those who 
seek to define it as a ‘non-organic’ or ‘psychogenic’ disorder. Within the umbrella of ‘non-organic’ 
there has often been little distinction between patients with a genuinely experienced functional 
neurological disorder (FND; also called psychogenic or conversion disorder) and those patients wilfully 
exaggerating symptoms for medical care or financial gain6,7. Voluntary feigning of CRPS signs and 
symptoms is sometimes found in rare cases of malingering or factitious disorder8–10 and must not be 
equated with "functional" or "psychogenic" disorders.  
 
FND describes the presence of disabling and/or distressing motor and sensory symptoms which can 
be identified by the presence of positive evidence of internal inconsistency such as Hoover’s sign or 
tremor entrainment sign, or other evidence of incompatibility with a structural disease process (i.e. 
incongruence). Such positive motor and sensory signs have been consistently identified as also 
characterising the motor and sensory features of CRPS. For example, there is no clinical difference 
between the fixed dystonia leading to clenched fist or plantarflexed/inverted ankle seen in CRPS and 
that seen in FND without pain11.  Tremor12, limb weakness13 and sensory disturbance14 has also been 
identified as having the same features in CRPS as in FND (Table One, Figure One). Importantly, the 
need for antecedent psychological stressors has been removed from the diagnostic criteria in DSM-IV 
for FND in recognition that, like CRPS, many patients don’t have identifiable stressors or psychiatric 
comorbidity. Concurrently, there is now a large literature on changes in brain function in patients with 
FND, including differences to feigning, which is changing previous narrow purely ‘psychogenic’ 
thinking about the disorder 15(Hallet et al., 2016). 
 
However, in the face of multiple indicators of central and peripheral changes in CRPS in contrast to a 
dualistic, anachronistic and traditionally poorly articulated idea of functional disorders as exclusively 
the domain of psychological disturbance, or worse still, malingering, it is perhaps not surprising that 
polarisation has persisted5,16. In much of the literature it is easy to detect, and understand, a defensive 
tone in which advocates for patients with CRPS defend the integrity of their patients against those 
who would ‘doubt’ them or accuse them of having a stigmatised psychiatric disorder. 
 
In a review from 2000, Ronald P. Pawl concludes that "[t]here is no convincing evidence that a primary 
organic dysfunction of the nervous system, in particular the autonomic nervous system, exists in 
[CRPS]" 17. Diametrically opposed, Hill and colleagues recently summarized that "there is no indication 
that psychological factors cause the onset of pain, autonomic dysfunction, and movement disorders 
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in CRPS patients"16. The dualistic nosological line of separation between CRPS and functional 
neurologic disorders (FND) is drawn with such unanimous certainty that it extends well into the 
newest international diagnostic criteria, that see FND as a differential diagnosis which strictly 
precludes CRPS2,18. Lastly, this polarized view is perhaps best exemplified in the recent UK guidelines 
which was authored without input from either neurologists or psychiatrists: "a combination of 
elements including inflammation, dysfunction within sympathetic and somatosensory nervous 
system, and cortical (not psychological) factors are thought to contribute to the generation and 
perpetuation of symptoms"19(emphasis added). With a recently reinvigorated interest in functional 
disorders of the nervous system, neurologists have been reasserting the conceptual proximity and 
physiological overlap of FND and CRPS20,21 but these have stopped short of challenging the dualistic 
thinking that has dogged both disorders. 
 
Most current authors on CRPS tend to acknowledge a limited (secondary) role of psychological factors, 
without considering an alternative possibility – that the conventional divide between ‘organic’ and 
‘non-organic’ disorders is no longer tenable in the face of what we know about the brain and body. 
Discarding this division allows for a new possibility. That it is possible to have a disorder of nervous 
system functioning which presents with physical symptoms and which can exist independently of 
psychiatric comorbidity but in which cognitive and behavioural factors are still relevant.  
 
This review will re-examine the clinical overlap and common pathology of CRPS and FND and will 
propose that the debate moves in this more productive middle ground. Providing first a brief overview 
of the pathophysiology of CRPS and FND (see Figure Two) we will then go on to present a unifying 
framework for understanding these disorders and will review the implications for treatment. In doing 
so we believe that patients, clinicians and researchers in both CRPS and FND could benefit.  
 
The overlaps between CRPS and sensorimotor FND 
 
CRPS is a chronic pain disorder with a combination of sensory, motor, autonomic and dystrophic 
changes22. These changes are usually triggered by an incipient event such as injury or surgery, but can 
occur spontaneously in a minority of cases23. Although traditionally FNDs have been associated with 
psychological trauma, systematic studies have revealed that they very often arise from physical 
injury24,25. In a systematic review of 869 cases, 37% of functional motor and sensory disorders had a 
history of physical injury, and In surgical settings similar to CRPS, 79% of sensorimotor FND are 
preceded by a physical precipitant25. In a prospective cohort of 50 patients with FMD (dystonia in 
36%), as many as 80% reported a precipitating "physical" noxious event within the preceding three 
months, with 38% fulfilling the criteria for panic attack in association with said event24. The 
combination of immobilisation (reflexive due to acute pain or iatrogenic through plaster cast 
bandaging) and excessive anxiety is considered a potential precipitant for FMD development24,26. 
Stressful life events precede FND only in about a half of cases27, similar to CRPS28, and their importance 
has been downgraded from a diagnostic criterion to an optional risk factor in the revision of DSM-529.  
Central to our argument is the nature of motor and sensory signs seen in both CRPS and FND (Table 
One, Figure One). In contrast to classic (idiopathic/primary) dystonia, functional dystonia is usually 
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immobile ("fixed"); develops acutely, often following minor injury; cannot be alleviated by sensory 
tricks (so-called geste antagoniste) but is instead intensified by any manipulation; is accompanied by 
other functional motor and sensory symptoms; and is usually associated with regional pain30. Even in 
functional paralysis without dystonic posturing, pain in the affected limb is reported in a third of 
cases31.  In their large series of "fixed dystonia", Schrag and colleagues reported a 20% overlap of 
CRPS11.  Meanwhile, Mailis-Gagnon and colleagues found that among 54 presumed CRPS cases, 
experts determined 18% to be suffering from “psychogenic” disorders32.  Limb weakness and 
bradykinesia are almost universally present in CRPS, with most having ‘give-way’ weakness13,28 and 
around 70% of patients develop movement disorders such as dystonic posturing, tremor and/or 
myoclonic jerks12,28,33,34.  Patients show reduced voluntary control35,36, and have problems initiating 
movement28 or assessing limb position37.  Sensory symptoms are often in a non-dermatomal 
distribution38 and resolution of hypoesthesia followed placebo injection occurred in 50% of 27 patients 
with CRPS and 0% in patients with a nerve lesion (n=13)7. Other positive diagnostic features used in 
the diagnosis of FND, such as distractibility, suggestibility, clinical inconsistency and physiological 
incongruity 39,40 can be found in CRPS patients. 
 
 
Figure Two. An illustration of the overlap between Complex Regional Pain Syndrome and Functional 
Neurological Disorder indicating ways in which understanding of one may benefit the other. 
 
 
The early alterations seen in CRPS are dominated by peripheral inflammatory changes and autonomic 
response18.  Local nerve injury is thought to underlie early neuropathic pain41 and can trigger 
neurogenic tissue inflammation mediated by neuropeptides such as substance P and calcitonin gene 
related peptide (CGRP) 42. Driven also by pro-inflammatory cytokines such as TNF-a, IL-1b, IL-2 and IL-
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6, this inflammatory state is thought to underlie hyperalgesia43 (Wegner et al., 2014), early allodynia44, 
and autonomic and dystrophic changes18,45. Autonomic changes can include so-called sympatho-
afferent coupling, whereby nociceptive fibres are thought to be activated by sympathetic nervous 
system activity1. The neuroimmunological interplay is further complicated by the potential 
contributions of neural autoantibodies4,46 and small noncoding RNA molecules called microRNA47.  
Importantly, such pro-inflammatory, autonomic and hyperalgesic regional tissue reactions can be 
observed reliably in (experimental models of) acute injury, transient immobilization and chronic pain 
in general48–53.  
 
So what keeps these pro-inflammatory processes in CRPS from abating normally over time, as they 
usually would after injury and temporary immobilisation? In CRPS, we hypothesise that the peripheral 
inflammation becomes interlocked with much wider-reaching nervous system maladaptations that 
are identical to those seen in FND. 
 
A temporary adaptation of movement to acute pain (or to the expectation of pain) is a physiological 
reaction, and involves a redistribution of muscle activity that leads to stiffening, restriction and 
slowing of movement, and favours relieving postures (Hodges & Tucker, 2011). Such adaptations, 
while normally only transient and largely under volitional control, can become entrenched in robust 
pathways through cycles of negative reinforcement until they are no longer within the reach of 
conscious control. Hypervigilance and avoidance based on anxious illness beliefs, catastrophizing 
tendencies, or excessive self-monitoring can imprint expectations of pain and immobility that can 
distort and even override incoming sensory information26,54.  Such failure to re-adapt has been 
proposed to underlying chronic dysfunction in FND, and can just as well explain sensory and motor 
symptoms in chronic CRPS. 
 
Studies of central nervous function using functional MRI and transcranial magnetic stimulation in both 
disorders have revealed subtle but comparable abnormalities of brain activations (see Aybek & 
Vuilleumier, 201655, and Di Pietro et al., 2013a56, 2013b57, for review). Most studies examining central 
function in CRPS and FND are too heterogenous to allow direct comparisons, but there is one group 
that has tested motor execution and imagery using the same paradigm in both CRPS58 and functional 
limb weakness ("conversion paralysis")59.  Compared to healthy controls, CRPS patients showed 
hypoactivation of the postcentral gyrus and inferior parietal cortex contralaterally during imagined 
movement of the affected hand58.  Similarly, patients with functional limb weakness ("conversion 
paralysis") showed decreased activity of the contralateral supramarginal cortex (part of the inferior 
parietal cortex) compared to controls on imagined movement in the affected hand59.  In van Velzen’s 
study of patients with CRPS, healthy controls and immobilised patients showed normal corticospinal 
activity during motor imagery and motor observation. The authors postulated that motor symptoms 
of weakness, slowness and dystonia in CRPS are due to abnormal afferent (peripheral) information 
processing and therefore treatment should be focused on normalising this by touch and use of the 
affected limb60.  However other neurophysiological investigation of peripheral mechanisms of CRPS 
and FMDs have demonstrated inhibition of sensorimotor integration and reduced corticospinal 
activity in motor imagery but not observation, suggesting a central mechanism of movement 
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inhibition61–63. In all likelihood both peripheral and central mechanisms are involved at different 
stages. 
 
Central sensory disturbances go hand-in-hand with functional motor symptoms54. Central pain 
hypersensitisation has been demonstrated in experimental immobilisation64,65and is reflected in the 
non-dermatomal distribution of sensory symptoms in CRPS66. While sensory symptoms in motor FNDs 
have received woefully little attention in research so far, clinical experience shows that if inquired 
about, they will be reported by nearly every person with functional weakness or functional movement 
disorder. In a cohort study of sensorimotor FND, many patients showed a fluid shift of symptoms over 
time between sensory and movement domains (Stone et al., 2003). Interestingly, even characteristic 
autonomic changes such as regional limb temperature changes can be induced experimentally using 
protocols for disrupted sense of limb ownership (rubber hand illusion), emphasizing the influence of 
top-down processes67. 
 
Given the well-documented overlap in clinical presentation and the common pathophysiological 
pathways described above, why is CRPS not considered a form of FND, and why have FND researchers 
devoted so little attention to sensory symptoms and inflammatory processes? The reason, we would 
argue, is in the historical framing and re-framing of these disorders addressed in the introduction. Pain 
specialists, decidedly impressed by the evidence of tissue changes that immunologists and molecular 
biologists have provided, have come to see top-down cognitive and behavioural processes as 
secondary effects of CRPS pathology. Of course, phobic avoidance and anxiety are being recognized 
and treated, but they are not seen as driving factors of the disorder per se. Similarly, neurologists, 
often troubled with the differentiation of organic vs. "non-organic", tend to see FNDs, once identified, 
as strictly psychogenic disorders. Sensory alterations and trophic changes are discarded as by-
products of a unidirectional top-down disorder and receive little attention both clinically and in 
research. Thus, CRPS and FND seem to occupy opposing lanes of the highway, with all the same 
landmarks of pathology clearly visible, but, alas, never the twain shall meet. 
 
However, this is not how organic systems works, especially recursive neuronal networks and their 
neurohumoural and neuroimmunological continuations. Bidirectional hierarchical models based on 
Bayesian inference have recently been formulated for both FND54 and CRPS68. They necessitate an 
urgent re-thinking for both disorders in which outdated ideas of "psychogenic vs. neurogenic" have to 
be shaken off permanently. "Top-down processes" do not refer to mysterious forms of subconscious 
symptom conversion. Rather, the expectation of pain will influence not just movement (kinesiophobia, 
avoidant disuse) but also pain perception itself, as any nocebo researcher will confirm69. Furthermore, 
these reiterative cognitive-behavioural patterns of pain expectation and pain perception, 
kinesiophobia and disuse, will imprint themselves into the neural systems that underly nociception 
and movement through synaptic and cortical plasticity, giving rise to central allodynia and functional 
limb weakness. Crucially, normalisation cannot be forced purely bottom-up through analgesic drugs, 
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Understanding CRPS and FND in this way has potential benefit for understanding and treatment of 
both disorders. In FND, there have been recent promising randomised controlled trials of 
physiotherapy that emphasise the importance of establishing the potential for reversibility in FMDs, 
often through scrutiny of the motor signs themselves. Conversely, FMD researchers have much to 
learn from mechanistic and treatment studies in CRPS  
 
In recent years there has been an evolution in how clinicians approach the explanation of FND. 
Previously patients may have been told they had a psychological problem and needed referral to a 
psychiatrist.  Now many clinicians have advocated an emphasis on understanding the mechanism of 
the motor symptom itself and considering psychological comorbidities separately. Of central 
importance to this approach, and to the new DSM-5 diagnosis of FND, is to demonstrate to the patient 
the positive clinical signs, such as Hoover’s sign of functional leg weakness, when weakness of hip 
extension normalises with contralateral hip flexion or tremor transiently abates with distraction. The 
positive signs of FND emphasize profoundly therapeutic feature of the diagnosis, that the symptoms 
are due to a functional rather than structural problem, arise from the brain (and not the limb), and 
have the potential for reversibility.  This ‘software rather than hardware’ framework for the patient 
to understand how and why the disorder has occurred, with a focus on correcting abnormal self-
directed attention and movement expectation, appears in many cases to be key to successful 
treatment. 70,71.  
 
Two randomised controlled trials of physiotherapy 72,73 have shown the potential success of this 
approach in FND. A recent trial of 60 patients randomised either to specific FMD therapy or a similar 
number of community physio sessions showed significant improvement in in functional independence 
and mobility scores in the treatment versus control arms (72% vs. 18%)  even in patients with long 
duration symptoms (5.8 years).  Patients in the control arm only improved in only 18% of cases and 
on six month follow up 32% had developed worsening symptoms (3% in the treatment arm). Another 
RCT, also of 60 patients with functional gait disorder demonstrated the normalisation of gait in most 
patients despite a 9 month duration of symptoms. More than half of the patients in Nielsen et al’s 
2016 study had pain or fatigue described as severe or extreme 72. Part of the treatment was education 
that the mechanisms for chronic pain and fatigue are similar to those for pain, are not correlated with 
worsening structural damage, potentially reversible by re-training 71.  
 
An updated Cochrane review of physiotherapy for patients with CRPS found some evidence of 
improvement in pain and functional disability with graded motor therapy and improvement in 
impairment one year after multimodal physiotherapy; however, evidence for both was classed as very 
low quality 74. Perceived harmfulness of activities and pain-related fear predicts functional limitations 
in CRPS 75 and patients with CRPS have increased phobic anxiety compared with patients with other 
types of chronic pain 76. Based on these principles, an RCT (n=46)  of exposure versus pain-contingent 
treatments has demonstrating significant benefit (p<0.05) in disability, reduced pain catatrophisation, 
pain intensity and increased physical and mental health-related quality of life at six months follow up 
(den Hollander et al., 2016). Treatment for patients with chronic CRPS (average 5.1 years) involved 
reducing pain related fear using exposure treatment with a similar paradiagm as used in the 
treatement of anxiety disorders. Another treatment series of 106 patients with ‘end stage CRPS’ who 
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had failed other CRPS treaments, described outpatient phsyiotherapy focused on achieving movement 
after an extensive explanation of CRPS as a ‘reversible degregulation of the nervous system’ and pain 
as a ‘false warning sign’ rather than something suggesting onoging tissue injury77. In these 106 patients 
function improved in 95 patients and a full functional recovery occurred in 49 (46%) despite 
medications being stopped and some increase in pain during treatment.  There is a clear overlap 
between these treatment approaches for CRPS and FND which mirrors the overlap in the disorders 
themselves.  
 
Psychological therapy is a first line therapy for patients with dissociative seizures and has some 
evidence for functional neurological disorders in general78,79.  Psychologists and psychiatrists play an 
important role in successful multi-disciplinary for patients with FMDs80.  From our experience, the best 
outcomes in patients with FMDs occur when patients have treatment which challenges their top down 
expectations and kinesiophobia and behavioural habits such as avoidance as well as physical therapy 
improving peripheral input.  The technique of formulation of the mechanism of FMDs, taken from 
cognitive behavioural therapy, along with self-reflection and a personalised physical and mental 
management plan for dealing with exacerbations may be the key differences between very successful 
and largely unsuccessful physical therapy in FMDs72. 
 
In summary, a case series and randomised controlled trials of educational based upon understanding 
both FMD and CRPS as due to an abnormal potentially reversible malfunctioning nervous system, 
followed by physiotherapy focused on regaining function even if pain is transiently increased, have 
demonstrated positive outcomes. This suggest that patients understanding is key and demonstrates 
that improvement is possible even in those patients who have had CRPS or FMD for many years. In 
our view education based physiotherapy which targets both top-down processes and expectations as 
well as bottom up sensorimotor inputs +/- peripherally acting medication adjuncts, should be the 
mainstay of treatment for both disorders.  
 
Conclusion 
Discussions involving CRPS and functional disorders have been adversarial in the past.  New 
understanding of what functional disorders are; centrally mediated processes of abnormal self-
directed attention, often triggered by peripheral stimuli with complex neural and social and emotional 
risk factors and perpetuation, and a removal of the suspicion of feigned symptoms from the 
conversation of what CRPS and FMDs are, leads us to a new path of learning from each disorder.  There 
is significant overlap between both CRPS and FMD in new mechanistic understanding, motor 
symptoms, imaging and neurophysiology studies (Figure Two) as well as uncertainty about the best 
treatment. In both CRPS and FMDs explanation-based physical treatment, which encompasses 
understanding of the disorders as reversible seems most positive.  During this review, we were 
surprised by the lack of interest in peripheral processes in the FMD literature. There is much for FMD 
researchers to learn from the work already done into peripheral and central mechanism of CRPS and 
more attention is required for investigating “bottom up” input into the mechanistic model of 
functional disorders.  Similarly, recognising shared social, emotional and cognitive risk factors and 
bidirectional input as the method of CRPS symptom production will allow for more encompassing 
explanation and treatment strategies.  We hope that presenting the similarities and learning from 
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both disorders, with open acknowledgment of the antagonistic history, will encourage researchers in 
CRPS and FMD to collaborate and open useful discussions on how to understand and treat these 
complex and important disorders. 
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Table One: Clinical overlap of Complex Regional Pain Syndrome (CRPS) and Functional Neurological Disorder(FND) 
 
 Complex Regional Pain 
Syndrome 





Physical injury or surgery 
 
Physical injury or surgery in 37-
80%25  
Dependent on disorder 
Sensory Loss or hyperalgesia81 
Non-dermatomal, dense28, may 
be whole limb38 or 
hemisensory38 
 
Common response to placebo7 
Loss or hyperalgesia82 
Non-dermatomal, dense, may be 
whole limb or hemisensory82,83 
 
Common response to placebol83 
 





















Rapid onset, often fixed, 
dystonia of hand or foot34,85 
Can spread to other limbs12 
May seek limb amputation86 
 
Entrainment of tremor possible 
and diminished by 
distraction85,84,87 
 
Combination of movement 
disorders or other FNDs 
common88 
 
Rapid onset, often fixed, dystonia 
of hand or foot89,88 
Can spread to other limbs89 
May seek limb amputation86,88 
 
Entrainment of tremor possible 
and diminished or stopped by 
distraction90 
 
Unusual to have several 
different movement disorders 
 
 
Gradual onset over 
months/years of mobile 
dystonia14 
Unlikely to seek amputation86 
 
Entrainment rare in patients 
with pathophysical tremor91 
Weakness 
 
Give-way13,28. Distribution and 




Global pattern of weakness with 
signs of internal inconsistency 
(e.g. Hoovers sign) 
 
Follows expected patterns 




“My mind tells my hand/foot to 
move, but it won’t work”,93,12 
 
“My painful limb feels as though 
it is not part of my body”35 
(described as neglect-like but 
actually involving increased 
attention and dissociation) 
“He found that when he walked, 
his left leg would sometimes drag 
behind him, accompanied by an 
odd sense that it did not belong 
to him.”94 
 
Common for patients to describe 
feelings of disconnection or lack 
of ownership of limbs. Usually 
interpreted as dissociative. 
Feeling of limb dissociation 
can be seen in some 
conditions such as parietal 
dysfunction. 
Neglect of limb involves 





Some evidence of excess 
comorbidity of functional 
disorders such a fibromyalgia 
although poorly studied9697 
 
Comorbid functional disorders 
including FND greatly in excess of 
population98, 99  
Functional disorders common 
in population, including those 
with disease 100,101 
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